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Abstract 
 
 
Disruption to regulatory mechanisms controlling gene expression is a hallmark of 
leukaemia, with disruption to transcription factors being one of the most prevalent. By 
identifying the gene expression profile under the control of these transcription factors, 
and understanding how the target genes are regulated, critical insight can be gained into 
the role of these transcription factors in haematopoiesis, as well as their role in leukaemia 
development. Evidence presented here suggests that the RUNX1 transcription factor 
regulates the expression of the α6β4 integrin receptor in haematopoietic cells by 
controlling the integrin genes ITGA6 and ITGB4. Engagement of integrin receptors with 
extracellular matrix components of the bone marrow and haematopoietic tissues plays an 
essential role in haematopoiesis. Integrin expression is also altered in many leukaemias, 
however the regulation of integrin gene expression both in normal and disease states has 
remained largely unexplored.  
 
Data presented here identified ITGA6 and ITGB4 as novel target genes of the RUNX1 
transcription factor in myeloid cells. RUNX1 was found to bind to the promoter regions 
of ITGA6 and ITGB4 in myeloid cells in ChIP assays. Furthermore, RUNX1 had a 
functional effect on both of the promoters in reporter assays. RUNX1 increased the 
activity of both promoters, while RUNX1-ETO, which is produced by a common 
chromosomal translocation in leukaemic cells, repressed promoter activity, consistent 
with its well-characterised role as a transcriptional repressor.  
 
While RUNX1 is commonly described as a sequence-specific DNA binding protein that 
binds to the consensus motif TGT/cGGT, it is becoming evident that the regulation of 
genes by RUNX1 is more complex than this and RUNX1 can regulate its target genes 
through a variety of mechanisms. Evidence presented here suggests that RUNX1 
regulates the ITGA6 and ITGB4 integrin genes via two distinct mechanisms. RUNX1 
was found to regulate the ITGA6 promoter through a consensus RUNX1 binding motif 
and RUNX1 activation of the promoter was dependent on this motif, in keeping with the 
traditional model of RUNX1 function described in the literature. In contrast, RUNX1 
does not target the ITGB4 promoter through a consensus sequence motif and may be 
recruited indirectly to the promoter by other haematopoietic transcription factors. 
 xviii 
 
Furthermore, the data presented here suggest that efficient regulation of the ITGB4 gene 
may require interactions between the promoter and an upstream enhancer. RUNX1 was 
also found to interact with the ITGB4 enhancer, and similarly to the promoter, these 
interactions do not require a RUNX1 consensus binding motif and may involve 
recruitment by other transcription factors. Recent evidence suggests that the traditional 
model of RUNX1 function through a consensus binding motif may represent only a small 
proportion of RUNX1 target genes. Genome-wide analysis suggests that a significant 
proportion of RUNX1 recruitment to DNA occurs in the absence of consensus binding 
motifs, as shown here for ITGB4. 
 
To regulate gene expression, transcription factors must operate in the context of the 
nuclear chromatin environment. RUNX1 influence on gene expression is therefore also 
dependent on the chromatin environment at its target genes and its interactions with this 
environment. In the present study, epigenetic mechanisms were also found to contribute 
to the regulation of ITGA6 and ITGB4 gene expression in myeloid cell lines. ITGB4 
expression was inversely correlated with DNA methylation of a large CpG island located 
at the promoter in KG-1a and Kasumi-1 myeloid cells. Furthermore, low levels of histone 
H3 and high levels of histone H3 acetylation at both ITGA6 and ITGB4 promoter regions 
was associated with higher expression of the genes in these cells. Expression of the 
ITGA6 and ITGB4 genes is likely to be a result of the interplay between transcription and 
epigenetic factors and in support of this, data presented here show that despite the 
presence of RUNX1 in KG-1a cells, ITGB4 is expressed at very low levels in these cells 
possibly due to high levels of DNA methylation at the promoter.  
 
This study has advanced our understanding of the mechanisms by which RUNX1 
regulates its target genes and has identified distinct molecular mechanisms by which it 
operates. These findings may also be relevant to the mechanisms by which other 
transcription factors operate. Additionally, these findings suggest that RUNX1 disruption 
in leukaemia may have different effects on its target genes depending on how they are 
regulated normally by RUNX1. Additional studies are therefore required to further dissect 
the mechanisms by which RUNX1 regulates its target genes, and to further elucidate the 
repertoire of RUNX1 controlled genes. In addition, this study has provided insight into 
the regulation of integrin genes in myeloid cells, which is likely to have relevance to the 
regulation of these genes in other cell types and disease states. 
 
1 
 
Chapter 1 
 
Introduction 
 
 
1.1 Haematopoiesis and Leukaemia 
 
1.1.1 Haematopoiesis 
Haematopoiesis, in an adult, is a process which occurs primarily in the bone marrow and 
results in the development of immature haematopoietic progenitor cells into mature 
differentiated haematopoietic cells (Speck and Gilliland 2002). Since mature 
haematopoietic cells have a relatively short life-span, haematopoietic stem cells in the 
bone marrow are responsible for replenishing these cells (Orkin and Zon 2008, Speck and 
Gilliland 2002). Haematopoietic stem cells have the ability to regenerate, using a process 
called self-renewal, and have the potential to differentiate into haematopoietic progenitors 
which later differentiate into the mature cells of the haematopoietic system (Orkin 1995, 
Orkin 2000). As the haematopoietic progenitors differentiate, the cells become committed 
to maturation along specific lineage pathways (Orkin 2000, Orkin and Zon 2008). 
Haematopoiesis is therefore important for maintaining the optimum number of mature 
functional haematopoietic cells for homeostasis, efficient delivery of oxygen and 
protection against infection (Speck and Gilliland 2002). Haematopoiesis is tightly 
controlled through the complex interplay between extrinsic growth factors and cytokines 
that act on the cells, modulating the intrinsic signal transduction pathways and cell 
specific gene expression programs (Broxmeyer 2001, Cantor and Orkin 2002, 
Georgopoulos 2002, Kaushansky 2006, Orkin and Zon 2008).  
 
1.1.2 Leukaemia 
Leukaemias arise as a result of abnormal and disordered haematopoiesis due to altered 
regulation of the mechanisms controlling haematopoietic cell development (Speck and 
Gilliland 2002). Leukaemia is classified into groups based on the clinical course: acute 
or chronic, and the lineage commitment: lymphoid or myeloid (Burmeister and Thiel 
2001). Leukaemias can also be sub-classified based on other characteristics such as 
morphology, cytochemistry, immunophenotype and genetic information (Vardiman et al. 
 2 
 
2009, Walter et al. 2013). The treatment of individuals with leukaemia varies depending 
on the classification of the leukaemia and other factors such as low or high-risk state of 
disease, the health of the affected individual and the age of the individual (Burnett et al. 
2011, Cripe and Hinton 2000, Wei et al. 2010). The development of leukaemia occurs 
when the haematopoietic progenitor cells acquire mutations which provide the cells with 
a survival and/or proliferative advantage, and impair differentiation and apoptosis 
(Rubnitz et al. 2010, Speck and Gilliland 2002).  
 
In the early 2000’s the two-hit model hypothesis for the development of leukaemia was 
proposed (Gilliland and Griffin 2002). It was suggested that in order for leukaemia to 
develop, a haematopoietic stem cell or progenitor cell accumulates genomic alterations 
which affect genes involved in regulating cell proliferation, cell death and cell 
differentiation (Gilliland and Griffin 2002, Renneville et al. 2008). These genetic 
alterations transform the haematopoietic cell into what is now recognised as a leukaemic 
stem cell which retains the ability of self-renewal (Gilliland and Griffin 2002, Renneville 
et al. 2008). According to the two-hit model, these mutations to the haematopoietic stem 
cell are divided into two classes: class I mutations activate signal transduction pathways 
which provide the cell with a proliferation or survival advantage and class II mutations 
affect transcription factors or factors of the transcriptional complex, which block myeloid 
differentiation and provide self-renewability (Döhner and Döhner 2008, Gilliland and 
Griffin 2002, Renneville et al. 2008). In support of the two-hit hypothesis, studies have 
shown the co-occurrence of these two classes of mutations in human leukaemias. For 
example, individuals with acute myeloid leukaemia (AML) with a class II mutation, such 
as to the RUNX1 gene, have a higher frequency of mutations in class I genes encoding 
signal transduction molecules, such as FLT3, N-RAS, PTPN11 and NF1, resulting in 
hyperactivation of receptor tyrosine kinase-RAS signalling pathways (Niimi et al. 2006, 
Tang et al. 2009). 
 
However, recent research suggests that the development of leukaemia is more complex 
than this and that additional classes of mutations are required which affect epigenetic 
modification, cell adhesion and DNA repair. A recent study found that around 50% of 
individuals with AML had at least two mutations in genes commonly disrupted in 
leukaemia (Rocquain et al. 2010). These genes were separated into four different classes: 
class I (transcription factors), which include RUNX1 and TET2 mutations, and cause 
clonal dominance of haematopoietic stem cells; class II (epigenetic), which include 
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ASXL1 and NPM1 mutations, and promote either primary or secondary AML; class III 
(signal transduction), which include CBL, FLT3, JAK2 and RAS mutations, and affect 
signalling pathways and proliferation, and class IV, which include IDH1, IDH2 and WT1, 
and are exclusive mutations but are found to co-occur with mutations of genes in other 
classes and are associated with the acute phase of leukaemia (Rocquain et al. 2010). It 
was suggested that at least one mutation in each class was required for the development 
of AML (Rocquain et al. 2010). 
 
Along similar lines, Thiede (2012) proposed that as well as the class I and class II 
mutations from the two-hit model, which promote cell proliferation and survival, and 
block differentiation, there are another three classes of mutations that are required for the 
development of leukaemia: class III mutations which affect epigenetic modifications; 
class IV mutations which affect cell adhesion and cell-cell interaction; and class V which 
affect DNA repair/RNA splicing (Thiede 2012). In contrast, Kitamura et al. (2015) 
recently proposed that there are four classes of cellular phenotypes caused by mutations 
which lead to the development of leukaemia: induction of proliferation (class I), survival 
or block of differentiation (class II), block of differentiation (class III) and 
immortalisation (class IV) (Kitamura et al. 2015). It was proposed that a combination of 
mutation-induced cellular phenotypes would induce acute leukaemia and can determine 
the disease phenotypes of leukaemia (Kitamura et al. 2015). This revised model focuses 
on the cellular phenotypes induced by gene mutations rather than the categories of the 
genes that are mutated, and it is suggested that this is a better representation of the 
molecular basis of leukaemogenesis (Kitamura et al. 2015). 
 
While the details of these proposed models differ, the overarching principle is that the 
development of leukaemia is complex and multiple genetic disruptions are required, 
which increase proliferation, block apoptosis, block differentiation and immortalise the 
haematopoietic cells. Further, a recurrent theme is that mutations to genes encoding 
transcriptional regulators are a common underlying cause of the disruption to 
haematopoiesis that occurs in leukaemia. 
 
1.1.3 Transcriptional Regulation of Haematopoiesis 
Conditional knock-out/expression studies conducted in mice have identified many of the 
transcription factors required for haematopoiesis, and not surprisingly, many of these are 
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also commonly disrupted in leukaemia (Figure 1.1). Through these studies, transcription 
factors such as PU.1, GATA1 and C/EBPα have been demonstrated to be required for 
specific cell lineages (Pevny et al. 1991, Scott et al. 1994, Zhang et al. 1997). Gata1 is 
required for normal differentiation of erythroid cells, as mice deficient in Gata1 lack 
mature red blood cells (Pevny et al. 1991). Furthermore, mice deficient in Pu.1 also 
showed disrupted erythroid cell differentiation, but additionally displayed defects in the 
generation of progenitors for B and T lymphocytes, monocytes and granulocytes (Scott 
et al. 1994). In addition, mice deficient in C/ebpα lack mature neutrophils and eosinophils 
in the blood and foetal liver, but other haematopoietic lineages were not affected (Zhang 
et al. 1997). 
 
Transcription factors such as SCL, GATA2 and LMO2 have been identified as essential 
for the emergence of haematopoietic stem cells. A study by Tsai et al (1994) determined 
that Gata2 is required for the normal development of mice as Gata-2 knock-out mice 
were found to die by embryonic days 10-11. On further analysis, it was determined that 
Gata-2 was important for the emergence of haematopoietic stem and progenitor cells as 
Gata2 chimeric mice embryos were deficient in these cells (Tsai et al. 1994). Similar to 
Gata-2, Lmo2 knock-out mice died at embryonic day 10.5 and also lacked yolk sac 
erythropoiesis (Warren et al. 1994). Additionally, absence of the transcription factor Scl 
in mice displayed a similar phenotype to Lmo2 knock-out mice with embryonic lethality 
at days 8.5-10.5 and a lack of nucleated red blood cells (Shivdasani et al. 1995).  
 
Furthermore, MLL, RUNX1 and TEL/ETV6 genes are also important for the emergence 
of haematopoietic stem cells. Mll, Runx1 and Etv6 knock-outs were found to be 
embryonic lethal (Hess et al. 1997, Okuda et al. 1996, Wang et al. 1998). Mll knock-out 
mice had reduced yolk sac haematopoiesis and Mll was found to be required for 
maintaining the correct number of haematopoietic progenitors as well as the appropriate 
differentiation of these cells (Hess et al. 1997). Additionally, the Etv6 transcription factor 
was found to be essential for the establishment of haematopoiesis of all lineages in the 
bone marrow (Wang et al. 1998). Runx1 knock-out mice, which showed a more severe 
phenotype, lacked foetal liver haematopoiesis and myeloid/erythroid progenitors were 
absent, suggesting that Runx1 is required for definitive haematopoiesis of all lineages 
(Okuda et al. 1996). 
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Not surprisingly, the majority of these transcription factors identified to be essential for 
haematopoiesis are targets of somatic mutations and/or chromosomal translocations in 
leukaemia; suggesting disruption to these transcription factor genes predisposes an 
individual to leukaemia (Orkin and Zon 2008).  
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Figure 1.1 – Role of transcription factors in haematopoiesis. The stages at which 
transcription factors are important for haematopoietic development are shown. Absence 
of these transcription factors have been shown to block haematopoietic development in 
knock-out mice studies. Adapted from Orkin et al. (2008).  
Abbreviations: LT-HSC = long-term haematopoietic stem cell; ST-HSC = short-term 
haematopoietic stem cell; CMP = common myeloid progenitor; CLP = common lymphoid 
progenitor; MEP = megakaryocyte/erythroid progenitor; GMP = 
granulocyte/macrophage progenitor; RBCs = red blood cells. 
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1.2 RUNX1 
 
1.2.1 Runt-Related Transcription Factors 
The Runt-related transcription factors (RUNX), which belong to a small group of 
heterodimeric transcription factors known as the core-binding factors (CBFs), play 
important roles in cellular development and differentiation (Goyama and Mulloy 2011, 
Ito 2004, Speck and Gilliland 2002, Wang et al. 2010). The RUNX family comprises 
three evolutionary conserved genes, RUNX1, RUNX2 and RUNX3, which encode an 
alpha DNA binding subunit that forms part of a CBF complex (Blyth et al. 2005, De 
Braekeleer et al. 2011, Goyama and Mulloy 2011, Speck and Gilliland 2002, Wang et al. 
2010). A single gene, CBFB, encodes the non-DNA binding beta subunit, CBFβ, which 
is important for the stability of the CBF complex, high affinity DNA binding of the 
RUNX subunits and protection of the RUNX subunits, particularly RUNX1, against 
degradation (Blyth et al. 2009, Goyama and Mulloy 2011, Huang et al. 2001, Kagoshima 
et al. 1996). The RUNX transcription factors all share a region of high sequence 
homology at the N-terminus, called the Runt domain or Runt homology domain (RHD), 
which is responsible for heterodimerisation with CBFβ and DNA binding (Blyth et al. 
2005, Goyama and Mulloy 2011, Kagoshima et al. 1996). This 128 amino acid Runt 
domain was first identified in the Drosophila Runt gene, which was found to be important 
for early embryonic segmentation (Blyth et al. 2005, Gergen and Butler 1988). The C-
terminus of the RUNX transcription factors is less conserved than the Runt domain and 
contains inhibitory and activation domains that interact with transcriptional co-repressors 
and co-activators (Blyth et al. 2005). The RUNX transcription factors therefore can have 
a positive or negative influence on the transcription of their target genes. 
 
The RUNX1 gene, which is located on chromosome 21, is required for definitive 
haematopoiesis and is a common target of chromosomal and genetic alterations in 
leukaemia (Blyth et al. 2005, Goyama and Mulloy 2011, Ito 2004, Okuda et al. 1996, 
Speck and Gilliland 2002, Wang et al. 1996, Yamagata et al. 2005). RUNX2, which is 
located on chromosome 6, is involved in osteogenesis and has been found to play a role 
in bone metastasis in breast and prostate cancer (Akech et al. 2009, Barnes et al. 2003, 
Barnes et al. 2004, Komori et al. 1997, Otto et al. 1997). RUNX3, which is located on 
chromosome 1, is important for neurogenesis, thymopoiesis and maintenance of gut 
epithelium, and has been associated with the development of gliomas and gastric cancer 
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(Levanon et al. 2001, Levanon et al. 2002, Li et al. 2002, Mei et al. 2011, Mueller et al. 
2007, Woolf et al. 2003).  
 
1.2.2 The RUNX1 Transcription Factor 
The RUNX1 gene, also known as AML1, CBFA2 and PEBP2aB, was first identified from 
the frequently occurring chromosomal translocation t(8;21) in AML (Miyoshi et al. 
1991). Further studies involving knock-out mice determined that RUNX1 was important 
for haematopoiesis. These studies found mice homozygous for mutant Runx1 died 
between embryonic days 11.5-12.5 due to haemorrhaging in the central nervous system 
(Okuda et al. 1996, Wang et al. 1996). The homozygous mice also lacked foetal liver 
haematopoiesis and were deficient in myeloid/erythroid progenitors, suggesting that 
RUNX1 is required for definitive haematopoiesis (Okuda et al. 1996, Wang et al. 1996). 
Further studies discovered that CBFβ is required for RUNX1 function and therefore, is 
also important for definitive haematopoiesis. In these studies, knock-out Cbfb mice were 
found to exhibit the same phenotype as the Runx1 knock-out mice (Sasaki et al. 1996, 
Wang et al. 1996). These mice also died at embryonic days 11.5-14.5 due to 
haemorrhaging in the central nervous system and the mice also lacked definitive 
haematopoiesis in the foetal liver (Sasaki et al. 1996, Wang et al. 1996) 
 
The expression of RUNX1 is controlled by two promoters, distal (P1) and proximal (P2), 
which direct transcription of RUNX1 isoforms (Blyth et al. 2005, De Braekeleer et al. 
2011, Ghozi et al. 1996, Lam and Zhang 2012, Miyoshi et al. 1995). Three RUNX1 
isoforms have been described: RUNX1a, RUNX1b and RUNX1c, which all possess the 
Runt domain in the N-terminal region (De Braekeleer et al. 2011, Lam and Zhang 2012, 
Miyoshi et al. 1995). The RUNX1a isoform, consisting of 250 amino acids, lacks the 
transcriptional regulatory domains located in the C-terminal region and therefore only 
possesses the DNA-binding N-terminal region of RUNX1 (De Braekeleer et al. 2011, 
Lam and Zhang 2012, Miyoshi et al. 1995). The RUNX1b isoform, consisting of 453 
amino acids, contains both the N-terminal region and C-terminal transcriptional 
regulatory domains (De Braekeleer et al. 2011, Lam and Zhang 2012, Miyoshi et al. 
1995). The RUNX1c isoform, consisting of 480 amino acids, is the longest RUNX1 
isoform and only differs from RUNX1b by 32 amino acids in the N-terminal region (De 
Braekeleer et al. 2011, Lam and Zhang 2012, Miyoshi et al. 1995). RUNX1c and 
RUNX1b both possess identical C-terminal regions and RUNX1a and RUNX1b both 
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share the same N-terminal region (De Braekeleer et al. 2011, Lam and Zhang 2012, 
Miyoshi et al. 1995). The expression of the RUNX1 isoforms has been shown to play an 
important and non-redundant role in haematopoiesis (Bee et al. 2010, Challen and 
Goodell 2010, Fujita et al. 2001, Li et al. 2002, Pozner et al. 2007, Ran et al. 2013, 
Sroczynska et al. 2009). 
 
As well as being transcriptionally regulated, RUNX1 is regulated by post-translational 
changes such as phosphorylation and methylation (Lam and Zhang 2012, Wang et al. 
2009). Phosphorylation at 2-3 serine residues of RUNX1 is generally associated with 
RUNX1 activation of transcription (Guo and Friedman 2011, Imai et al. 2004, Lam and 
Zhang 2012). Phosphorylation of RUNX1 increases the ability of RUNX1 to activate the 
transcription of target genes by decreasing RUNX1 interactions with transcriptional co-
repressors (Guo and Friedman 2011, Imai et al. 2004, Lam and Zhang 2012). However, 
phosphorylation of RUNX1 also results in the time-dependent degradation of RUNX1, 
therefore increased activation of RUNX1 by phosphorylation is transient (Biggs et al. 
2006, Imai et al. 2004). Methylation at two arginine residues of RUNX1 has also been 
found to contribute to RUNX1 activation of transcription by causing dissociation from 
transcriptional co-repressors (Zhao et al. 2008).  
 
1.2.3 RUNX1 in Leukaemia 
RUNX1 is a frequent target of genetic alteration in leukaemia (Blyth et al. 2005, Michaud 
et al. 2008, Speck and Gilliland 2002), with chromosomal translocations, mutations and 
gene amplification of RUNX1 all observed in individuals with the disease (Dal Cin et al. 
2001, Harewood et al. 2003, Miyoshi et al. 1991, Niini et al. 2000, Osato et al. 1999, 
Preudhomme et al. 2009, Song et al. 1999, Streubel et al. 2001). It is proposed that these 
alterations to RUNX1 predispose individuals to leukaemia. 
 
1.2.3.1 RUNX1 Chromosomal Translocations 
Chromosomal translocations involving the RUNX1 gene were the first alterations to 
RUNX1 detected in individuals with leukaemia. RUNX1 is implicated in approximately 
55 different translocations, but only 21 have been completely characterised (De 
Braekeleer et al. 2011). Of these, the most common are t(8;21)(q22;q22) which is 
observed in approximately 12% of AML and 40% of the M2 subtype of AML (Peterson 
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and Zhang 2004), and t(12;21)(p13;q22) which is observed in 20-25% of paediatric acute 
lymphoblastic leukaemia (ALL) (Liang et al. 1996, Romana et al. 1995). 
 
The t(8;21) chromosomal translocation was the first translocation involving the RUNX1 
gene to be discovered (Blyth et al. 2005). This translocation was first identified in an 
individual with acute leukaemia in 1973 (Rowley 1973), and led to the discovery of 
RUNX1 through the cloning of the gene on chromosome 21 involved in the t(8;21) 
chromosomal translocation (Miyoshi et al. 1991). In this study, the RUNX1 gene was 
found to be rearranged in individuals with AML with breakpoints of the gene in 16 out 
of 21 individuals clustered within the same region of RUNX1 (Miyoshi et al. 1991). 
Interestingly, detailed analysis of 3 of those individuals found the breakpoints to occur in 
the same intron of the RUNX1 gene, suggesting that all t(8;21) breakpoints most likely 
occur in that intron (Miyoshi et al. 1991). 
 
The other gene involved in the t(8;21) chromosomal translocation on chromosome 8 was 
subsequently discovered using a similar cloning method (Miyoshi et al. 1993). Miyoshi 
et al. (1993) discovered the novel MTG8 gene, also known as Eight Twenty One (ETO). 
Further analysis determined the chromosomal translocation encodes a RUNX1-ETO 
fusion transcript, which produces a RUNX1-ETO fusion protein. The fusion protein was 
found to contain the last 575 amino acids of the 604 amino acid ETO protein and the first 
177 amino acids of the RUNX1 protein containing the DNA binding Runt domain (Figure 
1.2A) (Miyoshi et al. 1993).  
 
Further studies indicate that the RUNX1-ETO protein mainly acts as a dominant negative 
inhibitor of RUNX1 function. This was shown in knock-in mouse studies in which 
heterozygous mice died as embryos due to haemorrhaging in the central nervous system 
and foetal liver haematopoiesis was absent, although these mice possessed a functional 
copy of one Runx1 gene (Yergeau et al. 1997). RUNX1-ETO has also been shown to 
bind to RUNX1 target genes (Frank et al. 1995, Westendorf et al. 1998) since the DNA 
binding domain of RUNX1 is retained in the fusion protein. RUNX1 normally interacts 
with transcriptional co-activators to activate gene expression (Kitabayashi et al. 1998), 
however, due to the replacement of the transactivation domain of RUNX1 with ETO, 
expression of target genes is generally repressed due to interactions with repressive co-
factors (Lutterbach et al. 1998, Wang et al. 1998). RUNX1-ETO therefore causes 
genome-wide changes in gene expression (Ptasinska et al. 2012), disrupting expression 
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of RUNX1 target genes and leading to inhibition of differentiation (Westendorf et al. 
1998), inhibition of apoptosis (Klampfer et al. 1996, Matsushita et al. 1999) and increased 
haematopoietic progenitor/stem cell proliferation (Mulloy et al. 2002, Okuda et al. 1998). 
 
Another common chromosomal translocation observed in leukaemia is t(12;21), which 
results in an ETV6-RUNX1 fusion protein. Involvement of the RUNX1 and ETV6 genes 
in this translocation was initially identified in two cases of childhood pre-B cell ALL 
(Golub et al. 1995). However, a subsequent study determined that there is a high 
frequency of this chromosomal translocation in childhood B-lineage ALL and the 
RUNX1-ETV6 fusion protein was detected in at least 16% of 121 individuals examined 
in one particular study (Romana et al. 1995).  
 
The t(12;21) translocation results in the fusion of most of RUNX1, including the DNA 
binding domain and transactivation domain, to the 5’ end of the ETV6 transcription 
factor, including the helix-loop-helix domain but not the DNA binding domain of the 
protein (Figure 1.2A) (Golub et al. 1995). Similar to the RUNX1-ETO fusion protein, 
ETV6-RUNX1 has been described as a transcriptional repressor (Chakrabarti and 
Nucifora 1999, Fenrick et al. 1999, Guidez et al. 2000). Since the RUNX1 DNA binding 
domain is retained in this fusion protein, ETV6-RUNX1 generally represses expression 
of RUNX1 target genes (Fears et al. 1997, Hiebert et al. 1996). 
 
Additionally to RUNX1 chromosomal translocations, the CBFβ subunit, which 
heterodimerises with RUNX1, is also involved in a common chromosomal alteration 
observed in adult AML and paediatric ALL, known as inv(16), which produces a CBFβ-
MYH11 fusion protein (Blyth et al. 2005, Lutterbach et al. 1999, Shurtleff et al. 1995). 
The CBFβ-MYH11 fusion protein blocks haematopoiesis and is thought to do so by 
disrupting normal RUNX1 activity (Castilla et al. 1996, Kanno et al. 1998, Kundu and 
Liu 2001). 
 
1.2.3.2 Mutations in RUNX1 
Since the discovery of RUNX1 chromosomal translocations and the importance of 
RUNX1 in haematopoiesis, mutations to the RUNX1 gene were subsequently identified 
as a common occurrence in leukaemia. A study by Osato et al. (1999) analysed 160 
individuals with leukaemia for mutations in the RUNX1 gene. In six of these individuals, 
 12 
 
silent, heterozygous missense, biallelic nonsense or frameshift mutations were identified. 
The mutations were found to be clustered within a region of the gene encoding the DNA 
binding Runt domain of RUNX1. The missense and biallelic mutations were associated 
with RUNX1 loss-of-function, suggesting that the mutations to RUNX1 could play a role 
in the development of leukaemia (Osato et al. 1999). Similarly, a study by Tang et al. 
(2009) discovered 63 distinct RUNX1 mutations in 62 of 470 adult patients with de novo 
AML. Of the 63 mutations, 7 were nonsense mutations, 24 were missense mutations, 28 
were frame-shift mutations and 4 were in-frame mutations (Figure 1.2) (Tang et al. 2009). 
Interestingly, most of the mutations occurred in either the DNA binding Runt domain or 
the transactivation domain of RUNX1 (Tang et al. 2009).  
 
In support of these studies, individuals with familial platelet disorder with a 
predisposition to AML (FPD/AML) are predisposed to AML due to haploinsufficiency 
of RUNX1 as a result of genetic mutations (Preudhomme et al. 2009, Song et al. 1999). 
Studies have shown that individuals with FPD/AML possess a mutation to one allele of 
the RUNX1 gene which causes the platelet defect and additional mutations to RUNX1 
can then contribute to the development of leukaemia (Preudhomme et al. 2009, Song et 
al. 1999).  
 
In more recent studies, it has been found that RUNX1 mutations are associated with lower 
complete remission rates, shorter overall survival and resistance to therapy in AML 
(Gaidzik et al. 2011, Mendler et al. 2012, Schnittger et al. 2011, Tang et al. 2009). A 
study has found that individuals with RUNX1 mutations have a significantly lower 
complete remission rate, shorter disease-free survival and overall survival than those 
individuals without RUNX1 mutations (Tang et al. 2009). These findings have also been 
supported by other studies, which also found a correlation between RUNX1 mutations and 
lower remission rates, disease-free survival and overall survival in AML (Gaidzik et al. 
2011, Mendler et al. 2012, Schnittger et al. 2011). In addition, RUNX1 mutations have 
also been associated with resistance to therapy. A study has shown that RUNX1 mutations 
in individuals with AML is associated with resistance to chemotherapy (Gaidzik et al. 
2011). RUNX1 mutations were identified in 53 out of 945 individuals with AML and 
those patients were shown to have lower complete remission rates, higher refractory 
disease rates and higher early/hypoplastic death rates in response to chemotherapy 
compared to individuals with no RUNX1 mutations (Gaidzik et al. 2011). 
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Figure 1.2 – Common chromosomal translocations and mutations in leukaemia. A) 
Schematic representation of RUNX1 protein, containing the Runt homology domain 
(RHD) and transactivation domain (TAD), RUNX1-ETO fusion protein produced from 
the t(8;21) chromosomal translocation and ETV6-RUNX1 fusion protein produced from 
the t(12;21) chromosomal translocation, containing the helix-loop-helix (HLH) domain 
of ETV6. Numbering of amino acids for RUNX1 (black), ETO (blue) and ETV6 (red) 
proteins are shown. B) Schematic of the RUNX1 protein showing the location of 63 
distinct mutations identified in 62 individuals with de novo AML (Tang et al. 2009). 
Missense mutations (circles), frameshift mutations (triangles) and in-frame mutations 
(squares), including insertions (black squares) and a deletion (white square), are shown. 
The point at which the stop codon for RUNX1 is shifted due to nonsense mutations are 
shown by the arrows. The numbering of the amino acids relative to the Runt homology 
domain (RHD) and transactivation domain (TAD) of the RUNX1 protein is shown. 
Adapted from Tang et al (2009). 
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1.2.3.3 RUNX1 Gene Amplification 
As well as decreased activity of RUNX1 caused by mutations or chromosomal 
translocations to the RUNX1 gene, increased expression of RUNX1 caused by polysomy 
of chromosome 21, increased copies of the RUNX1 gene or deregulation of the RUNX1 
promoter, has also been suggested as a contributing factor to the development of 
leukaemia (Mikhail et al. 2002, Mikhail et al. 2006). Amplification of RUNX1 has been 
observed in individuals with ALL, particularly childhood ALL (Dal Cin et al. 2001, 
Harewood et al. 2003, Mikhail et al. 2002, Niini et al. 2000), and it has been suggested 
that the increased dosage of RUNX1 in individuals with Down Syndrome, due to trisomy 
21, could contribute to the development of leukaemia in those individuals (Blyth et al. 
2005, Ito 2004, Yanagida et al. 2005).  
 
The leukaemogenesis of RUNX1 amplification has been supported by in vivo studies 
using mice predisposed to developing lymphoma or leukaemia (Wotton et al. 2002, 
Yanagida et al. 2005). In a study by Wotten et al. (2002), CD2-MYC mice, which are 
mice that develop lymphomas due to proviral insertional mutagenesis of the Myc gene 
(Stewart et al. 1993), were engineered to overexpress the Runx1 gene. Runx1 was found 
to act as a dominant oncogene with Myc to cause the development of T-cell lymphoma in 
the transgenic mice (Wotton et al. 2002). In another study, BXH2 mice, which are mice 
that develop myeloid leukaemia over time, were also engineered to overexpress Runx1 
(Yanagida et al. 2005). Overexpression of Runx1 caused an increased rate of leukaemia 
development in these mice and also caused an increase in the frequency of 
megakaryoblastic leukaemia (Yanagida et al. 2005). Together these studies suggest that 
the amplification of RUNX1 is leukaemogenic in haematopoietic lineages and therefore 
could contribute to the development of leukaemia in individuals with aberrant 
overexpression of RUNX1. 
 
1.2.3.4 RUNX1 Disruption and Predisposition to Leukaemia 
Although chromosomal translocations, mutations and gene amplification of RUNX1 are 
present in individuals with leukaemia and these alterations to RUNX1 have been shown 
to contribute to leukaemogenesis, alteration to the RUNX1 gene alone is not sufficient to 
cause leukaemia. In keeping with the multi-hit model of leukaemogenesis as described in 
Section 1.2.3, individuals with AML which possess RUNX1 mutations have a higher 
frequency of mutations to signalling transduction genes such as FLT3, N-RAS, PTPN11 
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and NF1 (Niimi et al. 2006, Tang et al. 2009). Further, this is supported by studies of 
transgenic RUNX1-ETO mice which do not spontaneously develop leukaemia (De 
Guzman et al. 2002, Higuchi et al. 2002, Rhoades et al. 2000, Yuan et al. 2001). Although 
these mice displayed haematopoietic developmental abnormalities which are also 
observed in humans with the t(8;21) chromosomal translocation, the chromosomal 
translocation alone was not sufficient to cause leukaemia in these mice (De Guzman et 
al. 2002, Higuchi et al. 2002, Rhoades et al. 2000, Yuan et al. 2001). However, treatment 
of these transgenic RUNX1-ETO mice with a DNA alkylating agent, N-ethyl-N-
nitrosourea, resulted in a large proportion of the mice developing leukaemia; suggesting 
that additional mutations which cooperate with RUNX1-ETO are required for the 
development of leukaemia (Higuchi et al. 2002, Yuan et al. 2001). Interestingly, a further 
study demonstrated that mutation to the receptor kinase gene c-Kit in these transgenic 
RUNX1-ETO mice also caused the mice to develop leukaemia (Nick et al. 2012). 
 
Although it has been shown that additional mutations of other genes are required to cause 
leukaemia, alteration to RUNX1 plays a key role in leukaemia development. Disruption 
to RUNX1 impacts cell differentiation, proliferation and apoptosis (Klampfer et al. 1996, 
Matsushita et al. 1999, Mulloy et al. 2002, Okuda et al. 1998, Westendorf et al. 1998) 
due to altered regulation of its target genes. 
 
 
1.3 Regulation of Gene Expression by RUNX1 
 
Transcription factors play a critical role in determining the gene expression profiles of a 
cell, which specifies their phenotype and function. They regulate transcription by binding 
to specific DNA sequences in regulatory regions of the genome, including proximal 
promoter and distal regulatory regions, to control transcription of their target genes 
(Latchman 1993). However, transcription factors operate within a complex layer of 
regulatory mechanisms, which control gene expression programs. Transcription factors 
generally exert their influence on transcription as part of large transcriptional complexes, 
which consist of other DNA bound transcription factors, transcriptional co-activators and 
co-repressors, and the transcriptional machinery (Kadonaga 2012). These transcriptional 
complexes not only interact with the DNA itself, but also with the chromatin proteins 
associated with the DNA. The interplay between transcription factors and the chromatin 
environment is complex; while transcription factors can modulate the chromatin 
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structure, the chromatin structure also regulates the ability of transcription factors to 
assemble on the DNA and regulate gene expression. 
 
1.3.1 Chromatin Structure 
In eukaryotic cells, DNA is packaged into chromatin which provides a mechanism to 
store the large amount of genomic material in the cell nucleus, but also provides a 
mechanism to control transcription of genes by regulating the accessibility of DNA to the 
transcription machinery (Uribesalgo and Di Croce 2011). Chromatin is composed of 
repeating units of nucleosomes which consist of an octamer of histone proteins, H3, H4, 
H2A and H2B, and approximately 146 bp of DNA is wrapped twice around the histone 
octamer (Luger et al. 1997, Uribesalgo and Di Croce 2011). The nucleosomes are 
connected by linker DNA and linker histone H1 protein binds to the linker DNA at the 
entry and exit points of the nucleosome to facilitate the folding and compaction of 
chromatin into higher order structures (Allan et al. 1980, Bednar et al. 1998, Virani et al. 
2012).  
 
At the nucleosomal level, the positioning of nucleosomes along the genome can provide 
a mechanism for regulating gene expression. For example, nucleosome positioning 
surrounding the transcription start sites of genes has been found to affect RNA 
polymerase II binding (Schones et al. 2008). Furthermore, positioning of nucleosomes at 
gene promoters regulates the accessibility of regulatory proteins to those regions (Jiang 
and Pugh 2009).  
 
Chromatin in the cell exists in two distinct states: euchromatin and heterochromatin. 
Euchromatin consists of loosely packed chromatin which is more accessible for 
transcription, whereas heterochromatin consists of tightly packed chromatin structures 
that are less accessible to regulatory proteins (Kouzarides 2007). In reality however, the 
chromatin structure exists in a continuum between these states and can be modulated by 
epigenetic enzymes, which modify the DNA and histone proteins, thus influencing 
chromatin structure and therefore gene expression. There is now a large array of enzymes 
known to modify DNA and histone proteins, including DNA methyltransferases (DMTs), 
histone acetyl transferases (HATs), histone methyltransferases (HMTs), histone 
deacetylases (HDACs) and histone demethylases (HDMs). 
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1.3.2 DNA Methylation 
DNA methylation is a stable modification to the DNA which is important for mammalian 
development through its role in regulating gene expression and chromatin structure 
(Sharma et al. 2010). In mammalian cells, DNA methylation primarily occurs on 
cytosines of cytosine-guanine (CpG) pairs by the addition of a methyl group to the fifth 
carbon of the cytosine nucleotide by DNA methyltransferases (Mazzio and Soliman 2012, 
Virani et al. 2012). Overall, CpGs are underrepresented throughout the genome but are 
clustered in short regions of DNA termed CpG islands (Jones and Takai 2001). CpG 
islands are frequently located at the 5’ end of genes, occupying approximately 60% of 
human gene promoters and their methylation is generally associated with gene silencing 
(Jones and Takai 2001, Sharma et al. 2010, Wang and Leung 2004). 
 
DNA methylation at promoter regions, is well characterised in the literature and is most 
commonly reported to inhibit transcription by either physically blocking transcription 
machinery from binding or by the recruitment of transcriptional repressors or chromatin 
modifying enzymes (Mazzio and Soliman 2012). However, it has now been recognised 
that the positioning of DNA methylation relative to the transcription start site may also 
play different roles in the regulation of gene expression. While DNA methylation at the 
transcription start site is associated with transcriptional repression, DNA methylation in 
the gene body is associated with active transcription and may stimulate transcription 
elongation or play a role in transcript splicing and alternative promoter usage (Bert et al. 
2013, Jones 2012, Laurent et al. 2010, Maunakea et al. 2010, Tekpli et al. 2016). 
Additionally, DNA methylation found in repeat regions, such as centromeres, is important 
for maintaining chromosomal stability (Jones 2012). 
 
In cancer, DNA methylation is highly dysregulated leading to hypermethylation of CpG 
islands at gene promoters, such as tumour suppressor genes, but overall the genome 
becomes hypomethylated, with hypomethylation observed at distal regulatory regions and 
repetitive elements (Ehrlich 2002, Virani et al. 2012). These changes in DNA methylation 
patterns cause altered gene expression profiles which contribute to the development and 
progression of cancer (Sharma et al. 2010). Altered DNA methylation profiles are 
frequently observed in leukaemia and has been found to correlate with different subtypes 
of the disease (Figueroa et al. 2010, Garcia-Manero et al. 2002, Nordlund et al. 2012, Pei 
et al. 2012). 
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1.3.3 Histone Modification 
The histone proteins that make up the nucleosomes are also subject to epigenetic 
modification. The N-terminal tails of the histone proteins extend out from the 
nucleosomes and are targeted by chromatin modifying enzymes such as HATs, HMTs, 
HDACs and HDMs (Sharma et al. 2010). The histone tails can undergo a variety of post-
translational modifications with more than 20 different modifications reported (Zhao and 
Garcia 2015), the best characterised being methylation and acetylation (Kouzarides 2007, 
Tessarz and Kouzarides 2014). Histone modifications function as docking sites for 
proteins that can recognise these modifications and recruit chromatin modifiers and 
remodelling enzymes to either promote transcriptional activation or repression of genes 
by modifying the chromatin environment (Tessarz and Kouzarides 2014). Histone 
modifications are also important for regulating DNA replication and DNA damage repair 
(Van Attikum and Gasser 2009). 
 
Histone acetylation occurs on lysine residues and is generally associated with 
transcriptional activation (Virani et al. 2012). Histone acetylation is thought to enhance 
transcription through disruption of the interaction of the negatively charged DNA with 
the positively charged histones by neutralising the charge on the histone proteins (Virani 
et al. 2012). In addition, particular acetyl residues can act as recruitment sites for 
chromatin modifiers or remodelers. Maintenance of histone acetylation is controlled by 
HATs, which acetylate the histone proteins, and HDACs which remove acetyl groups 
(Virani et al. 2012). 
 
Unlike histone acetylation, histone methylation can be associated with both 
transcriptional activation and repression (Virani et al. 2012). Histone methylation occurs 
at arginine and lysine residues of histone proteins, particularly H3 and H4 (Virani et al. 
2012). Di-methylation of H3 lysine 9 (H3K9me2) and tri-methylation of H3 lysine 27 
(H3K27me3) is associated with gene silencing, while mono-, di- and tri-methylation of 
histone H3 lysine 4 (H3K4me1, H3K4me2 and H3K4me3) are associated with gene 
expression (Pekowska et al. 2011). Histone methylation is maintained by HMTs, which 
methylate the histones, and HDMs, which remove the methyl groups (Virani et al. 2012).  
 
Interestingly, particular histone methylation and acetylation marks have been mapped to 
promoter and enhancer regions of the genome and further have been correlated with the 
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activity of these regulatory elements (Creyghton et al. 2010, Heintzman et al. 2007, Liang 
et al. 2004, Santos-Rosa et al. 2002). A study by Heintzman et al. (2007) determined the 
histone modification profiles in IFNγ-treated and untreated cells within a 30 Mb region 
of the genome. It was found that active promoters possess H3K4me3, while enhancers 
only possessed H3K4me1 and no trimethylation (Heintzman et al. 2007). This is 
supported by other studies which have also found the H3K4me3 mark at active genes 
(Liang et al. 2004, Santos-Rosa et al. 2002). H3K4me2 occurs at both active and inactive 
genes, however H3K4me3 only occurs at active genes and the conversion of H3K4me2 
to H3K4me3 is associated with gene activation (Santos-Rosa et al. 2002). Furthermore, 
methylated H3K4 as well as acetylated histone H3 lysine 9 and lysine 14 (H3K9/14) is 
located at the 5’ regions of transcriptionally active genes (Liang et al. 2004). Additionally, 
the histone mark histone H3 lysine 27 acetylation (H3K27ac) as well as H3K4me1 is 
associated with active enhancers while H3K4me1 alone is associated with inactive/poised 
enhancers (Creyghton et al. 2010). 
 
Similar to DNA methylation, histone modifications are also dysregulated in cancer. 
Altered histone modification profiles have been observed in leukaemia and have been 
shown to be able to predict event-free survival in individuals with AML (Dorrance et al. 
2006, Gelmetti et al. 1998, Krivtsov and Armstrong 2007, Müller-Tidow et al. 2010).  
 
1.3.4 RUNX1 Binds to Promoters/Enhancers to Regulate Gene Expression  
The RUNX1 transcription factor is commonly described as a sequence-specific DNA 
binding protein that binds to the consensus motif TGT/cGGT through its DNA binding 
Runt homology domain (Meyers et al. 1993). The Runt homology domain is also 
important for the interaction with CBFβ, which is required for efficient DNA binding of 
RUNX1 (Gu et al. 2000, Kanno et al. 1998). The C-terminal end of the RUNX1 protein 
is auto-inhibitory and inhibits DNA binding, however binding of CBFβ to RUNX1 
relieves this inhibition, allowing RUNX1 to bind to DNA, and exposes the transcriptional 
activation and inhibition domains at the C-terminal of RUNX1 (Gu et al. 2000, Kanno et 
al. 1998). 
 
Early studies characterising RUNX1 demonstrated regulation of genes important for 
haematopoietic function. A study by Takahashi et al. (1995) discovered that the 
granulocyte-macrophage colony-stimulating factor (GM-CSF) gene promoter possesses 
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the consensus binding motif for RUNX1. RUNX1 function at the promoter was 
determined using reporter assays and RUNX1 was found to increase GM-CSF promoter 
activity (Takahashi et al. 1995). Additionally, RUNX1 also targets the macrophage 
colony-stimulating factor (M-CSF) gene promoter via the RUNX1 consensus binding 
motif (Zhang et al. 1994). Gel shift assays demonstrated specific binding of RUNX1 to 
the consensus sequence and mutation to the sequence resulted in reduced RUNX1 binding 
(Zhang et al. 1994). 
 
RUNX1 binding to enhancer elements has been demonstrated for a number of genes. As 
well as regulating the GM-CSF promoter, RUNX1 also targets the GM-CSF enhancer. 
RUNX1 can target two overlapping RUNX1 consensus sites within a palindromic 
sequence of the GM-CSF enhancer and simultaneous binding of two RUNX1 proteins to 
both of these consensus sites leads to activation of the enhancer (Bowers et al. 2010). 
Furthermore, RUNX1 has been shown to be important for the assembly and function of 
the TCRδ enhancer, enabling c-Myb enhancer binding and activation of the gene 
promoter (Hernández-Munain and Krangel 2002). RUNX1 targets the consensus site 
TGTGGT in the TCRδ enhancer and binding of RUNX1 to the enhancer leads to a 
conformational change to the enhancer region, allowing c-Myb to bind, resulting in 
transcriptional activation (Hernandez-Munain and Krangel 1994, Hernández-Munain and 
Krangel 2002).  
 
1.3.5 RUNX1 Cooperates with Other Transcriptions Factors 
RUNX1 commonly functions as part of large transcriptional complexes to regulate gene 
expression. RUNX1 can physically interact with CCAAT enhancer-binding protein 
(C/EBP) and function cooperatively with C/EBP to activate the MCSF receptor promoter 
(Zhang et al. 1996). RUNX1 can also interact with ETS transcription factors such as ETS-
1, MEF and FLI1 (Giese et al. 1995, Gu et al. 2000, Huang et al. 2009, Mao et al. 1999). 
RUNX1 physically interacts with ETS-1 through the Runt homology domain and binding 
of ETS-1 to RUNX1 increases DNA binding of RUNX1 to a consensus site in 
electrophoretic mobility shift assays by 7 to 10 fold (Gu et al. 2000). Furthermore, 
RUNX1 has been shown to function cooperatively with ETS-1 to bind adjacent sites in 
the TCRα enhancer (Giese et al. 1995). RUNX1 also physically interacts with the MEF 
transcription factor through its Runt homology domain, and RUNX1 and MEF can 
function synergistically to transactivate the interleukin 3 promoter (Mao et al. 1999). 
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Additionally, RUNX1 can interact with the FLI1 transcription factor through protein-
protein interactions and through these interactions, synergistically activate the c-mpl 
promoter which contain both RUNX and FLI1 binding motifs (Huang et al. 2009). 
Furthermore, RUNX1 physically interacts with GATA1 and transfection studies have 
shown that RUNX1 increases GATA1 activation of promoters with GATA1 binding sites 
(Elagib et al. 2003, Waltzer et al. 2003). 
 
Interestingly, in genome-wide studies RUNX1 has been shown to frequently interact with 
numerous transcription factors simultaneously to form a protein complex to regulate gene 
expression (Beck et al. 2013, Tijssen et al. 2011, Wilson et al. 2010). A study by Wilson 
et al. (2010) reported simultaneous binding of six key haematopoietic transcription 
factors with RUNX1 in 1015 regions across the genome in haematopoietic cells. The 
transcription factors were bound within 200 bp or less and consensus binding motifs for 
all seven transcription factors were present at all regions (Wilson et al. 2010). Binding of 
all seven transcription factors was later shown to be the most common binding pattern 
and is associated with differential expression of genes in haematopoietic stem/progenitor 
cells (Beck et al. 2013).  
 
1.3.6 RUNX1 Interacts with Epigenetic Modifiers 
RUNX1 has also been shown to influence transcription of target genes through 
interactions with histone modifying enzymes such as HATs and HDACs, which alter the 
epigenetic state of target genes. To activate gene expression, RUNX1 interacts with the 
histone acetyltransferases p300 and CBP (Kitabayashi et al. 1998, Oakford et al. 2010). 
A study by Kitabayashi et al. (1998) used immunoprecipitation analysis to show that 
RUNX1 interacts with the histone acetyltransferase p300 and CBP. The C-terminal region 
of RUNX1 was required for the interaction with p300 and cooperation of RUNX1 and 
p300 is essential for RUNX1 activation of the MPO promoter, as RUNX1 or p300 alone 
did not transactivate the promoter (Kitabayashi et al. 1998). Another study analysing 
RUNX1 regulation of the GM-CSF gene found that RUNX1 is required for the 
hyperacetylation of the GM-CSF promoter via the interaction with CBP (Oakford et al. 
2010). CBP was found to co-activate the GM-CSF promoter and the presence of CBP at 
the promoter was associated with RUNX1 binding and histone hyperacetylation (Oakford 
et al. 2010). It was suggested that CBP is both required for the acetylation of chromatin 
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at the promoter and the acetylation of RUNX1 which increases transcriptional activity of 
the transcription factor (Oakford et al. 2010). 
 
While RUNX1 has most commonly been described as a transcriptional activator, it can 
also repress gene expression. This has been shown to be dependent on the interaction with 
the mSin3A co-repressor, which forms a repressor complex with HDACs, and SUV39H1 
histone methyltransferase (Lutterbach et al. 2000, Reed-Inderbitzin et al. 2006). A study 
by Lutterbach et al. (2000) demonstrated using immunoprecipitation assays that RUNX1 
interacts with the co-repressor mSin3A and RUNX1 repression of the p21Waf1/Cip1 
promoter is dependent on this interaction. A RUNX1 deletion mutant, which could not 
interact with mSin3A, failed to repress p21Waf1/Cip1 transcription (Lutterbach et al. 2000). 
Furthermore, RUNX1 has been shown to play a role in gene repression and possibly gene 
silencing during cell development via the interaction with repressive histone and DNA 
modifiers. To repress and silence the CD4 gene during T-cell maturation, RUNX1 
interacts with HDACs as well as the histone methyltransferase SUV39H1, which is 
involved in gene silencing (Reed-Inderbitzin et al. 2006). 
 
1.3.7 Involvement of RUNX1 in Higher Order Chromatin Structures 
RUNX1 is also involved in the formation of higher order chromatin structures to promote 
the expression of genes important in haematopoiesis. RUNX1 has been shown to be 
important for some enhancer-promoter interactions. A study by Levantini et al. (2011) 
found that RUNX1 regulates the CD34 gene through an enhancer located 17.4-19.6 kb 
downstream of the transcription start site, which is required for CD34 expression. It was 
discovered that the downstream enhancer region physically interacts with the CD34 
promoter and targeted mutagenesis of RUNX1 consensus sites leads to disruption of this 
interaction and decreased CD34 expression in haematopoietic cells (Levantini et al. 
2011). RUNX1 is therefore required to facilitate the interaction between the downstream 
CD34 enhancer and CD34 promoter, to enable CD34 expression in haematopoietic cells. 
 
Additionally, RUNX1 has been implicated in chromatin unfolding of transcription factor 
genes vital for haematopoiesis during development. A study by Hoogenkamp et al. (2009) 
demonstrated that transient binding of RUNX1 to PU.1 regulatory elements is required 
for the early chromatin unfolding and expression of the PU.1 gene important for 
myelopoiesis. Hoogenkamp et al. (2009) suggest that once the haematopoietic 
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transcription factors are expressed during development, stable transcription factor 
complexes are formed on the genes and active chromatin is maintained without RUNX1 
(Hoogenkamp et al. 2009). 
 
1.3.8 Disruption of RUNX1 in Leukaemia 
Not surprisingly, disruption to RUNX1 leads to genome-wide changes in gene expression 
due to altered regulation of its target genes. For example, the RUNX1-ETO fusion 
protein, which is produced from the t(8;21) chromosomal translocation, can bind to 
RUNX1 target genes since the RUNX1 DNA binding domain is retained, however, its 
effect on gene expression is different to RUNX1 due to the presence of the ETO protein. 
As demonstrated in Figure 1.3, RUNX1 normally interacts with transcriptional co-
activators such as p300 and CBP to activate gene expression (Kitabayashi et al. 1998), 
however, due to the replacement of the transactivation domain of RUNX1 with ETO, 
expression of target genes is generally repressed due to interactions with repressive co-
factors such as N-CoR, mSin3A and HDACs (Lutterbach et al. 1998, Wang et al. 1998). 
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Figure 1.3 – RUNX1 and RUNX1-ETO effects on transcription. Schematic of A) 
RUNX1 and B) RUNX1-ETO regulation of RUNX1 target genes. RUNX1 and RUNX1-
ETO both bind to RUNX1 consensus sites at target genes and heterodimerise with CBFβ. 
RUNX1 interacts with histone acetyltransferases CBP and p300 to activate gene 
expression, while RUNX1-ETO blocks RUNX1 binding and represses gene expression 
by interacting with co-repressors mSin3A, N-CoR and HDACs. DNA is shown as aqua 
lines wrapped around nucleosomes (blue balls). Transcription start site is shown by the 
black right-angled arrow. 
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1.3.9 Use of Genome-Wide Studies to Understand RUNX1 Function 
Although many target genes of RUNX1 have been identified through candidate gene 
analysis, the full repertoire of RUNX1 controlled genes remains to be determined. More 
recently, the advent of genome-wide technology has facilitated the understanding of the 
spectrum of genes under the control of RUNX1. 
 
In the 2000’s, microarray studies by Ichikawa et al. (2006), Michaud et al. (2008), Valk 
et al. (2004) and Wotten et al. (2008) aimed to identify gene expression profiles of 
haematopoietic cells with RUNX1 or CBFβ disrupted. Through these studies, genes 
involved in several cellular pathways were identified as potential RUNX1 target genes. 
Interestingly, genes which play an important role in the cell cycle, cell growth and 
proliferation, and DNA replication and repair had altered expression in haematopoietic 
cells with RUNX1 or CBFβ disrupted, suggesting that RUNX1 may be important in 
regulating these pathways (Ichikawa et al. 2006, Michaud et al. 2008, Valk et al. 2004, 
Wotton et al. 2008). Disruption to these pathways are known to play key roles in cancer 
development (Evan and Vousden 2001, Molinari 2000) and it has been demonstrated that 
disruption to RUNX1 leads to increased cell proliferation (Matsushita et al. 1995, Mulloy 
et al. 2002, Okuda et al. 1998, Rhoades et al. 2000), inhibition of cell differentiation 
(Burel et al. 2001, Heidenreich et al. 2003, Tonks et al. 2004, Westendorf et al. 1998) 
and inhibition of apoptosis (Klampfer et al. 1996, Matsushita et al. 1999). 
 
Interestingly, genes involved in cell adhesion and migration were also found to have 
altered expression in haematopoietic cells when RUNX1 or CBFβ gene expression was 
disrupted, suggesting that RUNX1 may also regulate genes involved in these pathways 
(Ichikawa et al. 2006, Michaud et al. 2008, Valk et al. 2004, Wotton et al. 2008). While 
genes involved in cell adhesion and migration pathways have been linked to cancer cell 
metastasis (Albelda 1993, Hood and Cheresh 2002), the role of RUNX1 in cell adhesion 
and migration in haematopoietic cells has not been explored. Many of these genes 
identified to be involved in cell adhesion and migration were found to encode cell surface 
or extracellular ligands (Ichikawa et al. 2006, Michaud et al. 2008, Valk et al. 2004, 
Wotton et al. 2008). Expression of two genes encoding integrin adhesion receptors, 
ITGB4 and ITGB5, were commonly identified to be disrupted in these microarray studies, 
therefore suggesting that they may be regulated by RUNX1 (Ichikawa et al. 2006, 
Michaud et al. 2008, Valk et al. 2004, Wotton et al. 2008). 
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In addition, previous microarray studies conducted in our laboratory have also identified 
the integrin genes, ITGB4 and ITGB5, as potential targets of RUNX1 (Oakford and 
Holloway, unpublished). RUNX1 expression was knocked down in Jurkat T cells by 
transfecting the cells with siRNAs targeted to RUNX1. It was found that the decrease in 
RUNX1 expression caused an increase in ITGB4 and ITGB5 expression.  
 
 
1.4 RUNX1 and Integrins 
 
1.4.1 Integrins 
Integrins are transmembrane adhesion receptors which are involved in cell-ECM and cell-
cell interactions (Barczyk et al. 2010, Takada et al. 2007). Integrin receptors are 
heterodimeric and consist of non-covalently bound alpha and beta glycoprotein subunits 
(van der Flier and Sonnenberg 2001). Integrins are comprised of three domains: an 
extracellular ligand-binding globular head, a hydrophobic transmembrane domain and an 
intracellular cytoplasmic tail (Scales and Parsons 2011). The integrins form a large family 
and in humans at least 18 α and 8 β subunits have been identified, forming at least 24 
heterodimeric receptors (Figure 1.4) (Shimaoka and Springer 2003). Integrins function in 
linking the exterior of the cells to the interior by connecting the ECM or other cells to the 
cytoskeleton (Margadant et al. 2011, Takada et al. 2007, van der Flier and Sonnenberg 
2001). Integrins bind to specific ligands and therefore can be grouped based on their 
ligand specificity, which is shown in Figure 1.4. In humans, there are laminin-binding 
integrins, collagen-binding integrins, leukocyte-specific integrins and 
arginylglycylaspartic acid (RGD)-recognising integrins (Barczyk et al. 2010, Takada et 
al. 2007). 
 
Although integrins play an important role in maintaining tissue integrity through adhesive 
interactions between other cells and the ECM, they also play a vital role as signalling 
receptors (Ivaska and Heino 2010). Integrins can transmit bi-directional signals across the 
plasma membrane through inside-out and outside-in signalling (Hu and Luo 2013). 
Inside-out signalling generally causes the activation of integrins in the low-affinity state, 
through signalling from within the cell, which results in the conformational change of the 
integrins into a high affinity state (Hu and Luo 2013). Once integrins are activated and 
have a high affinity for ligands, binding of extracellular ligands to integrins then transmit 
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signals into the cell through outside-in signalling (Hu and Luo 2013). Outside-in 
signalling can have a significant effect on the cell and it has been found to modulate cell 
adhesion, proliferation, survival, shape, polarity, motility, differentiation and gene 
expression (Hu and Luo 2013, Takada et al. 2007). Integrins play important roles in many 
biological pathways such as development, angiogenesis, inflammation, tissue repair and 
also homeostasis of the haematopoietic system (Shimaoka and Springer 2003). 
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Figure 1.4 – The integrin family. This diagram represents the various α and β subunits 
produced by specific integrin genes in humans. The solid lines joining the different 
subunits depict the formation of a heterodimer and the different type of heterodimeric 
integrin receptors are shown. Taken from Barczyk et al. (2010). 
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1.4.2 The Role of Integrins in Haematopoiesis 
The interactions of integrins on haematopoietic progenitors and stem cells with bone 
marrow ligands is important for the regulation of haematopoiesis (Hurley et al. 1995, 
Prosper and Verfaillie 2001). In the bone marrow, haematopoietic progenitors grow in 
close proximity to stromal cells which produce regulatory cytokines that have a positive 
and negative effect on the proliferation and differentiation of the haematopoietic 
progenitors (Eaves et al. 1991, Hurley et al. 1995, Watowich et al. 1996). Integrins on 
haematopoietic cells can bind to ligands on stromal cells as well as the stromal ECM and 
these interactions can also have an effect on the proliferation and differentiation of 
haematopoietic cells (Verfaillie et al. 1994).  
 
In early research into the role of integrins in haematopoiesis, it was found that 
proliferation of haematopoietic cells was significantly higher when the cells were cultured 
away from stromal cells compared to cells which were adherent to the stroma, suggesting 
that close stroma and haematopoietic progenitor cell interactions could function in 
regulating or inhibiting haematopoietic cell proliferation (Hurley et al. 1995, Verfaillie 
and Catanzaro 1996). It was also found that the integrin receptor α4β1, also known as 
very late activation antigen-4 (VLA-4), is responsible for the adhesion of haematopoietic 
cells to the stroma, and thus could play a role in the regulation of haematopoietic 
proliferation (Hurley et al. 1995). Further studies revealed that adhesion of 
haematopoietic cells to the bone marrow ECM component fibronectin via α4β1 receptors 
is important for the adhesion and retention of haematopoietic cells in the bone marrow, 
as well as the regulation of proliferation and differentiation of haematopoietic cells 
(Hurley et al. 1995, Krämer et al. 1999, Schofield et al. 1998, Verfaillie et al. 1991, 
Weinstein et al. 1989, Williams et al. 1991).  
 
As well as the proliferation and differentiation of haematopoietic cells, integrins have 
been found to play a role in the homing and mobilisation of haematopoietic cells in the 
bone marrow. During steady-state haematopoiesis, there is a continuous mobilisation of 
haematopoietic stem cells into the peripheral blood and homing of haematopoietic stem 
cells from the peripheral blood back into the bone marrow (Kondo et al. 2003, Qian et al. 
2006). The role of the continuous mobilisation and homing of haematopoietic stem cells 
is not well understood, but it is a physiological process which occurs in adults and is 
utilised in stem cell transplantation for individuals with leukaemia (Bonig and 
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Papayannopoulou 2012, Kondo et al. 2003). It is thought that the constant mobilisation 
and homing of haematopoietic stem cells in the adult is important for sustained normal 
haematopoiesis (Papayannopoulou and Nakamoto 1993).  
 
The integrin receptor α4β1 has been found to play a central role in mobilisation and 
homing of haematopoietic cells. Deletion or inhibition of α4 integrin results in the 
mobilisation and accumulation of haematopoietic stem cells in the blood stream 
(Papayannopoulou and Nakamoto 1993, Scott et al. 2003). Furthermore, in 
transplantation studies in mice, the conditional deletion of α4 integrin impairs the homing 
of haematopoietic stem cells to the bone marrow (Scott et al. 2003). Studies have shown 
that the expression of the α4 integrin and the activation state of the α4β1 integrin receptor 
is correlated with the mobilisation and homing of haematopoietic stem cells to the bone 
marrow. Haematopoietic stem cells in the peripheral blood have decreased expression of 
α4 and the α4β1 receptor is deactivated, whereas haematopoietic stem cells in the bone 
marrow have increased expression of α4 and the α4β1 receptor is in an activated state 
(Lichterfeld et al. 2000, Prosper et al. 1998). Similar results have been reported for the 
β1 integrin. In transplantation studies, β1 null haematopoietic stem cells failed to engraft 
in irradiated recipient mice due to impaired homing of the haematopoietic stem cells to 
the bone marrow (Potocnik et al. 2000), suggesting both α4 and β1 are important for 
mobilisation and homing of haematopoietic stem cells.  
 
In addition to the α4β1 receptor, the α5β1 receptor, also known as VLA-5, is also 
expressed on haematopoietic cells and plays a role in the homing and mobilisation of 
haematopoietic cells in the bone marrow (Levesque et al. 1995, Van der Loo et al. 1998, 
Wierenga et al. 2006). Additionally, the α6β1 receptor, which is expressed in human and 
mouse haematopoietic stem and progenitor cells, is involved in homing of foetal liver 
multi-lineage repopulating haematopoietic stem cells in mice (Qian et al. 2006). 
Inhibition of the α6 integrin by α6 antibodies was found to inhibit stem cell homing, but 
did not have an effect on the mobilisation of stem cells in the bone marrow (Qian et al. 
2006). Further studies of α6 integrin in the bone marrow determined that α6 is not 
required for the homing and engraftment of multi-lineage repopulating haematopoietic 
stem cells and is only functional during the homing of foetal liver haematopoietic stem 
cells (Qian et al. 2007). 
 
 31 
 
1.4.3 Involvement of Integrins in Leukaemia 
Not surprisingly, given their physiological roles, integrins also play key roles in cancer 
development and progression. Integrins have been implicated in cancer cell proliferation, 
invasion, migration and survival (Desgrosellier and Cheresh 2010, Guo and Giancotti 
2004, Hood and Cheresh 2002). The up-regulation and down-regulation of integrins has 
been linked to many cancers including leukaemia, melanoma, glioblastoma, non-small-
cell lung carcinoma and breast, colon, kidney, lung, ovarian, cervical, pancreatic, prostate 
and skin cancer (Desgrosellier and Cheresh 2010, Mizejewski 1999). Tumour cells 
increase expression of integrins that aid in proliferation, survival and migration, whereas 
integrins that inhibit cancer growth, survival and migration are down-regulated (Guo and 
Giancotti 2004). Integrin expression on cancer-associated cells can also contribute to the 
development of cancer by facilitating angiogenesis, desmoplasia, lymphangiogenesis and 
inflammation (Desgrosellier and Cheresh 2010). 
 
As mentioned previously, integrins regulate haematopoiesis through promoting the 
interaction of haematopoietic cells with bone marrow stromal cells, as well as the stromal 
ECM. Disruption of these interactions necessarily disturbs haematopoietic processes. Not 
surprisingly then, the dysregulation and disruption to integrin genes has been identified 
in many types of leukaemia including acute myeloid leukaemia (Brouwer et al. 2001), B 
cell chronic lymphocytic leukaemia (CLL) (Csanaky et al. 1997), B cell acute 
lymphoblastic leukaemia (Geijtenbeek et al. 1999) and chronic myeloid leukaemia 
(CML) (Verfaillie et al. 1992). Although the involvement of integrin genes in leukaemia 
was identified more than 20 years ago, the importance of integrins in leukaemia 
development, therapy resistance and potential biomarkers/therapeutic targets for the 
disease have only been elucidated more recently. 
 
In CML, the haematopoietic cells are released prematurely from the bone marrow and 
proliferate aberrantly due to decreased adhesion to the bone marrow stroma and 
fibronectin through β1 heterodimeric receptors (Bhatia et al. 1996, Verfaillie et al. 1992). 
In normal haematopoietic development, engagement of β1 receptors on haematopoietic 
stem cells with fibronectin within the bone marrow causes decreased cell proliferation 
due to β1-mediated inhibitory signalling (Hurley et al. 1995). CML cells also express the 
integrins α2 and α6 which bind to laminin and collagen, whereas the expression of these 
integrins are usually absent from normal haematopoietic cells (Verfaillie et al. 1992). It 
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is therefore suggested that aberrant proliferation of CML haematopoietic cells could be 
due to a combination of a lack of inhibitory cell proliferation signals due to decreased 
adhesion of haematopoietic cells to stroma and fibronectin through β1 receptors, and a 
gain of adhesive interactions with laminin and collagen due to an up-regulation of α2 and 
α6 integrins, therefore causing an early release of haematopoietic cells from the bone 
marrow stroma. 
 
In addition to altered adhesion of haematopoietic cells in CML, altered adhesion of 
haematopoietic cells has also been observed in B-lineage ALL. Similar to the decrease in 
adhesion through β1 receptors observed in CML (Bhatia et al. 1996, Verfaillie et al. 
1992), it has also been shown that individuals with ALL have decreased adhesion through 
α4β1 integrin receptor (Geijtenbeek et al. 1999). It was found that 7 out of 20 individuals 
with ALL possessed leukaemic cells which expressed normal levels of the α4β1 integrin 
receptor, however the receptor was not functional in those cells, suggesting a defect in β1 
integrin signalling (Geijtenbeek et al. 1999). In addition to altered function of α4β1, high 
levels of the integrin receptor have also been observed in children with B-cell precursor 
ALL at first relapse and is associated with poor outcome (Shalapour et al. 2011). It was 
discovered that high expression of α4β1 at first relapse was associated with poor 
prognosis, poor response to therapy and decreased likelihood of event-free and overall 
survival (Shalapour et al. 2011). 
 
In addition to CML and ALL, altered expression of the α4β1 integrin receptor has also 
been associated with CLL (Baldini et al. 1992, Eksioglu-Demiralp et al. 1996). In an early 
study it was shown the α4β1 receptor was expressed at higher levels in 37.1% of 
individuals with B-cell CLL compared to normal B cells (Baldini et al. 1992). In addition, 
the study also reported that the α3β1 integrin receptor was expressed at higher levels in 
87.1% of individuals with CLL compared to normal B cells (Baldini et al. 1992). 
Furthermore, another study conducted a few years later, discovered that in B-cell CLL, 
expression of the α4 subunit is related to different stages of the disease (Eksioglu-
Demiralp et al. 1996). Individuals in the early stage of CLL were shown to have lower 
expression of α4 compared to normal controls, whereas individuals in the advanced stage 
of CLL were shown to have higher expression of α4 compared to normal controls 
(Eksioglu-Demiralp et al. 1996). In support of these findings, recent studies have shown 
that high expression of α4 in individuals with CLL is associated with advanced clinical 
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stage of the disease as well as aggressive disease biology (Baumann et al. 2016) and also 
is associated with poor overall survival (Dal Bo et al. 2016).  
 
Changes in α4β1 expression has also been reported in AML, however the studies have 
reported conflicting results. In earlier studies it was found that individuals with AML 
positive for α4β1 had significantly lower complete remission rates, higher relapse rates 
and lower overall survival rates at 5 years (Matsunaga et al. 2003). However, in contrast 
to these findings, more recent studies reported that in paediatric AML, individuals with 
high α4β1 expression were found to have a lower relapse rate and higher disease-free 
survival after 3 years compared to individuals with low α4β1 expression (Walter et al. 
2010). Furthermore, in newly diagnosed adult individuals with AML, individuals with 
favourable or intermediate cytogenetic risk were found to have higher levels of α4β1 
expression (Bae et al. 2015). In addition, individuals with higher levels of α4β1 had a 
higher probability of complete remission, showed longer relapse-free survival and higher 
overall survival rates when compared to individuals with lower levels of α4β1 (Bae et al. 
2015). The differences in the outcomes associated with α4β1 expression may be due to 
other genetic abnormalities present in these individuals contributing to the different 
disease states. 
 
In addition to the α4β1 receptor, increased expression of integrin genes ITGAM, ITGAL, 
ITGB4 and ITGA6 have also been associated with AML, with increased expression of 
these integrins associated with poorer outcomes (Brouwer et al. 2001, Chen et al. 2013, 
Paietta et al. 1998, Xu et al. 2015, Yamakawa et al. 2012). Increased levels of ITGAM 
integrin gene has been associated with lower complete remission rate and shorter overall 
survival (Chen et al. 2013, Paietta et al. 1998, Xu et al. 2015). Additionally, the ITGAL 
integrin gene has been associated with a significantly shorter five-year survival in patients 
with high expression of the integrin gene (Brouwer et al. 2001). Furthermore, ITGB4 and 
ITGA6 integrin genes, which form the α6β4 integrin receptor, has been associated with 
increased drug resistance in AML with high EVI1 expression (Yamakawa et al. 2012). 
 
1.4.3.1 Involvement of Integrins in Drug Resistance in Leukaemia 
The importance of integrins in drug resistance has only been highlighted in recent years. 
In AML, approximately 60-70% of patients will relapse due to minimal residual disease 
(Venditti et al. 2000). AML cells have been shown to bind to bone marrow ECM 
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components fibronectin and laminin through α4β1 and α5β1 integrin receptors (Bendall 
et al. 1993). It has also been shown that AML cells bind to bone marrow stromal cells 
through a combination of β1 and β2 integrin mechanisms, and this is also true for B-CLL 
cells (Bendall et al. 1993, Lagneaux et al. 1999). In a more recent study, the α4β1 receptor 
was shown to contribute to drug resistance through the interaction with fibronectin 
expressed by bone marrow stromal cells (Matsunaga et al. 2003). Interaction of α4β1 on 
AML cells with fibronectin activated the PI-3K/AKT/Bcl-2 signalling pathway, therefore 
resulting in resistance to drug-induced apoptosis (Matsunaga et al. 2003). More recently 
it was found that that the inhibition of α4β1 integrin receptor by specific inhibition of the 
α4 integrin sensitised chemotherapy-resistant pre-B ALL cells to chemotherapy (Hsieh et 
al. 2013), further confirming the importance of α4β1 in leukaemia, particularly AML and 
ALL/CLL. 
 
Minimal residual disease is also responsible for drug resistance observed in CML and is 
also caused by β1-integrin mediated adhesion but through α5β1 integrin receptor to 
fibronectin of bone marrow stromal cells (Damiano et al. 2001). It has been shown that 
the BCR-ABL fusion protein frequently observed in CML increases β1-integrin mediated 
adhesion to stromal cells (Fierro et al. 2008), and interaction of CML cells with 
fibronectin of stromal cells results in the cells becoming resistant to apoptosis induced by 
BCR-ABL inhibitors, DNA damaging agents and γ-irradiation (Damiano et al. 2001). 
The use of a chemotherapeutic drug, arsenic trioxide, on a CML cell line, K562, was 
shown to overcome cell adhesion-mediated drug resistance by down-regulating the 
expression of β1 integrin (Guo-Bao et al. 2010). Additionally, in ALL which is positive 
for the BCR-ABL fusion protein, the inhibition of α5β1 integrin, by the use of a α5 
antibody, inhibited adhesion of leukaemic cells to fibronectin (Hu and Slayton 2014). The 
use of the α5 antibody was found to act synergistically with the chemotherapeutic drug 
imatinib to induce apoptosis in the leukaemic cells (Hu and Slayton 2014). It was 
suggested that by altering the interactions of leukaemic cells positive for BCR-ABL with 
the bone microenvironment, it may increase their susceptibility to therapy (Hu and 
Slayton 2014). 
 
Taken together, these studies suggest that integrin receptors α4β1 and α5β1 play 
important roles in cell adhesion-mediated drug resistance in leukaemia. The expression 
and function of β1 integrin receptors, particularly α4β1, is disrupted in leukaemia, 
contributing to the irregular development of the haematopoietic cells, due to a change in 
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interactions of the haematopoietic cells with the bone marrow stroma. However, 
leukaemic cells have also been shown to up-regulate integrin receptors, particularly α4β1, 
to increase binding to bone marrow stroma components, which allows the cells to become 
drug resistant and is thought to contribute to minimal residual disease. In fact, it has 
recently been proposed that leukaemic cells may manipulate the expression of integrin 
genes during the course of the malignancy for their development and survival, as shown 
in Figure 1.5 (Brachtl et al. 2014). Leukaemic cells may up-regulate α4β1 to bind to bone 
marrow stromal cells which increases their survival and resistance to drugs (Brachtl et al. 
2014). The leukaemic cells may then down-regulate α4β1 expression to decrease their 
interaction with the bone marrow, therefore allowing the cells to proliferate and then leave 
the bone marrow, migrating to the blood stream (Brachtl et al. 2014). The leukaemic cells 
may then migrate back into the bone marrow by increasing α4β1 expression which allows 
the cells to bind to the endothelial cells of the bone marrow and enter the bone marrow 
through transendothelial migration (Brachtl et al. 2014). 
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Figure 1.5 – Mobilisation and homing of leukaemic cells. Figure adapted from Brachtl 
et al. (2014) shows the proposed disease development model of CLL. CLL cells bind to 
endothelial cells of the bone marrow/lymph node through α4β1 integrin receptors (ITGA4 
is expressed) and CLL cells roll along the endothelial cells where the cells are arrested. 
The CLL cells then enter the bone marrow/lymph node through transendothelial 
migration, which may contribute, to CD38 expression. A macromolecular complex 
(MMC) is important for the invasion of CLL cells within the bone marrow and lymphoid 
tissue. Binding of CLL cells to bone marrow or lymph node cells through α4β1 and CD38 
receptors, as well as the MMC, promotes survival. Expression of CD38 promotes 
proliferation of CLL cells within the bone marrow, and decrease of ITGA4 expression 
allows the CLL cells to detach from the bone marrow/lymphoid cells and migrate to the 
blood stream. ITGA4 and CD38 in light grey text shows hypothesised roles of the 
receptors. MMC: macromolecular complex including ITGA4, ITGB1, CD38, MMP9 and 
CD44v. 
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1.4.4 Regulation of Integrin Genes by Epigenetic Mechanisms 
It is known that gene expression is controlled by epigenetic and transcriptional 
mechanisms, however the specific mechanisms that control integrin genes are relatively 
uncharacterised. However, recent evidence suggests that integrin genes may be regulated 
by epigenetic mechanisms such as DNA methylation and histone modification. These 
mechanisms have also been found to be disrupted in many types of cancer. 
 
The ITGA4 gene, which encodes the α4 subunit, is aberrantly methylated in human 
gastric cancer (Park et al. 2004). It has been reported that ITGA4 gene expression is lost 
in gastric cancer cell lines due to CpG methylation-dependent silencing (Park et al. 2004). 
Hypermethylation of the ITGA4 gene is also observed in early stage oesophageal 
squamous cell carcinoma (Lee et al. 2008) and prostate cancer (Mostafavi-Pour et al. 
2015). In CLL with trisomy 12, expression of the ITGA4 gene was found to increase due 
to hypomethylation of the ITGA4 gene, whereas low expression of ITGA4 in CLL without 
trisomy 12 was due to increased methylation of the ITGA4 gene (Zucchetto et al. 2013). 
In addition, integrin genes ITGA7 and ITGA2 have been found to be regulated by 
methylation. In malignant pleural mesothelioma, cells have increased migratory potential 
due to the down-regulation of ITGA7 caused by hypermethylation (Laszlo et al. 2015). It 
was found when cells have forced ITGA7 expression, cell motility was inhibited (Laszlo 
et al. 2015). In prostate cancer cell lines, expression of the ITGA2 gene was found to be 
correlated with methylation of key CpG sites within the ITGA2 promoter (Chin et al. 
2015).  
 
In addition to DNA methylation, histone modification is another epigenetic mechanism 
found to regulate integrin gene expression. In hepatocellular carcinoma cell line (Hep3B), 
treatment with a HDAC inhibitor resulted in the activation and increased expression of 
integrin genes ITGA4, ITGB2 and ITGB6, while resulting in a down-regulation of 
ITGA6, ITGA10 and ITGB8 integrin genes (Lin et al. 2005). Furthermore, treatment of 
haematopoietic stem cells and acute myeloid leukaemia blast cells with a HDAC inhibitor 
resulted in down-regulation of integrin receptor α4β1 (Mahlknecht and Schönbein 2008). 
Decreased expression of α4β1 was associated with decreased adhesion to mesenchymal 
stromal cells. It was therefore concluded that HDAC inhibitor treatment may inhibit stem 
cell homing, but it may improve peripheral blood stem cell mobilisation, which could 
help reduce minimal residual disease from AML (Mahlknecht and Schönbein 2008). 
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1.4.5 Regulation of Integrins by RUNX Transcription Factors 
Through previous studies, both integrin genes and RUNX transcription factors have been 
found to be commonly disrupted in leukaemia (Brouwer et al. 2001, Csanaky et al. 1997, 
Dal Cin et al. 2001, Geijtenbeek et al. 1999, Miyoshi et al. 1991, Osato et al. 1999, 
Verfaillie et al. 1992), suggesting that both classes of proteins play important roles in 
leukaemogenesis. Interestingly, there is evidence to suggest that RUNX transcription 
factors may regulate integrin genes in haematopoietic cells. In lymphoid and myeloid 
cells, the ITGAL integrin gene has been found to be regulated by RUNX1 and RUNX3, 
respectively (Puig-Kröger et al. 2000, Puig-Kröger et al. 2003). Both RUNX1 and 
RUNX3 bind to the ITGAL promoter, and disruption to this site resulted in a significant 
decrease in promoter activity (Puig-Kröger et al. 2000, Puig-Kröger et al. 2003). When 
RUNX3 was overexpressed in the human lymphoid cell line, U937, the expression of 
ITGAL was also increased, and chromatin immunoprecipitation assays confirmed 
RUNX3 binding to the ITGAL promoter in vivo (Puig-Kröger et al. 2003). In mature 
monocyte-derived dendritic cells, the integrin gene ITGA4 has also been found to be 
targeted by the RUNX3 transcription factor (Domínguez-Soto et al. 2005). RUNX3 could 
activate the ITGA4 promoter and increased expression of ITGA4 in mature monocyte-
derived dendritic cells correlated with increased expression of RUNX3 (Domínguez-Soto 
et al. 2005). Altogether, these studies demonstrate that RUNX transcription factors have 
the potential to regulate integrin genes, which suggests that the disruption to RUNX 
transcription factors in leukaemia could lead to altered expression of integrin genes due 
to altered regulation by RUNX transcription factors. 
 
 
1.5 Research Aims 
 
RUNX1 plays an important role in haematopoiesis and is one of the most commonly 
disrupted genes in leukaemia. Understanding the mechanism by which it regulates gene 
expression in key pathways, is crucial for understanding its role in leukaemia 
development and identifying potential therapeutic targets in the disease. Microarray 
studies conducted by our team, and others, have identified several integrin genes as 
putative novel RUNX1 target genes. As detailed above, integrins are important for 
haematopoiesis by facilitating interactions between haematopoietic cells and extracellular 
matrix components of the bone marrow and haematopoietic tissues. Integrin expression 
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is also altered in many leukaemias, however the regulation of integrin gene expression is 
poorly understood. Hence, the hypothesis of this project is: The RUNX1 transcription 
factor and epigenetic mechanisms cooperatively regulate the expression programs of key 
integrins in haematopoietic cells and disruption of RUNX1 and epigenetic mechanisms is 
responsible for altered expression of these integrins in leukaemic cells. To address this 
hypothesis, three main aims were addressed: 
 
1. Determine the integrin genes that are regulated by RUNX1 in haematopoietic 
cells. 
2. Characterise RUNX1 regulation of selected integrin genes in haematopoietic 
cells. 
3. Determine the epigenetic mechanisms that regulate the selected integrin genes in 
haematopoietic cells. 
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Chapter 2 
 
Materials and Methods 
 
 
2.1 Cell Culture 
 
Commercially available leukaemic cell lines were used to analyse integrin and RUNX1 
expression, as well as RUNX1 and epigenetic regulation of integrin genes. 
 
2.1.1 Cell Lines and Culture Conditions 
Cells lines K562, KG-1a and Kasumi-1 were purchased from American Type Culture 
Collection and were cultured in Gibco® Roswell Park Memorial Institute (RPMI) 1640 
medium (Life Technologies, USA) containing D-glucose (2 g/L), glutathione (1 mg/L), 
HEPES (6 g/L) and sodium bicarbonate (2 g/L) which was supplemented with 10% heat-
inactivated (56 ˚C for 30-60 minutes) foetal bovine serum (FBS; 20% for Kasumi-1 cells; 
Life Technologies, USA) and penicillin (100 U/mL)/streptomycin (100 µg/mL, Sigma-
Aldrich, USA). K562 cells were subcultured every 2-3 days and were maintained between 
1x105 and 1x106 cells/mL; KG-1a cells were also subcultured every 2-3 days and were 
maintained between 2.0x105 and 1.0x106 cells/mL; and Kasumi-1 cells were subcultured 
once a week and maintained between 2.0x105 and 2.0x106 cells/mL. All cell lines were 
cultured in a humidified incubator at 37˚C and 5% CO2. 
 
2.1.2 Cell Treatments 
2.1.2.1 Phorbol 12-myristate 13-acetate Treatment 
The effect of phorbol 12-myristate 13-acetate (PMA) treatment on integrin expression 
was examined in leukaemic cell lines. K562 and KG-1a cells lines were subcultured to 
2x105 cells/mL and were treated with PMA (20 ng/mL; Boehringer Mannheim, Australia) 
for 72 hours. Kasumi-1 cells were subcultured to 4x105 cells/mL and were treated as 
described for K562 and KG-1a cell lines. 
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2.1.2.2 5-aza-2'-deoxycytidine and Trichostatin A Treatment 
To determine if integrin gene expression is affected by the DNA methylation and histone 
acetylation status of the gene, leukaemic cell lines were treated with epigenetic inhibitors, 
5-aza-2’-deoxycytidine (DAC) and Trichostatin A (TSA).  
 
DAC, which is currently being used as a therapy for AML (Blum et al. 2010, Cashen et 
al. 2010, Issa et al. 2004), is a potent DNA methylation inhibitor. Once taken up by cells, 
DAC is metabolised to form DAC-triphosphate which can be used as substrate for the 
DNA replication machinery, and therefore can be incorporated into the DNA, replacing 
normal cytosines (Stresemann and Lyko 2008). Azacytosine-guanine dinucleotides are 
recognised by DNA methyltransferases which bind to the azacytosine via a covalent bond 
(Stresemann and Lyko 2008). While this covalent bond is normally broken during DNA 
methylation, the DNA methyltransferase remains covalently bound to azacytosine and is 
unable to methylate the DNA (Stresemann and Lyko 2008). Furthermore, the entrapment 
of the DNA methyltransferases triggers DNA damage signalling which results in 
degradation of the methyltransferases (Stresemann and Lyko 2008). The action of DAC 
therefore leads to a global loss of methylation during DNA replication (Stresemann and 
Lyko 2008). 
 
TSA is a HDAC inhibitor and acts by binding to the catalytic domains within class I and 
II HDACs (Drummond et al. 2005). Binding of TSA to the HDAC inhibits the enzyme’s 
ability to deacetylate histones due to chelation of the zinc cation and displacement of the 
water molecule present in the active site of the enzyme (Drummond et al. 2005). 
 
K562 and KG-1a cells lines were subcultured to 2x105 cells/mL and were treated with 
either DAC (500 ng/mL; Sigma-Aldrich, USA) or TSA (200 ng/mL) or a combination of 
DAC and TSA. Cells were treated with DAC for 72 hours, during which time the cells 
would normally replicate 2-3 times, thus ensuring that the agent was incorporated into the 
DNA, leading to a loss of methylation after cell division. Additionally, both untreated and 
DAC treated cells were treated with TSA for 6 hours. Kasumi-1 cells were subcultured 
to 4x105 cells/mL and were treated as described for K562 and KG-1a cell lines. 
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2.2 Cloning of Promoter/Distal Regions 
 
Integrin promoter/distal regions were cloned into a pXPG plasmid, containing a luciferase 
gene, to use in reporter assays to determine the effects of RUNX1 on these regions. 
 
2.2.1 Primer Design 
Upstream regions of the integrin genes ITGB4, ITGB5, ITGA6, ITGAV and ITGB1 were 
cloned into the pXPG luciferase reporter plasmid (provided by Professor Peter Cockerill, 
Bert et al. 2000). Primers shown in Table 2.1 were designed using the Primer3 program 
(http://bioinfo.ut.ee/primer3-0.4.0/) to amplify a region approximately 500-1000 bp 
upstream of the transcription start site of the integrin genes which incorporated the DNA 
sequence bound by RUNX1 in SKNO-1 cells in the ChIP-seq study by Martens et al. 
(2012) and putative RUNX1 binding sites identified using the MatInspector tool in the 
Genomatix bioinformatics suite (http://www.genomatix.de/). Additional primers also 
described in Table 2.1 were designed either to amplify sub-regions of the already cloned 
integrin promoters or to mutate putative RUNX1 binding motifs. All primers were 
checked for specificity using the NCBI Blast program, nucleotide blast 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The New England Biolabs® (NEB) cutter V2.0 
program (http://nc2.neb.com/NEBcutter2/) was used to identify restriction enzymes that 
did not digest the DNA within the promoter regions but digested the pXPG plasmid once 
in the multiple cloning site. The recognition sites of the selected enzymes were added to 
the 5’ end of the primer sequences along with five random nucleotides to increase 
digestion efficiency (Table 2.1). 
 
2.2.2 PCR Amplification of Promoter/Distal Regions 
2.2.2.1 PCR Amplification Using Phusion Taq 
Genomic DNA (gDNA) was isolated from K562 cells using the AllPrep DNA/RNA Mini 
Kit (Qiagen, USA) and used as template DNA for the PCR amplification of ITGA6, 
ITGAV and ITGB1 promoter regions, and ITGB4 distal regions, while pXPG-ITGB5 
plasmid was used as template DNA for the PCR amplification of ITGB5 Del-5 and Del-
6, pXPG-ITGB4 plasmid was used as template DNA for the PCR amplification of ITGB4 
Del-6 promoter region, and pXPG-ITGA6 was used as template DNA for the PCR 
amplification of ITGA6 Del-1 and ITGA6 Mutant promoter regions. A 20 µL reaction 
containing 1X Phusion® High-Fidelity PCR Master Mix with GC Buffer (New England 
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Biolabs, USA) and 0.5 µM of primers (Table 2.1) was used to amplify DNA (20 ng 
gDNA, 1ng plasmid) following the manufacturer’s instructions. DNA was amplified 
using a Veriti® 96 Well Thermal Cycler (Applied Biosystems™, USA) under the following 
cycling conditions: initial denaturation step of 30 seconds at 98˚C and then 35 cycles 
consisting of 98˚C for 10 seconds, 62-72˚C (depending on the primer set used) for 10 
seconds and 72˚C for 20-30 seconds (30 seconds per kb of DNA to be amplified). 
Following the last cycle, samples were held at 72˚C for 7 minutes. PCR products were 
visualised by agarose gel electrophoresis and amplified promoter/distal regions were 
excised from the gels. PCR products were extracted and purified from the agarose gel 
using the GeneJET Gel Extraction Kit (Thermo Fisher Scientific, USA) following the 
manufacturer’s instructions. Samples were eluted in 10-20 µL of Elution Buffer. 
 
2.2.2.2 PCR Amplification Using GoTaq 
pXPG-ITGB4 plasmid DNA (1 ng, Section 2.3.1) was used as template DNA for the PCR 
amplification of ITGB4 Del-2, Del-3, Del-4 and Del-5 promoter regions, while pXPG-
ITGB5 plasmid DNA (1 ng, Section 2.3.1) was used as template DNA for the PCR 
amplification of ITGB5 Del-4 promoter region. A 20 µL reaction containing 1X GoTaq® 
Green Master Mix (Promega, USA) with 0.45 µM of primers (Table 2.1) was used to 
amplify DNA following the manufacturer’s instructions. DNA was amplified using a 
Veriti® 96 Well Thermal Cycler (Applied Biosystems™, USA) under the following 
cycling conditions: initial denaturation step of 95˚C for 3 minutes and then 35 cycles 
consisting of 95˚C for 15 seconds, 52-62˚C (depending on primer set used) for 30 seconds 
and 72˚C for 30-60 seconds (1 minute per kb of DNA to be amplified). Following the last 
cycle, samples were held at 72˚C for 7 minutes. PCR products were visualised by agarose 
gel electrophoresis to verify a single product amplified. PCR products were purified using 
illustra GFX PCR DNA and Gel Band Purification Kit following the manufacturer’s 
instructions and were eluted in 20 µL of Elution Buffer Type 4.  
 
2.2.3 Ligation of Amplified DNA into pXPG 
Purified PCR products and pXPG luciferase reporter plasmid were first digested 
overnight with the appropriate enzymes detailed in Table 2.1. Digested DNA was purified 
using the illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, UK) 
following the manufacturer’s instructions and samples were eluted in 20 µL of Elution 
Buffer Type 4. For ITGB4 Del-5 Fragment 1 (amplified using Forward1 and Reverse1 
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primers detailed in Table 2.1), PCR products were first digested with SmaI (New England 
Biolabs, USA) for 6 hours, followed by an overnight digestion with XhoI and HindIII 
enzymes (New England Biolabs, USA) to obtain different sized products which could be 
visualised by agarose gel electrophoresis. Digested ITGB4 Del-5 Fragment 1 PCR 
products were subjected to agarose gel electrophoresis using a 3% gel. Digested PCR 
products were electrophoresed at 100V for 1 hour and 40 minutes to allow the separation 
of digested PCR products at the sizes of 466 bp and 436 bp. Digested PCR products at 
the size of 466 bp were excised from the agarose gel, purified using the GeneJET Gel 
Extraction Kit (Thermo Fisher Scientific, USA) following the manufacturer’s instructions 
and were eluted in 10 µL of Elution Buffer.  
 
For the cloning of the ITGB4 distal regions, ITGB4 Del-6 was used as the vector and was 
digested with BamHI and XhoI enzymes (New England Biolabs, USA). The digested 
plasmid was purified using the illustra GFX PCR DNA and Gel Band Purification Kit 
(GE Healthcare, UK) following the manufacturer’s instructions and samples were eluted 
in 20 µL of Elution Buffer Type 4. 
 
Purified digested PCR products and plasmid were quantified using a NanoDrop® ND-
1000 spectrophotometer (NanoDrop Technologies, USA). A 10 µL reaction containing 
1X T4 DNA Ligase Reaction Buffer (New England Biolabs, USA), 1 µL of T4 DNA 
Ligase (New England Biolabs, USA), 50 ng of plasmid (vector) and an appropriate 
volume of PCR products (insert) to ensure a 1:3 vector to insert molar ratio was used. The 
ligation reactions were incubated at room temperature overnight. 
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Promoter/
Distal 
Region 
Primer Sequences 
Fragment 
Size 
RE 
ITGB4 
Del-2 
Forward: 5’ – 
TGCTACTCGAGCTGCTCTCAGAGGACTGACG – 3’ 
924 bp 
SmaI 
HindIII Reverse: 5’ – TGCTAAAGCTTCCCGTCCTGGACCTACCT – 
3’ 
ITGB4 
Del-3 
Forward: 5’ – TGCTACTCGAGATGCAGCCGGTCTGACTC – 
3’ 
223 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTCCCGTCCTGGACCTACCT – 
3’ 
ITGB4 
Del-4 
Forward: 5’ – TGCTACTCGAGATGCAGCCGGTCTGACTC – 
3’ 
92 bp 
XhoI 
HindIII Reverse: 5’ – TGCTCAAGCTTAGGCGGGCAGCGCTTTAT – 
3’ 
ITGB4 
Del-5 
Forward1: 5’ – 
TGCTACTCGAGCTGCTCTCAGAGGACTGACG – 3’ 
924 bp 
XhoI 
SmaI 
HindIII 
Reverse1: 5’ – TGCTAAAGCTTCCCGTCCTGGACCTACCT – 
3’ 
Forward2: 5’ – TGCTACCCGGGATGCAGCCGGTCTGACTC 
– 3’ 
223 bp 
SmaI 
HindIII Reverse2: 5’ – TGCTAAAGCTTCCCGTCCTGGACCTACCT – 
3’ 
ITGB4 
Del-6 
Forward: 5’ – TGCTACTCGAGCTAGCCGATCGGGGCGCT – 
3’ 
319 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTCCCGTCCTGGACCTACCT – 
3’ 
ITGB4 
Mutant 
Forward: 5’ – ATTAACCCGGGGCAGTCCGCGCA – 3’ 
170 bp 
SmaI 
BglII 
Reverse: 5’ – ATTAAAGATCTCCCGCGGCGCCCGCCCA – 
3’ 
Forward: 5’ – ATTAAAGATCTAGCCCTTTCCGGGGGGCGG 
– 3’ 
301 bp 
BglII 
HindIII Reverse: 5’ – TGCTAAAGCTTCCCGTCCTGGACCTACCT – 
3’ 
ITGB4 
Distal-1 
Forward: 5’ – TGCTAGGATCCGAGGCGGCAGCTCATTGT – 
3’ 
334 bp 
BamHI 
XhoI Reverse: 5’ – TGCTACTCGAGGTGCCATTTCAGACCACCT 
– 3’ 
ITGB4 
Distal-2 
Forward: 5’ – 
TGCTAGGATCCCTAGGGCTCGATTTCCAAAG – 3’ 
332 bp 
BamHI 
XhoI Reverse: 5’ – 
TGCTACTCGAGCCTCCTGAGTAGCTGGGAAT – 3’ 
ITGB5 
Del-4 
Forward: 5’ – TGCTACTCGAGCGTCTCGGAGCCCAAGTC – 
3’ 125 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTCCGGGACTCCTAGTGT – 3’ 
ITGB5 
Del-5 
Forward: 5’ – TGCTACTCGAGCTGCTCTCCCTCTCGCAGT 
– 3’ 
464 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTGACTTGGGCTCCGAGACG – 
3’ 
ITGB5 
Del-6 
Forward: 5’ – TGCTACTCGAGTACCCGGAGCAGCCCGCT – 
3’ 77 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTCCGGGACTCCTAGTGT – 3’ 
ITGA6 
Forward: 5’ – 
TGCTACTCGAGCATCCTTGACTTGCGTGACT – 3’ 
939 bp 
XhoI 
HindIII Reverse: 5’ – 
TGCTAAAGCTTCGACAGGTAGAGCAAGCACA – 3’ 
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ITGA6 
Del-1 
Forward: 5’ – TGCTACTCGAGCAGCTGGAGACGCCAGAG 
– 3’ 
404 bp 
XhoI 
HindIII Reverse: 5’ – 
TGCTAAAGCTTCGACAGGTAGAGCAAGCACA – 3’ 
ITGA6 
Mutant 
Forward: 5’ – 
TGCTACTGGAGCATCCTTGACTTGCGTGACT – 3’ 
460 bp 
XhoI 
EcoRV Reverse: 5’ – 
TGCTAGATATCTGCCGAGTAGCACAGAGCGA – 3’ 
Forward: 5’ – 
TGCTAGATATCATTCTGTCCACAGAGGGCGG – 3’ 
495 bp 
EcoRV 
HindIII Reverse: 5’ – 
TGCTAAAGCTTCGACAGGTAGAGCAAGCACA – 3’ 
ITGAV 
Forward: 5’ – 
TGCTACTCGAGACAACAGTCGCACGGAAGTT – 3’ 
545 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTCAAGAGGGCTGAGCTTCG – 
3’ 
ITGB1 
Forward: 5’ – 
TGCTACTCGAGTTAGCCAGTTCCCTTCCAGA – 3’ 
809 bp 
XhoI 
HindIII Reverse: 5’ – TGCTAAAGCTTCGGCGGCTTTAAGTGCTG – 
3’ 
 
 
Table 2.1 – Primers used for molecular cloning. This table details the primers used to 
clone the various regions of the integrin genes. The restriction enzyme recognition site 
within the primers are underlined. Expected PCR product size as well as the restriction 
enzymes used to digest the PCR products are shown. 
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2.2.4 Plasmid Transformation and Isolation 
Ligated DNA (5 µL) was transformed into One Shot® TOP10 Chemically Competent 
E.coli Cells (25 µL; Life Technologies, USA) or JM109 Competent cells (25 µL; 
Promega, USA) following the manufacturer’s instructions. Transformed cells were plated 
on agar plates containing 100 µg/mL ampicillin (Sigma-Aldrich, USA) and incubated 
overnight at 37˚C. Plasmid DNA from 6-12 selected colonies was isolated and purified 
using either Wizard® Plus SV Minipreps Purification System (Promega, USA) or 
QIAprep Spin Miniprep Kit (Qiagen, USA) following the manufacturer’s instructions. 
DNA was eluted in 30-50 µL of nuclease-free water or Buffer EB and 500-1000 ng of 
plasmid DNA was analysed for successfully ligated recombinant plasmid by restriction 
enzyme digestion and agarose gel electrophoresis. 
 
2.2.5 DNA Sequencing 
Plasmid DNA identified as containing insert by restriction enzyme digestion (Section 
2.2.4) was sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, USA) to verify the correct insert sequence was cloned and to ensure there 
were no mutations in putative RUNX1 binding motifs. A 10 µL reaction consisting of 
1.75 µL of BigDye® Terminator sequencing buffer, 0.25 µL of BigDye® Terminator, 
0.528 µM of pXPG reverse primer (5’ TGGAAGACGCCAAAAACATAAAG 3’) or 
0.528 µM of forward primer used to clone the specific integrin region (Table 2.1) and 
100-200 ng of purified plasmid DNA was used for the dye-terminator sequencing. Dye-
terminator sequencing was performed using a Veriti Thermal Cycler (Applied 
Biosystems, USA) under the following conditions: initial denaturation step of 96˚C for 1 
minute and then 25 cycles consisting of 96˚C for 10 seconds, 50˚C for 5 seconds and 60˚C 
for 4 minutes. Products were purified using the Agencourt® CleanSEQ® kit (Agencourt 
Bioscience Corporation, USA) and were eluted in 40 µL of water. Purified DNA was 
sequenced using an ABI Prism® 310 Genetic Analyzer (Applied Biosystems, USA) and 
sequencing data was recovered using 310 Data Collection and Sequence Analysis 
Software (Applied Biosystems, USA). Sequencing files were analysed using the 
computer software program Sequencher 4.10.1 (Gene Codes Corporation, USA). 
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2.3 Luciferase Reporter Assays 
 
Luciferase reporter assays were used to monitor RUNX1 effects on integrin 
promoter/enhancer activity in K562 cells. 
 
2.3.1 Plasmid Preparation 
Plasmids summarised in Table 2.3 were transformed into One Shot® TOP10 Chemically 
Competent E.coli Cells (25 µL; Life Technologies, USA; section 2.2.4) following the 
manufacturer’s instructions. Starter cultures were first made by inoculating 1 mL of L 
broth (containing the appropriate antibiotic) with a single isolated colony or from a 
glycerol culture. Starter cultures were incubated for 6 hours at 37˚C with shaking, before 
inoculating 99 mL of L broth (containing appropriate antibiotic). Cultures were incubated 
overnight at 37˚C with shaking. The plasmid DNA was extracted and purified using either 
the Qiagen Plasmid Maxi Kit (Qiagen, USA) or the Qiagen Plasmid Plus Maxi Kit 
(Qiagen, USA) following the manufacturer’s instructions. Plasmid DNA was eluted in 
50-100 µL of either Tris/EDTA (TE) Buffer or Buffer EB and was quantified using a 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, USA). Plasmid DNA 
was diluted to 1000 ng/µL and re-quantified. Purified plasmid DNA was stored at -20˚C. 
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Plasmid Name 
Promoter/Distal 
Region Name 
Description Source 
pXPG - 
- Size = 6087 bp 
- Ampicillin 
resistance gene 
Bert et al. (2000) 
pGL3-Control - 
- Size = 5256 bp 
- Ampicillin 
resistance gene 
- Contains SV40 
promoter and 
enhancer sequences 
which results in 
strong expression of 
luciferase gene 
Promega 
RcCMV - 
- Size = 5446 bp 
- Ampicillin 
resistance gene 
Invitrogen (Life 
Technologies) 
pCMV5-
AML1B 
(RUNX1) 
- 
- Size = ~5.8 kb 
- Ampicillin 
resistance gene 
Addgene 
Meyers et al. 
(1995) 
pCMV5-AML1-
ETO 
(RUNX1-ETO) 
- 
- Size = ~9 kb 
- Ampicillin 
resistance gene 
Addgene 
Meyers et al. 
(1995) 
pXPG-ITGB4 ITGB4 
- Size = 7406 bp 
- Contains -1199 bp 
to +144 bp of human 
ITGB4 gene 
- Ampicillin 
resistance gene 
Cloned by Jessica 
Phillips (2012) 
pXPG-ITGB4 
Del-2 
ITGB4 Del-1 
- Size = 6965 bp 
- Contains -758 bp to 
+144 bp of ITGB4 
gene 
- Ampicillin 
resistance gene 
Cloned by Jessica 
Phillips (2012) 
pXPG-ITGB4 
SmaI 
ITGB4 Del-2 
- Size = 6514 bp 
- Contains -295 bp to 
+144 bp of human 
ITGB4 gene 
-Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB4 
Del-3 
ITGB4 Del-3 
- Size = 6264 bp 
- Contains -57 bp to 
+144 bp of human 
ITGB4 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
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pXPG-ITGB4 
Del-4 
ITGB4 Del-4 
- Size = 6133 bp 
- Contains -57 bp to 
+13 bp of human 
ITGB4 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB4 
Del-6 
ITGB4 Del-5 
- Size = 6730 bp 
- Contains -758 bp to 
-290 bp and -57 bp 
to +144 bp of human 
ITGB4 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB4 
Del-8 
ITGB4 Del-6 
- Size = 6382 bp 
- Contains -175 bp to 
+144 bp of human 
ITGB4 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB4 
Mutant2 
ITGB4 Mutant 
- Size = 6514 bp 
- Contains -295 bp to 
+144 bp of human 
ITGB4 gene 
- Possesses BglII 
recognition sequence 
mutation at site -141 
bp to -136 bp of 
human ITGB4 gene 
Ampicillin resistance 
gene 
Refer to Section 
2.2 
pXPG-ITGB4 
Del-8 Enhancer 
1 
ITGB4 Distal-1 
- Size = 6730 bp 
- Contains -13,815 
bp to -14,178 bp and 
-175 bp to +144 bp 
of human ITGB4 
gene 
-Ampicillin 
resistance gene  
Refer to Section 
2.2 
pXPG ITGB4 
Del-8 Enhancer 
2 
ITGB4 Distal-2 
-Size = 6698 bp 
- Contains -12,077 
bp to -12,408 bp and 
-175 bp to +14 bp of 
human ITGB4 gene 
-Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB5 ITGB5 
- Size = 6633 bp 
- Contains -496 bp to 
+74 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Originally cloned 
into pXP1 by 
Paulynn Chin 
(2009) and sub-
cloned into pXPG 
by Jessica Phillips 
(2014) 
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pXPG-ITGB5 
Del-1 
ITGB5 Del-1 
- Size = 6590 bp 
- Contains -453 bp to 
+74 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Cloned by Jessica 
Phillips (2012) 
pXPG-ITGB5 
Del-2 
ITGB5 Del-2 
- Size = 6546 bp 
- Contains -409 bp to 
+74 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Cloned by Jessica 
Phillips (2012) 
pXPG-ITGB5 
Del-3 
ITGB5 Del-3 
- Size = 6445 bp 
- Contains -308 bp to 
+74 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Cloned by Jessica 
Phillips (2012) 
pXPG-ITGB5 
Del-5 
ITGB5 Del-4 
- Size = 6166 bp 
- Contains -20 bp to 
+74 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB5 
Del-6 
ITGB5 Del-5 
- Size = 6505 bp 
- Contains -453 bp to 
-12 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB5 
Del-7 
ITGB5 Del-6 
- Size = 6118 bp 
-Contains +20 bp to 
+74 bp of human 
ITGB5 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGA6 ITGA6 
- Size = 6980 bp 
- Contains -675 bp to 
+242 bp of human 
ITGA6 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGA6 
Del-1 
ITGA6 Del-1 
- Size = 6445 bp 
- Contains -140 bp to 
+242 bp of human 
ITGA6 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGA6 
Mutant 
ITGA6 Mutant - Size = 6980 bp 
Refer to Section 
2.2 
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- Contains -675 bp to 
+242 bp of human 
ITGA6 gene 
- Possesses EcoRV 
recognition sequence 
mutation at site -237 
bp to -232 bp of 
human ITGA6 gene 
- Ampicillin 
resistance gene 
pXPG-ITGAV ITGAV 
- Size = 6586 bp 
- Contains -398 bp to 
+125 bp of human 
ITGAV gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
pXPG-ITGB1 ITGB1 
- Size = 6850 bp 
- Contains -485 bp to 
+302 bp of human 
ITGB1 gene 
- Ampicillin 
resistance gene 
Refer to Section 
2.2 
 
 
Table 2.2 – Details and source of plasmids used in reporter assays. 
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2.3.2 Transfection of Myeloid Cell Lines 
K562 cells (4.5 x 106 cells in 300 µL of RPMI containing 20% FCS) were transfected 
with purified plasmid DNA (Section 2.3.1) using electroporation. Briefly, plasmid DNA 
(1-10 µg) and cells were added to a Gene Pulser® electroporation cuvette (4 mm; Bio-
Rad, USA) and electroporated using a Gene Pulser® Xcell™ system (Bio-Rad, USA) at 
270 V with a capacitance of 950 µFarad and a resistance of infinity. Next, 1 mL of RPMI 
(10% FCS) was added to the cuvette and cells were allowed to recover for 5-10 minutes 
at room temperature. Cells were then added to a tissue culture flask containing 3.7 mL 
RPMI medium (10% FCS) and were incubated in a humidified incubator at 37˚C with 
5% CO2 for 24 hours. Transfections were performed in duplicate and combined after 
electroporation. Supplementation with RcCMV plasmid was used to ensure equal 
amounts of plasmid DNA were transfected into the cells.  
 
To isolate the protein from transfected cells, cells were first centrifuged at 500 x g for 5 
minutes and the cell pellet was washed with 10 mL of phosphate buffered saline (PBS; 
Thermo Fisher Scientific, USA). Cells were centrifuged again and the cell pellet was 
resuspended in 100 µL of 1X Lysis Buffer (Promega, USA). Cell lysate was either stored 
at -20˚C for later analysis or incubated on ice for approximately 2 minutes. Cell lysate 
was then centrifuged at 13,000 x g for 5 minutes, the supernatant was retained and stored 
at -20˚C for later analysis. 
 
2.3.3 Determination of Protein Concentration by Bradford Assay 
Bradford assay was used to determine protein concentration of cell lysates described in 
Section 2.3.2. Briefly, an aliquot of cell lysate was first diluted 1:10 to be measured for 
protein concentration. A standard curve was generated using bovine serum albumin 
(BSA; New England Biolabs, USA) at concentrations of 0.1, 0.2, 0.3, 0.4 and 0.5 mg/mL. 
The Protein Assay Dye Reagent Concentrate (Bio-Rad, USA) was diluted 1:5 and 990 
µL was added to 10 µL of diluted cell lysate and BSA standards. Samples were mixed 
well and allowed to stand at room temperature for 5 minutes. Protein absorbance was 
measured at 595 nm using a SpectraMax® Plus384 Microplate Reader Spectrophotometer 
(Molecular Devices, USA) and BSA standard curves were constructed using Microsoft® 
Excel to determine protein concentration of cell lysate samples. 
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2.3.4 Analysis of Promoter and Enhancer Activity by Luciferase Assay 
The effects of RUNX1 and RUNX1-ETO transcription factors on integrin promoter or 
enhancer activity was analysed using the Luciferase Reporter System (Promega, USA). 
Firstly, 50 µg of protein extracts (10 µg was used for ITGAV and ITGB1 samples due to 
high luminescence) were added to each well of a 96-well plate (Greiner Bio-one, 
Germany) and assays were performed in duplicate. Samples were made up to a total 
volume of 100 µL with 1X Lysis buffer (Promega, USA) and 100 µL of Luciferase 
reagent was added to each well. The light emitted from the luciferase-cataylsed 
chemiluminescent reaction, in relative light units, was measured using a 2.5 second 
integration time on a Veritas™ Microplate Luminometer (Turner Biosystems, USA), and 
therefore represent relative luciferase activity/units.  
 
 
2.4 Analysis of mRNA Levels by Reverse Transcription Quantitative PCR 
 
Integrin and RUNX1 expression was analysed in leukaemic cell lines by the detection of 
mRNA levels using real-time reverse transcription quantitative PCR (RT-qPCR). 
 
2.4.1 RNA Extraction 
RNA was extracted from cells using TRI Reagent® (Sigma-Aldrich, USA) following the 
manufacturer’s instructions. Briefly, cell pellets (approximately 4 x 106 cells) were lysed 
with 500 µL of TRI Reagent® and incubated at room temperature for 5 minutes. Samples 
underwent phase separation by the addition of 100 µL of chloroform. Samples were 
shaken vigorously for 15 seconds and incubated at room temperature for 10 minutes. 
After centrifugation at 13,000 x g for 15 minutes at 4˚C, the top aqueous phase containing 
RNA was transferred to a new tube and RNA was precipitated overnight at -20˚C by the 
addition of 250 µL of isopropanol. Precipitated RNA collected by centrifugation was 
washed with 75% ethanol and resuspended in diethylpyrocarbonate-treated water. RNA 
was quantified using a NanoDrop® ND-1000 spectrophotometer (NanoDrop 
Technologies, USA). 
 
2.4.2 cDNA Synthesis 
RNA samples (up to 1 µg) were first incubated with 1 unit of DNase I (Sigma-Aldrich, 
USA) in 1X First Strand Buffer (Life Technologies, USA) for 30 minutes at 37˚C. DNase 
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I enzyme was heat-inactivated at 75˚C for 5 minutes, then 5 µM of oligo dT (Geneworks, 
AUS) was added to the samples and incubated at 70˚C for 10 minutes. RNA was reverse 
transcribed using 100 units of SuperScript® III Reverse Transcriptase enzyme (Life 
Technologies, USA) in 1X First Strand Buffer containing 10mM DTT (Life 
Technologies, USA) and 1mM of dNTPs (Sigma-Aldrich, USA) at 42˚C for 50 minutes. 
SuperScript® III enzyme was heat-inactivated at 70˚C for 15 minutes and cDNA samples 
were stored at -20˚C. 
 
Alternatively, in some experiments cDNA was synthesised using the iScript™ cDNA 
synthesis kit (Bio-Rad, USA) following the manufacturer’s instructions. 
 
2.4.3 RT-qPCR 
RT-qPCR was performed as described previously (Qadi et al. 2016). cDNA synthesised 
in Section 2.4.2 was used as template DNA to detect the expression of genes described in 
Table 2.3. Primers shown in Table 2.3 were designed to amplify a region 50-150 bp of 
mRNA of selected integrin genes using the Primer3 program 
(http://bioinfo.ut.ee/primer3-0.4.0/). All primers were checked for specificity using the 
NCBI Blast program, nucleotide blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). A 25 µL 
reaction containing 1X QuantiTect SYBR® Green PCR Master Mix (Qiagen, USA) and 
0.38 µM of each forward and reverse primer (Table 2.3), was used to amplify cDNA (50 
ng) following the manufacturer’s instructions. cDNA was amplified using a Corbett 
Rotor-Gene Cycler (Qiagen, USA) under the following conditions: initial denaturation 
step at 95˚C for 15 minutes and then 40 cycles consisting of 94˚C for 15 seconds and 
60˚C for 60 seconds. The amplification of human GAPDH mRNA or β2-Microglobulin 
(primers detailed in Table 2.3) was also conducted in parallel to all PCRs to normalise 
for discrepancies in cDNA synthesis and RNA input. To ensure a single PCR product was 
generated, PCR product melt curves were analysed for a single peak and the products 
were visualised by agarose gel electrophoresis. To determine copy number from the cycle 
threshold values from the amplification plots, a standard curve was generated for each 
primer pair with serial dilutions of the PCR product. 
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Gene Primer Sequence 
Product 
Size 
GAPDH 
Forward: 5’ – AAATATGATGACATCAAGAAGG – 
3’  67 bp 
Reverse: 5’ – AGCCCAGGATGCCCTTGAGGG – 3’ 
β2-
Microglobulin 
Forward: 5’ – ACTGAATTCACCCCCACTGA – 3’ 
114 bp 
Reverse: 5’ – CCTCCATGATGCTGCTTACA – 3’ 
RUNX1 
Forward: 5’ – CACCTACCACAGAGCCATCA – 3’ 
109 bp 
Reverse: 5’ – CTCGGAAAAGGACAAGCTCC – 3’ 
RUNX1-ETO Forward: 5’ – AATCACAGTGGATGGGCCC – 3’ 87 bp 
Reverse: 5’ – TGCGTCTTCACATCCACAGG – 3’ 
ITGB4 
Forward: 5’ – TTAAGAGAGCCGAGGAGGTG – 3’ 
138 bp 
Reverse: 5’ – GGCAGTCCTTCTTCTTGTGC – 3’ 
ITGB5 
Forward: 5’ – AGCCAGAGTGTGGAAACACC – 3’ 
105 bp 
Reverse: 5’ – CAAGCAGCTTCCAGATAGCC – 3’ 
ITGA6 
Forward: 5’ – CCAAAAATTACTTTGGGGCTAA – 
3’ 
122 bp 
Reverse: 5’ – 
TCAGCTTTCATATCTATTCAGTCTCTG – 3’ 
ITGAV 
Forward: 5’ – TGCAAAATGTAATGATGAGCTTG – 
3’ 102 bp 
Reverse: 5’ – CCAAGAATGCAAACAAGGTG – 3’ 
ITGB1 
Forward: 5’ – 
TTTTGAAAATAATGTTGTAATTCATGC – 3’ 104 bp 
Reverse: 5’ – GAAAAGGTCAAAAAGGCACAA – 3’ 
 
Table 2.3 – RT-qPCR primers. Detailed are the primers used in RT-qPCR to detect the 
mRNA levels of specific genes and the expected size of the resultant PCR product. 
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2.5 Analysis of Protein by Western Blot Analysis 
 
Protein expression in leukaemic cell lines was analysed using Western Blot analysis. 
 
2.5.1 Cytosolic and Nuclear Protein Extraction 
Cytosolic and nuclear extracts were prepared from cells using a modified version of the 
method described by (Schreiber et al. 1989). Briefly, cells (up to 1.25 x 107 cells) were 
pelleted at 500 x g for 5 minutes at 4˚C and washed in 10 mL of ice-cold PBS (Thermo 
Fisher Scientific, USA). Cell pellets were resuspended in 1 mL of ice-cold Lysis Buffer 
(10 mM Tris at pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1 mM EDTA at pH 8.0 and 0.5% 
Igepal) and incubated on ice for 5 minutes. Nuclei were pelleted by centrifugation at 500 
x g for 5 minutes at 4˚C and supernatant containing cytoplasmic proteins was transferred 
to a new tube and retained. The nuclei were washed in 1 mL of ice-cold Igepal-free buffer 
(10 mM Tris at pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 0.1 mM EDTA at pH 8.0) and 
centrifuged at 500 x g for 5 minutes at 4˚C. Nuclei were resuspended in 25 µL of Nuclei 
Lysis Buffer (400 mM NaCl, 7.5mM MgCl2, 0.2mM EDTA at pH 8.0 and 1mM DTT) 
supplemented with 1 µL aprotinin (2 mg/mL; Sigma-Aldrich, USA) leupeptin (1 mg/mL; 
Amersham Biosciences, USA) and Complete EDTA-Free Protease Inhibitor Cocktail 
(Roche Applied Science, Switzerland) and incubated on ice with shaking for 15 minutes. 
The nuclear lysate was centrifuged at 13,000 x g for 5 minutes at 4˚C and the supernatant 
containing nuclear proteins was transferred to a new tube and retained. Protein extracts 
were quantified using the Bradford assay (Section 2.3.4). 
 
2.5.2 SDS-PAGE and Western Blotting 
Protein extracts prepared in Section 2.5.1 (10-20 µg) were first denatured at 95˚C for 5 
minutes in sample loading buffer (62.5 mM Tris HCl pH 6.8, 10% Glycerol, 2% SDS, 
0.005% Bromophenol blue, 10% β-mercaptoethanol). Proteins were then separated by 
SDS-PAGE through a 4-20% Mini-PROTEAN® TGX™ pre-cast gel (Bio-Rad, USA) in 
SDS-PAGE Running Buffer (192 mM Glycine, 25 mM Tris and 0.1% SDS) and were 
transferred to 0.45 µM nitrocellulose membrane (Bio-Rad, USA) through a wet transfer 
in Western Transfer Buffer (192 mM Glycine, 25 mM Tris and 20% methanol). Proteins 
were transferred overnight at 20 V at 4˚C and were then subjected to western blot analysis 
using the antibodies described in Table 2.4 with the corresponding peroxidase-conjugated 
secondary antibodies. Proteins were visualised using the Supersignal West Pico 
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Chemiluminescent kit (Thermo Fisher Scientific, USA) following the manufacturer’s 
instructions. For the analysis of additional proteins, membranes were stripped using 
Restore™ PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific, USA) 
following the manufacturer’s instructions and were re-probed. 
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Antibody Type Dilution Supplier 
Anti-RUNX1 (H-
65) 
Rabbit polyclonal 1:1000 
Santa Cruz 
Biotechnology (sc-
28679) 
Anti-RUNX1 (N-
20) 
Goat polyclonal 1:500 
Santa Cruz 
Biotechnology (sc-8563) 
Anti-ETO (C-20) Goat polyclonal 1:500 
Santa Cruz 
Biotechnology (sc-9737) 
Anti-Histone H3 Rabbit polyclonal 1:700 Abcam (ab1791) 
2º Anti-Goat HRP Rabbit polyclonal 1:2000 Dako (P0449) 
2º Anti-Rabbit 
HRP 
Goat polyclonal 1:1000 Dako (P0448) 
 
Table 2.4 – Antibodies used for Western Blot analysis. 
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2.6 DNA Methylation Analysis 
 
DNA methylation of integrin promoter regions was determined using the bisulphite 
sequencing technique as developed by Frommer et al. (1992). Bisulphite sequencing 
involves the treatment of DNA with bisulphite which converts cytosine into uracil while 
methylated cytosines are resistant to treatment and therefore remain as cytosines 
(Frommer et al. 1992). The bisulphite treated DNA is then amplified by PCR using 
primers to a specific region of DNA to be analysed, and then PCR products can be cloned 
and sequenced to provide methylation maps of single DNA molecules (Frommer et al. 
1992). During the PCR process, all uracil and thymines are amplified as thymine, while 
methylated cytosines are amplified as cytosines (Frommer et al. 1992). Methylated and 
unmethylated CpGs are determined by comparing bisulphite-converted sequences to a 
reference sequence. 
 
2.6.1 DNA Isolation and Bisulphite Conversion 
Genomic DNA was isolated and purified from K562, KG-1a and Kasumi-1 cells using 
the Allprep DNA/RNA Mini kit (Qiagen, USA) or QIAamp DNA Blood Mini Kit 
(Qiagen, USA) following the manufacturer’s instructions. Genomic DNA from K562, 
KG-1a and Kasumi-1 cell lines was bisulphite converted using the EZ DNA Methylation 
Gold kit (Zymo Research, USA) following the manufacturer’s instructions and bisulphite 
converted DNA was eluted in 10 µL of M-Elution Buffer. Human DNA samples 
originating from the Royal Hobart Hospital were also analysed. Genomic DNA from a 
68 year old female individual with t(8;21)-positive leukaemia (LK7770) and from non-
leukaemic age and sex match controls were bisulphite converted following the protocol 
used for the leukaemic cell lines. Use of these samples were approved by Human 
Research Ethics Committee (Tasmanian network), reference number: H8551. 
 
2.6.2  Primer Design 
Primers used for the PCR amplification of bisulphite converted DNA were designed using 
the MethPrimer program (http://www.urogene.org/methprimer/index.html) which can 
locate CpG islands within a query sequence and design primers around the predicted CpG 
islands (Li and Dahiya 2002).  
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2.6.3 PCR of Bisulphite Converted DNA 
Bisulphite converted gDNA (20 ng) was amplified by PCR using the EPIK Amplification 
kit (Bioline, USA). A 20 µL reaction containing 1X EPIK amplification mix and 0.4 µM 
of primers (Table 2.5) was used to amplify DNA following the manufacturer’s 
instructions. DNA was amplified using a Veriti® 96 Well Thermal Cycler (Applied 
Biosystems™, USA) under the following cycling conditions: initial denaturation step of 2 
minutes at 95ºC and then 45 cycles consisting of 15 seconds at 95ºC, 15 seconds at 54ºC 
and 30-60 seconds at 72ºC (30 seconds per 500 bp to be amplified).  
 
2.6.4 Molecular Cloning 
PCR products generated from bisulphite converted DNA as described in Section 2.6.3 
were visualised by gel electrophoresis and were excised from the gels. PCR products were 
extracted and purified from the agarose gel using the GeneJET Gel Extraction Kit 
(Thermo Fisher Scientific, USA) following the manufacturer’s instructions. Samples 
were eluted in 10-20 µL of Elution Buffer. Purified PCR products were ligated into a 
pGEM®-T Easy Vector (Promega, USA) following the protocol described in Section 2.2.3 
and ligated DNA was transformed into One Shot® TOP10 Chemically Competent E.coli 
Cells (25 µL; Invitrogen, USA) following the manufacturer’s instructions. Transformed 
cells were plated on agar plates, containing 100 µg/mL ampicillin (Sigma-Aldrich, USA) 
and 50 µg/mL X-gal (Promega, USA), to allow blue/white colour selection of 
recombinant plasmids, and incubated overnight at 37˚C. 
 
Plasmid DNA from up to 10 white colonies was isolated and purified using the QIAprep 
Spin Miniprep Kit (Qiagen, USA) following the manufacturer’s instructions. DNA was 
eluted in 30 µL Buffer EB and 100-1000 ng of plasmid DNA was analysed for 
successfully ligated recombinant plasmid by restriction enzyme digestion and agarose gel 
electrophoresis. Plasmid DNA identified as containing the insert by restriction enzyme 
digestion was sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, USA) following the protocol described in Section 2.2.5 using the 
sp6 reverse primer (5’ – TATTTAGGTGACACTATAGAAT – 3’). 
 
Sequencing was analysed using BiQ Analyzer software (Max Planck Institute Informatik, 
Germany) and bubble maps were generated using CpG Bubble Chart Generator, Version 
20061209 Alpha (created by Mark A. Miranda). 
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Bisulphite 
PCR 
Primers 
Primer Sequence 
Product 
Size 
Gene 
Position 
ITGB4 
Fragment A 
Forward: 5’ – GTGAATTGTAGAGTAGAGTTGGGA 
– 3’ 
792 bp 
-516 bp 
to +276 
bp 
Reverse: 5’ – AAACCTATCAACCTTCAAAAAAAA 
– 3’ 
ITGB4 
Fragment B 
Forward: 5’ – 
GGTAGTAGTAGTAGTATAGTTTGGTG – 3’ 
666 bp 
-390 bp 
to +276 
bp 
Reverse: 5’ – AAACCTATCAACCTTCAAAAAAAA 
– 3’ 
ITGA6 
Fragment A 
Forward: 5’ – AATAGGTTGTTTAGGTTATGAGGTT 
– 3’ 
569 bp 
-329 bp 
to +240 
bp 
Reverse: 5’ – 
ACAAATAAAACAAACACAACTACCC – 3’ 
ITGA6 
Fragment B 
Forward: 5’ – GGGTAGTTGTGTTTGTTTTATTTGT 
– 3’ 
605 bp 
+216 bp 
to +821 
bp 
Reverse: 5’ – AAAACCTAAACCATCCTAAAACTAC 
– 3’ 
 
Table 2.5 – Primers used for PCR amplification of bisulphite converted DNA. 
Detailed are the primers used for the PCR amplification of ITGB4 and ITGA6 CpG rich 
regions. Primers were designed using the MethPrimer program (Li and Dahiya 2002). 
Locations of the regions are shown as well as the expected PCR products size. 
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2.7 Chromatin Analysis 
 
Chromatin immunoprecipitation (ChIP) analysis was used to determine if RUNX1 binds 
to the endogenous integrin promoters/distal regions in leukaemic cell lines, and to 
determine histone H3 occupancy and acetylation at integrin promoter regions. 
 
2.7.1 ChIP Assay 
ChIP assays were performed as previously described (Brettingham-Moore et al. 2008). 
To cross-link proteins to DNA, KG-1a and Kasumi-1 cells (15 mL at 5.0 x 105 cells/mL) 
were treated with 1% formaldehyde for 8 minutes at room temperature on a rotary wheel. 
To halt the cross-linking process, 0.125 M glycine was added and cells were incubated at 
room temperature for 10 minutes on a rotary wheel. Cells were recovered by centrifuging 
at 500 x g for 5 minutes at 4˚C and washed twice in 10 mL of ice-cold PBS at 500 x g for 
5 minutes at 4˚C. Nuclei were extracted following the protocol described in Section 2.5.1 
and nuclei (2.0 x 106) were resuspended in 200 µL of SDS Lysis Buffer (1% SDS, 10 
mM EDTA and 50 mM Tris pH 8.1; Merck Millipore, USA) supplemented with 0.4% of 
Roche protease inhibitor cocktail (Roche Applied Science, Switzerland). Nuclei were 
incubated on ice for 10 minutes and were sonicated using a Bioruptor® Plus sonication 
device (Diagenode, Belgium) on high for 5 rounds of 10 cycles of 30 seconds ON and 30 
seconds OFF, which was empirically determined to fragment the DNA into sizes between 
100-500 bp. Sonicated nuclei were centrifuged twice at 13,000 x g for 5 minutes at 4˚C 
to remove debris. ChIP Dilution Buffer (1 mL, 0.01% SDS, 1.1% Triton, 1.2 mM EDTA, 
16.7 mM Tris-HCl pH 8.1 and 167 mM NaCl; Merck Millipore, USA) supplemented with 
0.1% Roche protease inhibitor cocktail was added and samples were pre-cleared with 60 
µL of salmon sperm DNA/protein A agarose slurry (Merck Millipore, USA) for 2 hours 
at 4˚C on a rotary wheel. Antibodies described in Table 2.6 were added to 450 µL of the 
pre-cleared samples, which were made up to 1 mL with the addition of ChIP Dilution 
Buffer supplemented with 0.1% Roche protease inhibitor cocktail, and incubated 
overnight at 4˚C on a rotary wheel, while 100 µL of the pre-cleared sample was retained 
as the Total Input (TI) fraction.  
 
Immune complexes were recovered by incubation with 60 µL of salmon sperm 
DNA/protein A agarose slurry for 2 hours at 4˚C on a rotary wheel and samples were 
centrifuged at 500 x g for 1 minute at 4ºC to pellet the immune complex bound protein A 
 64 
 
agarose beads. The supernatant was discarded and the beads were washed sequentially 
with 1 mL of Low Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl pH 8.1 and 150 mM NaCl; Merck Millipore, USA), High Salt Wash Buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1 and 500 mM NaCl; 
Merck Millipore, USA), LiCl wash buffer (0.25 M LiCl, 1% IGEPAL-CA630, 1% 
deoxycholic acid, 1 mM EDTA and 10 mM Tris pH 8.1; Merck Millipore, USA), and 
twice with TE Buffer (10 mM Tris-HCl and 1 mM EDTA, pH 8.0; Merck Millipore, 
USA). The immune complexes were eluted in 410 µL of Elution Buffer (1% SDS and 10 
mM NaHCO3). To reverse the cross-links, samples (380 µL) were incubated overnight at 
65ºC with the addition of Proteinase K (20 µg; Qiagen, USA) and 4M NaCl (20 µL or 10 
µL for TI sample). 
 
DNA was purified using phenol/chloroform extraction (50% phenol, 50% chloroform) 
and precipitated overnight at -20ºC with 10% volume of 3M sodium acetate and 2.5X 
volume of 100% ethanol. DNA was washed 3 times in 70% ethanol, resuspended in 50 
µL of water and 5 µL of DNA was used in qPCR following the protocol described in 
Section 2.4.3, using primers described in Table 2.7. Primers were designed to amplify a 
region of 50-190 bp of the ITGB4 and ITGA6 promoter/distal regions using the Primer3 
program (http://bioinfo.ut.ee/primer3-0.4.0/). All primers were checked for specificity 
using the NCBI Blast program, nucleotide blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
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Antibody Type Amount Used Supplier 
Anti-Histone H3 Rabbit polyclonal 2 µg Abcam (ab1791) 
Anti-Acetyl 
Histone H3 
Rabbit polyclonal 4 µg 
Merck Millipore 
(06-599) 
Anti-RUNX1 (N-
20) 
Goat polyclonal 5 µg 
Santa Cruz 
Biotechnology (sc-
8563) 
 
Table 2.6 – Details and source of antibodies used for ChIP assays. 
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Promoter/Distal 
Region 
Primer Sequences 
Fragment 
Size 
Rhodopsin 
Forward: 5’ – CCAATCTCCCAGATGCTGAT 
– 3’ 
54 bp 
Reverse: 5’ – TAAAGTGACCTCCCCCTCCT – 
3’ 
ITGB4 Promoter 
Forward: 5’ – CTCGGACAGTCCCTGCTC – 3’ 
53 bp 
Reverse: 5’ – GCTGCCGCTAGGAGATGG – 3’ 
ITGA6 Promoter 
Forward: 5’ – GCGTCCTCGTCACTTGATAA – 
3’ 
56 bp 
Reverse: 5’ – AATGAGCCCGTTGTTCTCTG – 
3’ 
ITGB4 Distal-1 
Forward: 5’ – TGAAACGGGTTTCCCAGAC – 
3’ 
64 bp 
Reverse: 5’ – ATCGCCAAAGATCATGAAGG 
– 3’ 
ITGB4 Distal-2 
Forward: 5’ – GCTATTGAGCCTGGTGCAGT 
– 3’ 
189 bp 
Reverse: 5’ – CCTCCTGAGTAGCTGGGAAT – 
3’ 
 
Table 2.7 – Primers used for ChIP analysis. Detailed are primer sequences used for 
qPCR for ChIP analysis and the expected sized PCR product. 
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Chapter 3 
 
Identifying Integrin Genes Regulated by RUNX1 
 
 
3.1 Introduction 
 
3.1.1 Importance of RUNX1 in Haematopoiesis  
The RUNX1 transcription factor plays a vital role in haematopoiesis and in addition is 
one of the most commonly disrupted genes in leukaemia. Point mutations, gene 
amplification and chromosomal translocations of RUNX1 have all been reported in 
individuals with leukaemia (Dal Cin et al. 2001, Harewood et al. 2003, Miyoshi et al. 
1995, Niini et al. 2000, Osato et al. 1999, Preudhomme et al. 2009, Song et al. 1999, 
Streubel et al. 2001). Disruption to RUNX1 contributes to the development of leukaemia 
due to altered regulation of its target genes. Therefore, the identification of genes and 
biological pathways targeted by RUNX1, and the mechanism by which it regulates gene 
expression, is crucial for understanding its role in haematopoiesis, as well as its role in 
leukaemia development, and in identifying potential biomarkers or therapeutic targets for 
the disease. Yet, while many RUNX1 target genes have been identified through candidate 
gene analyses, the full repertoire of RUNX1 controlled genes remains to be determined. 
 
3.1.2 RUNX1 Regulation of Integrin Genes 
Through genome-wide studies, potential RUNX1 target genes have been identified and 
many of these have been found to be involved in cell signalling and cell adhesion. Further, 
a number of studies have demonstrated regulation of integrin genes by RUNX 
transcription factors. The ITGAL integrin gene is regulated by RUNX1 and RUNX3 in 
lymphoid and myeloid cells, respectively (Puig-Kröger et al. 2000, Puig-Kröger et al. 
2003). Additionally, RUNX3 regulates the ITGA4 integrin gene in mature monocyte-
derived dendritic cells (Domínguez-Soto et al. 2005). Interestingly, expression of the 
RUNX1-ETO fusion protein, produced from the t(8;21) chromosomal translocation, has 
been associated with increased expression of ITGB1, suggesting that RUNX1-ETO may 
target this gene in t(8;21) transformed cells (Ponnusamy et al. 2014). Furthermore, in 
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mouse studies, Runx1 and Runx3 were shown to regulate the expression of integrin genes 
Itga2b and Itgae, respectively (Grueter et al. 2005, Tanaka et al. 2012).  
 
In addition, previously published microarray studies have shown altered expression of the 
integrin gene ITGB4, in individuals with leukaemia in which RUNX1 activity is altered. 
A study conducted by Valk et al. (2004) determined the gene expression profiles in 
samples of peripheral blood or bone marrow from 285 individuals with AML. In their 
analysis, they classified samples into groups based on their different molecular signatures, 
using cluster analyses. The different clusters of genes were found to be driven by the 
presence of chromosomal translocations such as t(8;21) and inv(16), as well as genetic 
mutations and oncogene expression (Valk et al. 2004). In the gene cluster which was 
driven by the presence of the t(8;21) chromosomal translocation, the integrin gene ITGB4 
was significantly upregulated with a SAM score (assessing the minimal difference in gene 
expression compared to other AML samples) of 20.55 and a q-value of 0.14% (Valk et 
al. 2004). Additionally, a study by Ichikawa et al. (2006) determined the gene expression 
profiles of individuals with AML. The aim of this study was to identify genes whose 
dysregulation is associated with t(8;21) and inv(16) as well as genes with expression 
disrupted by both chromosomal translocations. Through this analysis, the ITGB4 gene 
was similarly identified to be significantly upregulated in the presence of the t(8;21) 
chromosomal translocation. 
 
Furthermore, previous microarray studies have also shown altered expression of the 
ITGB5 gene in individuals with leukaemia with disrupted RUNX1. A study by Michaud 
et al. (2008) determined the gene expression profiles of cell lines with RUNX1 mutations 
from individuals with FPD-AML and HeLa cells with RUNX1 and CBFβ overexpressed. 
Through their analysis, ITGB5 was found to be down-regulated in HeLa cells with 
RUNX1 and CBFβ overexpressed, with a M-value (log2 of fold change) of -0.24 and -
0.43 for each of the two biological replicates (Michaud et al. 2008). Additionally, another 
microarray study demonstrated that RUNX1, RUNX2 and RUNX3 transcription factors 
regulate a common set of genes involved in cell adhesion and survival (Wotton et al. 
2008). In this study, RUNX1, RUNX2 and RUNX3 were overexpressed in NIH 3T3 
fibroblast cells and changes in gene expression compared to control cells were measured. 
Through this analysis, ITGB5 was found to be highly regulated by all three RUNX 
transcription factors and was up-regulated in fibroblast cells with RUNX1, RUNX2 and 
RUNX3 overexpressed, with fold changes of 1.68, 1.96 and 2.71, respectively (Wotton 
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et al. 2008). Furthermore, the study by Ichikawa et al. (2006) described above found 
altered expression of the ITGB5 gene to be associated with the inv(16) chromosomal 
translocation, suggesting that RUNX1 may be involved in the regulation of ITGB5, since 
CBFβ is required for RUNX1 function. 
 
In support of these findings, a previous microarray study conducted by our research group 
also showed altered ITGB4 and ITGB5 expression in haematopoietic cells with RUNX1 
expression disrupted. This microarray study analysed changes in gene expression when 
RUNX1 was altered in Jurkat T cells to identify potential target genes. Novel RUNX1 
target genes were identified according to altered gene expression profiles following 
down-regulation of RUNX1 by transfection of Jurkat T-cells with RUNX1 siRNAs 
(Oakford and Holloway, unpublished). The knock-down of RUNX1 in Jurkat T-cells 
resulted in altered expression of a large number of genes, including known RUNX1 target 
genes, such as GM-CSF and IL-3. In this dataset, integrin genes ITGB4 and ITGB5 were 
found to have significantly altered gene expression. Knock-down of RUNX1 resulted in 
increased expression of ITGB4 and ITGB5, with log2 fold changes of 1.623 and 0.957, 
respectively (Oakford and Holloway, unpublished). 
 
Thus, analysis of previously published microarray studies, as well as a study conducted 
by our research group, identified the integrin genes, ITGB4 and ITGB5, as potential 
RUNX1 target genes due to their deregulation when RUNX1 or CBFβ was altered in 
haematopoietic cells. Interestingly, while RUNX1 generally functions as a transcriptional 
activator, its disruption consistently resulted in upregulation of ITGB4, while the effect 
on ITGB5 was different depending on the cellular context. This suggests that investigation 
of the regulation of these genes by RUNX1 may provide important insight into the 
function of this transcription factor. In addition, although integrins have been known to 
play key roles in cell-cell interactions in both normal and disease processes, the regulation 
of integrin gene expression and the mechanisms contributing to their dysregulation 
remains largely unexplored. Therefore, an aim of this study was to investigate the 
regulation of integrin genes by RUNX1 in haematopoietic cells and particularly to 
determine if the integrin genes, ITGB4 and ITGB5, are directly regulated by RUNX1. 
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3.2 Results 
 
3.2.1 Identification of Integrin Genes as Potential RUNX1 Targets 
While ITGB4 and ITGB5 were identified as potential RUNX1 target genes through 
microarray studies, this type of analysis does not distinguish between direct and indirect 
targets. Therefore, publicly available ChIP-seq data investigating RUNX1 binding across 
the genome in haematopoietic cells were interrogated (Beck et al. 2013, Martens et al. 
2012, Pencovich et al. 2011, Tijssen et al. 2011). The BloodChIP database 
(http://www.med.unsw.edu.au/CRCWeb.nsf/page/BloodChIP; Chacon et al. 2014) was 
used to interrogate these ChIP-seq studies (Beck et al. 2013, Martens et al. 2012, 
Pencovich et al. 2011, Tijssen et al. 2011). This database  has assembled genome-wide 
binding profiles of seven key haematopoietic transcription factors (RUNX1, FLI1, ERG, 
GATA2, SCL, LYL1 and LMO2) in human CD34+ haematopoietic stem/progenitor cells 
(GSE45144), megakaryocytes (GSE24674), the SKNO-1 AML cell line which is positive 
for the t(8;21) chromosomal translocation (GSE23730), and the K562 CML cell line 
(GSE24779, GSE29196 and GSE31477). The database is designed to enable researchers 
to easily interrogate and visualise data from these studies. The database also contains 
information on genome-wide gene expression in the different cell lines (GSE30029, 
GSE34594 and GSE28135), as well as histone profiles (GSE18927 and GSE29611) and 
the presence of DNase I hypersensitive sites (GSM646567). Data from two further ChIP-
seq studies examining RUNX1 binding became available during the course of this study 
(Ptasinska et al. 2014, Trombly et al. 2015). These studies were performed in Kasumi-1 
cells with an ETO and/or RUNX1 antibody, therefore representing RUNX1-ETO and/or 
RUNX1 binding, and was downloaded and visualised using the UCSC Genome Browser 
(Kent et al. 2002). 
 
Firstly, to examine the quality of the available ChIP-seq data, integrin genes ITGAL and 
ITGA2B previously identified to be regulated by RUNX1 in human and mouse cells, 
respectively (Puig-Kröger et al. 2000, Puig-Kröger et al. 2003, Tanaka et al. 2012), were 
interrogated for RUNX1/RUNX1-ETO binding at their promoter regions in these 
datasets. A region spanning from -1000 bp to +300 bp of the transcription start site is 
typically examined when interrogating regions surrounding the transcription start site for 
regulatory elements and was therefore analysed in this study. Promoters generally 
encompass approximately 250 bp upstream of the transcription start site and can span to 
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250 bp downstream (Butler and Kadonaga 2002, Maston et al. 2006). As expected, 
RUNX1 and RUNX1-ETO were detected at promoter regions of both ITGAL and ITGA2B 
in CD34+ cells (Beck et al. 2013), megakaryocytes (Tijssen et al. 2011), SKNO-1 cells 
(Martens et al. 2012) and Kasumi-1 cells (Ptasinska et al. 2014, Trombly et al. 2015), 
thus providing confidence in the quality of these data (Figure 3.1). However, specific 
RUNX1 binding was not detected at these integrin promoter regions in K562 cells 
(Pencovich et al. 2011), which may be due to lower levels of RUNX1 in these cells 
(Figure 3.1). The data generated in K562 cells may therefore be less reliable for detecting 
RUNX1 binding, and this is also supported by the absence of RUNX1 at the well-
described target genes GM-CSF and M-CSF (data not shown).  
 
Since binding of RUNX1/RUNX1-ETO was detected at the promoters of the known 
target genes ITGAL and ITGA2B, these data were further interrogated for 
RUNX1/RUNX1-ETO binding at promoter regions of ITGB4 and ITGB5. While peaks 
can be visualised across the ITGB4 and ITGB5 genes in all the ChIP-seq studies, the only 
peak ‘called’ at both of the integrin promoters was in the SKNO-1 cell dataset (Figure 
3.2). The peak calling used in this analysis was obtained from the original studies (Beck 
et al. 2013, Martens et al. 2012, Pencovich et al. 2011, Tijssen et al. 2011, Trombly et al. 
2015). Trombly et al. (2015) used the peak calling program MACS with default settings, 
using a p value of <10-20, while data in the BloodChIP database (Beck et al. 2013, Martens 
et al. 2012, Pencovich et al. 2011, Tijssen et al. 2011) were interrogated using HOMER, 
MACS and Partek, and peaks were included if they were called by 2 or more of the 3 
programs. Therefore, whether a peak is ‘called’ or not is dependent on the thresholds set 
in the analysis, but the peaks that could be visualised in the other datasets were relatively 
small and therefore potentially represent background. Regardless, the presence of 
RUNX1 at the ITGB4 and ITGB5 promoters in SKNO-1 cells suggests that it has the 
potential to regulate these integrin genes.  
 
Integrin receptors are formed by the binding of α and β subunits, which are encoded by 
separate genes. The β4 subunit produced by the ITGB4 gene heterodimerises with the α6 
subunit, encoded by the ITGA6 gene. While the β4 subunit heterodimerises only with α6, 
the α6 subunit can also heterodimerise with the β1 subunit, encoded by the ITGB1 gene. 
Similar to the β4 subunit, the β5 subunit, encoded by ITGB5, only heterodimerises with 
one subunit, αV, which is encoded by the ITGAV gene. To determine whether RUNX1 
and RUNX1-ETO may also target the genes encoding these binding partners, which 
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would enable co-regulation of these genes, ITGA6, ITGB1 and ITGAV were also 
examined for binding of these transcription factors. Interestingly, RUNX1 was detected 
at the ITGA6 promoter in megakaryocytes, SKNO-1 cells and Kasumi-1 cells (Figure 
3.3A), while RUNX1-ETO was detected at the ITGA6 promoter in Kasumi-1 cells 
(Figure 3.3 and 3.4). RUNX1 was also detected at the ITGB1 and ITGAV promoters in 
CD34+, SKNO-1 cells and Kasumi-1 cells (Figure 3.3B and 3.4), Together, these data 
suggest that RUNX1 may regulate integrin genes ITGA6, ITGB1 and ITGAV, in addition 
to ITGB4 and ITGB5. 
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Figure 3.1 - RUNX1 and RUNX1-ETO binding of ITGAL and ITGA2B in 
haematopoietic cells. Data from ChIP-seq studies (Beck et al. 2013, Martens et al. 2012, 
Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et al. 2015) 
were downloaded and visualised using the UCSC Genome Browser (Kent et al. 2002). 
Screen shots were taken from the UCSC browser and show RUNX1 (R) and RUNX1-
ETO (RE) binding across (A) ITGAL and (B) ITGA2B integrin genes in different cell 
types. Peaks and lines represent RUNX1/RUNX1-ETO binding. The transcription start 
site for each integrin gene is shown at the bottom of the figure by a black right-angled 
arrow. The integrin gene is represented at the bottom of the figure with exons shown as 
bars. The major transcript is in black. 
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Figure 3.2 - RUNX1 and RUNX1-ETO binding of ITGB4 and ITGB5 in 
haematopoietic cells. Data from ChIP-seq studies (Beck et al. 2013, Martens et al. 2012, 
Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et al. 2015) 
were downloaded and visualised using the UCSC Genome Browser (Kent et al. 2002). 
Screen shots were taken from the UCSC browser and show RUNX1 (R) and RUNX1-
ETO (RE) binding across (A) ITGB4 and (B) ITGB5 integrin genes in different cell types. 
Peaks and lines represent RUNX1/RUNX1-ETO binding. The transcription start site for 
each integrin gene is shown at the bottom of the figure by a black right-angled arrow. The 
integrin gene is represented at the bottom of the figure with exons shown as bars. The 
major transcript is in black/dark blue. 
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Figure 3.3 - RUNX1 and RUNX1-ETO binding of ITGA6 and ITGB1 in 
haematopoietic cells. Data from ChIP-seq studies (Beck et al. 2013, Martens et al. 2012, 
Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et al. 2015) 
were downloaded and visualised using the UCSC Genome Browser (Kent et al. 2002). 
Screen shots were taken from the UCSC browser and show RUNX1 (R) and RUNX1-
ETO (RE) binding across (A) ITGA6 and (B) ITGB1 integrin genes in different cell types. 
Peaks and lines represent RUNX1/RUNX1-ETO binding. The transcription start site for 
each integrin gene is shown at the bottom of the figure by a black right-angled arrow. The 
integrin gene is represented at the bottom of the figure with exons shown as bars. The 
major transcript is in black/dark blue. 
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Figure 3.4 - RUNX1 and RUNX1-ETO binding of ITGAV in haematopoietic cells. 
Data from ChIP-seq studies (Beck et al. 2013, Martens et al. 2012, Pencovich et al. 2011, 
Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et al. 2015) were downloaded and 
visualised using the UCSC Genome Browser (Kent et al. 2002). Screen shots were taken 
from the UCSC browser and show RUNX1 (R) and RUNX1-ETO (RE) binding across 
ITGAV integrin gene in different cell types. Peaks and lines represent RUNX1/RUNX1-
ETO binding. The transcription start site for ITGAV is shown at the bottom of the figure 
by a black right-angled arrow. The integrin gene is represented at the bottom of the figure 
with exons shown as bars. The major transcript is in black. 
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3.2.2 Integrin Expression and Response to PMA in Leukaemic Cell Lines 
3.2.2.1 Integrin Expression in Leukaemic Cell Lines 
Based on the analysis outlined above, the integrin genes ITGB4, ITGB5, ITGA6, ITGAV 
and ITGB1 were identified as potential targets of RUNX1/RUNX1-ETO in 
haematopoietic cells. To determine whether these integrin genes are expressed in 
haematopoietic cells, mRNA levels were analysed in K562, KG-1a and Kasumi-1 
myeloid cell lines using RT-qPCR. The K562 cell line is derived from an individual with 
CML and resemble undifferentiated granulocytes and erythrocytes (Lozzio and Lozzio 
1975); the KG-1a cell line, which are promyeloblasts, is derived from an individual with 
AML and resemble myeloblasts (Koeffler et al. 1980); and the Kasumi-1 cell line is 
derived from an individual with AML and resemble myeloblasts (Asou et al. 1991).  The 
K562 cell line was chosen for analysis as it represents cells that are more differentiated 
than the other cell lines and the Kasumi-1 cell line was included in the analysis because 
it possesses the t(8;21) chromosomal translocation and therefore produces the RUNX1-
ETO fusion protein.  
 
RNA was isolated from the cell lines and analysed by RT-qPCR for ITGB4, ITGB5, 
ITGA6, ITGAV and ITGB1 expression, as well as the expression of RUNX1 and RUNX1-
ETO. To distinguish between RUNX1 and RUNX1-ETO mRNA, specific primers were 
used that bind to an exon that is only present in RUNX1, while primers which span the 
RUNX1-ETO junction were used to specifically detect this transcript. All mRNA levels 
were normalised to GAPDH mRNA levels to account for discrepancies in cDNA 
synthesis and RNA input. RUNX1 mRNA was detected in all three leukaemic cell lines 
although at significantly higher levels in Kasumi-1 cells. As expected, RUNX1-ETO 
mRNA was only detected in the Kasumi-1 cell line (Figure 3.5). Analysis of integrin 
mRNA levels determined that the integrins are differentially expressed across the cell 
lines. The ITGB4 gene is expressed at higher levels in the Kasumi-1 cell line, very low 
levels in K562 cells, and was not detected in the KG-1a cell line (Figure 3.6A). In 
contrast, the ITGA6 gene is expressed in both KG-1a and Kasumi-1 cell lines but 
expressed at very low levels in the K562 cell line (Figure 3.6A). The ITGB1 gene is 
expressed in all cell lines, although at higher levels in Kasumi-1 cells (Figure 3.6A). 
ITGB5 is expressed at higher levels in the K562 cell line and at relatively low levels in 
the KG-1a and Kasumi-1 cell lines (Figure 3.6B), while ITGAV mRNA was detected in 
all cell lines examined (Figure 3.6B). This expression data is in keeping with the data 
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available through the BloodChIP database which shows ITGB4 and ITGA6 expressed at 
lower levels in K562 cells (GSE28135), compared to ITGB1 and ITGB5 which are 
expressed at higher levels (data not shown). Additionally, ITGB4, ITGA6, ITGB1 and 
ITGB5 mRNA was detected in SKNO-1 cells, which like Kasumi-1 cells are positive for 
the t(8;21) chromosomal translocation (data not shown). 
 
Based on the integrin mRNA levels detected by RT-qPCR, it is likely that the myeloid 
cell lines express different integrin receptors on their surface. The Kasumi-1 cell line may 
express both the integrin receptors α6β4 and α6β1, whereas the KG-1a cell line is likely 
to only express the integrin receptor α6β1 due to low levels of ITGB4 gene expression. 
In contrast, the data suggests that the K562 cell line does not have the capacity to express 
either α6β4 or α6β1, due to low levels of both ITGB4 and ITGA6 mRNA, but different 
β1 integrin receptors may be expressed by these cells due to the presence of ITGB1 
mRNA. The results also suggest that only the K562 cell line is likely to express the αVβ5 
receptor due to high levels of ITGB5 and ITGAV mRNA detected, whereas the KG-1a 
and Kasumi-1 cells are less likely to express the αVβ5 receptor, due to low levels of 
ITGB5 mRNA, but may express a different αV receptor, such as αVβ3, αVβ6 or αVβ8. 
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Figure 3.5 – RUNX1 and RUNX1-ETO mRNA levels in leukaemic cell lines. Total 
mRNA was isolated from K562, KG-1a and Kasumi-1 cell lines, reversed transcribed and 
RUNX1 and RUNX1-ETO mRNA levels were analysed using RT-qPCR. mRNA levels 
were normalised to GAPDH. Values are expressed as mean ±SEM (n=3). Statistical 
significance was determined using one-way ANOVA, Newman-Keuls Multiple 
Comparison Test, *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 80 
 
 
A 
 
B 
 
Figure 3.6 – Integrin mRNA levels in leukaemic cell lines. Total mRNA was isolated 
from K562, KG-1a and Kasumi-1 cell lines, reversed transcribed and (A) ITGB4, ITGA6 
and ITGB1, and (B) ITGB5 and ITGAV mRNA levels were analysed using RT-qPCR. 
mRNA levels were normalised to GAPDH. Values are expressed as mean ±SEM (n=3). 
Statistical significance was determined using one-way ANOVA, Newman-Keuls 
Multiple Comparison Test, ***p<0.001. 
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3.2.2.2 Effect of PMA on Integrin Expression in Myeloid Cell Lines 
Myelogenous leukaemia cell lines, such as K562, KG-1a and Kasumi-1, can be induced 
to differentiate in response to treatment with agents such as phorbol esters. Treatment of 
myelogenous leukaemia cell lines with phorbol esters results in increased adhesion and 
increased number of phagocytic cells due to differentiation of the cell lines (Koeffler et 
al. 1980, Pegoraro et al. 1980). Since integrins play a critical role in cell adhesion, the 
functional and morphological changes observed when myelogenous leukaemia cells are 
treated with phorbol esters may be at least partly attributed to changes in integrin 
expression. Therefore, ITGB4, ITGA6, ITGB1, ITGB5 and ITGAV gene expression was 
analysed in K562, KG-1a and Kasumi-1 leukaemic cell lines following treatment with 
the phorbol ester, PMA. 
 
The leukaemic cell lines were treated with PMA for 72 hours and changes in morphology 
and adhesion were monitored using microscopy. Percentage of flattened/adherent cells 
was determined by visually observing the cells and counting the flattened cells in several 
fields of view. Expression of the integrin genes as well as RUNX1 and RUNX1-ETO was 
determined by RT-qPCR. Treatment with PMA resulted in changes in morphology, 
specifically flattening and increased adherence of all cell lines (data not shown). The 
Kasumi-1 cells displayed the most flattened/adherent morphology, while KG-1a cells 
only displayed minimal changes in morphology and adherence. Treatment with PMA 
resulted in no change in RUNX1 mRNA levels in all three cell lines, and there was also 
no change in RUNX1-ETO mRNA levels in the Kasumi-1 cell line (Figure 3.7). In 
contrast, expression of all integrin genes examined increased in K562 cells following 
PMA treatment, with a significant increase detected for ITGB4, ITGB5 and ITGAV 
(Figure 3.8 and 3.9). In contrast to K562 cells, no significant change in expression of any 
of the integrins examined was detected in KG-1a and Kasumi-1 cells following treatment 
with PMA (Figure 3.8 and 3.9). Together, these data suggest that increased adhesion of 
the K562 PMA treated cells may be in part due to increased expression of the integrins 
examined here. Although Kasumi-1 treated cells displayed the most flattened/adherent 
phenotype of the cell types examined, this increased adhesion is likely due to altered 
expression of other integrins or cell adhesion molecules, that were not examined here. 
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Figure 3.7 – RUNX1 and RUNX1-ETO mRNA levels in PMA treated leukaemic cell 
lines. Total mRNA was isolated from untreated and PMA treated K562, KG-1a and 
Kasumi-1 cell lines, reversed transcribed and (A) RUNX1 and (B) RUNX1-ETO mRNA 
levels were analysed using RT-qPCR. mRNA levels were normalised to GAPDH. Values 
are expressed as mean ±SEM (n=3). Statistical significance was determined using 
Students’ t Test, with no significant difference detected between untreated and PMA 
treated cells. 
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Figure 3.8 – ITGB4, ITGA6 and ITGB1 mRNA levels in PMA treated leukaemic cell 
lines. Total mRNA was isolated from untreated and treated K562, KG-1a and Kasumi-1 
cell lines, reversed transcribed and (A) ITGB4, (B) ITGA6 and (C) ITGB1 mRNA levels 
were analysed using RT-qPCR. mRNA levels were normalised to GAPDH. Values are 
expressed as mean ±SEM (n=3). Statistical significance was determined using Students’ 
t Test, **p<0.01. 
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Figure 3.9 – ITGB5 and ITGAV mRNA levels in PMA treated leukaemic cell lines. 
Total mRNA was isolated from non-activated and activated K562, KG-1a and Kasumi-1 
cell lines, reversed transcribed and (A) ITGB5 and (B) ITGAV mRNA levels were 
analysed using RT-qPCR. mRNA levels were normalised to GAPDH. Values are 
expressed as mean ±SEM (n=3). Statistical significance was determined using Students’ 
t Test, ***p<0.001, *p<0.05. 
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3.2.3 Regulation of Integrin Promoters by RUNX1 
Analysis of RUNX1/RUNX1-ETO genome localisation data (Section 3.2.1) identified 
RUNX1 and RUNX1-ETO bound to the promoters of ITGB4, ITGA6, ITGB1, ITGB5 and 
ITGAV in haematopoietic cells. Furthermore, these integrin genes were found to be 
expressed, albeit at different levels, in myeloid cell lines (Section 3.2.2). Therefore, to 
investigate the potential RUNX1 regulation of these integrin genes in haematopoietic 
cells further, integrin promoter regions were analysed bioinformatically for RUNX 
binding motifs and RUNX1 regulation of integrin promoters was analysed using reporter 
assays. Promoter regions of each integrin gene examined for RUNX binding sites and 
used in reporter assays was determined based on the ChIP-seq analysis. Regions 
incorporating the DNA sequence corresponding to RUNX1 peaks in the ChIP data 
analysed in Section 3.2.1 were examined in reporter assays, and the presence of RUNX 
binding motifs was investigated within those regions. 
 
The presence of RUNX binding motifs was determined using the MatInspector tool in the 
Genomatix bioinformatics suite (http://www.genomatix.de/). MatInspector identifies 
potential transcription factor binding sites within a query sequence. The stringency of this 
tool can be altered to determine higher or lower affinity binding sites by altering core or 
matrix similarity values. The core similarity value represents the most conserved bases 
within a RUNX binding motif and is pre-set to consider 4 bases of a potential RUNX site. 
A core similarity value of 1 is given when there are no mismatches in the core sequence. 
The core sequence of RUNX binding sites therefore can be any 4 bases which match the 
TGT/cGGT binding motif. The matrix similarity value analyses the bases adjacent to the 
core sequence and determines the frequency of the most conserved nucleotide at a 
particular position relative to the core sequence. A matrix similarity of 0.80 or greater is 
considered as a good match for a binding motif. Therefore, analysis of core and matrix 
similarity values allows the evaluation of potential binding affinity for a particular site. 
Taken together, RUNX binding motifs with high binding affinities considered in this 
study had minimum values of 0.90 for core similarity and 0.75 for matrix similarity. Using 
these settings, at least one RUNX motif was identified within the promoter regions of all 
integrin genes examined (Table 3.1).  
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Integrin Position 
Core 
Similarity 
Matrix 
Similarity 
Strand Sequence 
ITGB4 
-1096 to -
1110 
1 0.807 (+) catgGTGGttcacgc 
-976 to -990 1 0.808 (+) gggcGTGGtggcggg 
-884 to -898 1 0.802 (-) tgcaGTGGtgcaatc 
-773 to -787 1 0.847 (+) acccGTGGtaagcag 
-370 to -384 1 0.822 (-) ggcTGTGctgctgct 
-190 to -204 1 0.759 (+) agcgGTGGctcctcc 
-132 to -146 0.909 0.8 (-) ggctGCGGctcccgc 
ITGA6 
-644 to -658 1 0.806 (-) gctTGTGgaagaagt 
-473 to -487 1 0.834 (+) cgcTGTGatcattt 
-335 to -349 1 0.813 (-) agatGTGGgcccacg 
-240 to -254 1 0.815 (+) ctcTGTGctactcgg 
-229 to -243 1 0.973 (-) aatTGTGgttgccga 
-217 to -231 1 0.86 (-) ctctGTGGacagaat 
+10 to +24 0.909 0.786 (+) ttcaGCGGtcgcgag 
+110 to 
+124 
0.909 0.904 (+) ggctGCGGtagcagc 
+219 to 
+233 
1 0.857 (+) agcTGTGcttgctct 
ITGB1 
-454 to -468 1 0.771 (-) ccacGTGGtccttct 
-447 to -461 1 0.873 (+) ccacGTGGtttttgg 
+240 to 
+254 
1 0.821 (+) gggtGTGGgagcgcg 
ITGB5 
-420 to -434 0.909 0.75 (-) aaagGCGGttgctag 
-318 to -332 1 0.887 (+) ctcaGTGGtttcgag 
-169 to -183 1 0.833 (+) ccgtGTGGcggccgg 
ITGAV -94 to -108 1 0.829 (-) tgctGTGGagctgga 
 
 
Table 3.1 – RUNX binding motifs identified in integrin promoter regions. Binding 
motifs of the RUNX transcription factors were identified in integrin promoter regions 
using the MatInspector tool from the Genomatix bioinformatics suite 
(http://www.genomatix.de/). The locations of the motifs are defined relative to the 
transcription start site. The core and matrix similarity values indicate the potential binding 
affinities of each site. The RUNX binding motifs are shown in red and the core sequences 
identified by MatInspector are shown in captial letters. RUNX binding motifs located on 
the sense strand are denoted with a (+) while motifs located on the antisense strand are 
denoted with a (-). 
 
 
 
 
 
 
 
 87 
 
RUNX1 and RUNX1-ETO effects on the integrin promoters were analysed using 
luciferase reporter assays. Integrin 5’ UTRs, depicted schematically in Figure 3.10, were 
cloned adjacent to a luciferase gene in the pXPG plasmid, as detailed in Chapter 2, 
Section 2.2. Regions analysed incorporated the region identified as binding RUNX1 in 
ChIP data analysed in Section 3.2.1 (Martens et al. 2012). The integrin reporter constructs 
were transfected into K562 myeloid cells along with RUNX1 or RUNX1-ETO expression 
plasmids. Cells were harvested 24 hours after transfection and luciferase activity was 
measured. To ensure that RUNX1 and RUNX1-ETO were successfully overexpressed in 
the K562 cells, protein levels were analysed in transfected cells using Western Blot 
analysis. Protein from K562 cells, was isolated 24 hours post transfection and 
RUNX1/RUNX1-ETO proteins were detected using RUNX1 and ETO specific 
antibodies. As a positive control, RUNX1 and RUNX1-ETO overexpression was also 
monitored in the Cos-7 cell line. Western Blot analysis shown in Figure 3.11 
demonstrates that both RUNX1 and RUNX1-ETO proteins were successfully 
overexpressed in K562 and Cos-7 cells.  
 
Firstly, to determine the basal level of activity of the integrin reporter constructs, cells 
were transfected with the constructs alone and monitored for luciferase activity. Changes 
in luciferase activity with RUNX1 and RUNX1-ETO overexpressed were therefore 
compared to the basal level of activity of the reporter. Transfection of K562 cells with the 
RUNX1 expression plasmid resulted in increased luciferase activity for all integrin 
reporters except for ITGB1, with a significant increase detected for both ITGB4 and 
ITGA6 (Figure 3.12).  
 
While RUNX1 activated the ITGA6 promoter, overexpression of RUNX1-ETO repressed 
the ITGA6 reporter (Figure 3.12B). In contrast, RUNX1-ETO did not appear to have any 
effect on the ITGB4 or ITGAV promoters (Figure 3.12A and 3.12E). However, on further 
analysis, RUNX1-ETO was shown to repress RUNX1 activation of the ITGB4 promoter 
in a dose-dependent manner, as demonstrated in Figure 3.13. Interestingly, while RUNX1 
did not have an effect on the ITGB1 reporter, overexpression of RUNX1-ETO resulted 
in a significant decrease in activity (Figure 3.12C). In contrast to the other integrins, 
overexpression of RUNX1-ETO was shown to increase the activity of the ITGB5 reporter 
in a similar fashion to RUNX1 (Figure 3.12D). 
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Taken together, these results suggest that RUNX1 activates the ITGB4 and ITGA6 
promoters and that RUNX1-ETO can repress both ITGB4 and ITGA6 promoters, 
competing with RUNX1 to block RUNX1 activation of the promoters. While RUNX1 
increased activity of the ITGB5 and ITGAV promoters, this was not statistically 
significant. Additionally, RUNX1-ETO can activate the ITGB5 promoter to similar levels 
as to RUNX1 and can repress the ITGB1 promoter.  
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Figure 3.10 – Integrin promoter constructs. Schematic representation of integrin 
promoter regions analysed in reporter assays. RUNX motifs identified by MatInspector 
(http://www.genomatix.de/) are denoted by the small black rectangles (with a further 4 
within the -700 to -1200 region of ITGB4 not depicted). The boxes with diagonal lines 
correspond to the DNA sequence bound by RUNX1 in SKNO-1 cells in the ChIP-seq 
study by Martens et al (2012), as depicted in Figures 3.1-3.4. Primers were designed to 
amplify the depicted regions of ITGB4, ITGA6, ITGB1, ITGB5 and ITGAV integrin 
genes. These regions were cloned into the pXPG plasmid containing a luciferase gene for 
reporter assays. The scale indicates base pairs relative to the transcription start site, which 
is represented by the arrow. 
 
 
 
 
 
 
-500 -400 -300 -200 +100 +200 -700 -1200 -100 -600 
ITGB4 
+300 
ITGA6 
ITGB1 
ITGB5 
ITGAV 
 90 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 – Overexpression of RUNX1 and RUNX1-ETO in cell lines. Western blot 
analysis was used to examine RUNX1 and RUNX1-ETO expression in nuclear extracts 
prepared from (A) myeloid cell lines or (B) Cos-7 cells either untransfected or transfected 
with control plasmid (CMV), RUNX1 expression plasmid (RX1) or RUNX1-ETO 
expression plasmid (RX1-E). Nuclear extracts were subjected to Western Blot analysis 
with the indicated antibodies used. Arrows indicate RUNX1 and RUNX-ETO protein 
bands. Histone H3 was monitored as a loading control. 
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Figure 3.12 – RUNX1 and RUNX1-ETO effects on integrin promoters. K562 cells 
were transfected with an integrin promoter luciferase reporter construct (pXPG-ITGB4, 
pXPG-ITGA6, pXPG-ITGB1, pXPG-ITGB5 or pXPG-ITGAV) along with a construct 
expressing RUNX1 or RUNX1-ETO. After 24 hours, protein was extracted and luciferase 
activity was measured. Values are expressed as mean ±SEM (n=3, n=4 for ITGB1) and 
fold change in integrin promoter activity with RUNX1 or RUNX1-ETO overexpressed is 
shown. Statistical significance was determined using Students’ t Test, ***p<0.001, 
**p<0.01, *p<0.05.  
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Figure 3.13 – Inhibition of RUNX1 activation of the ITGB4 promoter by RUNX1-
ETO. K562 cells were transfected with pXPG-ITGB4 with 5 µg of RUNX1 expression 
plasmid and increasing amounts of RUNX1-ETO expression plasmid, as indicated. After 
24 hours, protein was extracted and luciferase activity measured. Fold change relative to 
reporter activity in cells transfected with RUNX1 alone are depicted. Values are 
expressed as mean ±SEM (n=3). Statistical significance was determined using one-way 
ANOVA, Newman Keuls Multiple Comparison Test, **p<0.01, *p<0.05. 
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3.3 Discussion 
 
Several lines of evidence presented here suggest that expression of the α6β4 integrin 
receptor is regulated by RUNX1 in haematopoietic cells. Firstly, previously published 
microarray studies (Ichikawa et al. 2006, Valk et al. 2004), and a microarray study 
conducted by our research group (Oakford and Holloway, unpublished), showed altered 
ITGB4 expression in haematopoietic cells with RUNX1 disrupted. These data suggest 
that ITGB4 may be a target gene of RUNX1, although a limitation of microarray studies 
is that they do not distinguish between direct and indirect targets. 
 
Secondly, analysis of publicly available ChIP-seq data (Beck et al. 2013, Martens et al. 
2012, Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et al. 
2015) demonstrated RUNX1 binding to the promoter of ITGB4 in SKNO-1 cells, 
therefore confirming that ITGB4 is a direct target of RUNX1 (Martens et al. 2012). 
Interestingly, although ITGA6 was not identified as a potential RUNX1 target gene in the 
microarray studies, data from ChIP-seq studies suggest that it is also a direct target of 
RUNX1. RUNX1 was shown to bind to the ITGA6 promoter in megakaryocytes, SKNO-
1 cells and Kasumi-1 cells, and RUNX1-ETO was detected at the ITGA6 promoter in 
Kasumi-1 cells (Martens et al. 2012, Ptasinska et al. 2014, Tijssen et al. 2011, Trombly 
et al. 2015). While ChIP-seq analysis provides information on DNA-protein interactions 
which occur in cells, a limitation of ChIP-seq is that it provides no information about the 
functional outcome of the transcription factor binding.  
 
A third line of evidence indicating that RUNX1 regulates the ITGB4 and ITGA6 genes 
comes from reporter analysis of the respective promoters. RUNX1 was shown to have a 
functional effect on both ITGB4 and ITGA6 promoters. RUNX1 increased the activity of 
both of the promoters, while RUNX1-ETO decreased promoter activity, which is 
consistent with previous studies of other gene promoters describing RUNX1-ETO as a 
transcriptional repressor (Frank et al. 1995, Gelmetti et al. 1998, Wang et al. 1998). 
However, while RUNX1-ETO was shown to repress activity of the ITGB4 promoter in 
reporter assays, this is in contrast to available microarray data (Ichikawa et al. 2006, Valk 
et al. 2004) which show increased expression of ITGB4 in cells positive for the t(8;21) 
chromosomal translocation compared to normal controls (Figure 3.14). In keeping with 
this, ITGB4 was also found to be expressed at higher levels in the t(8;21) positive Kasumi-
1 cells compared to KG-1a and K562 cells in the present study. These findings suggest 
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that RUNX1-ETO functions differently on the isolated ITGB4 promoter than in the 
context of the endogenous gene, and this warrants further investigation. 
 
While RUNX1-ETO is commonly described as a transcriptional repressor, there is 
evidence that RUNX1-ETO can act as a transcriptional activator in reporter assays. 
RUNX1-ETO has been shown to work synergistically with RUNX1 to transactivate the 
M-CSF receptor promoter (Rhoades et al. 1996). Additionally, RUNX1-ETO can activate 
the transcription of the BCL-2 gene through the RUNX1 binding motif TGTGGT 
(Klampfer et al. 1996) and RUNX1-ETO can activate the G-CSF gene but independently 
of a RUNX1 binding site (Shimizu et al. 2000). Furthermore, in the present study, 
RUNX1-ETO was shown to increase activity of the ITGB5 promoter in reporter assays.  
 
In recent studies, it has been shown that the truncated leukaemogenic form of RUNX1-
ETO, RUNX1-ETO9a, which does not possess the C-terminal NcoR/SMRT-interacting 
domains, can act as a strong activator of transcription (Yan et al. 2004, Yan et al. 2006). 
This variant transcript can increase the expression of the integrin gene ITGB1 in murine 
bone marrow progenitor cells (Ponnusamy et al. 2014). In addition, down-regulation of 
RUNX1-ETO in Kasumi-1 cells results in decreased expression of ITGB1, suggesting 
that expression of ITGB1 is dependent on the presence of the RUNX1-ETO fusion protein 
(Ponnusamy et al. 2014). These data are consistent with expression analysis in this study, 
which showed higher levels of ITGB1 mRNA in Kasumi-1 cells compared to K562 and 
KG-1a cells. Furthermore, a previous study has demonstrated that the RUNX1-ETO9a 
transcript is expressed in the Kasumi-1 cell line and in 27 of 37 individuals with t(8;21) 
AML (Yan et al. 2006). Taken together, higher levels of ITGB4 in cells positive for the 
t(8;21) chromosomal translocation may be due to transcriptional activation by the variant 
transcript RUNX1-ETO9a. Further studies are therefore required to determine if RUNX1-
ETO9a can activate the ITGB4 promoter. 
 
Interestingly, PMA treatment of K562 cells increased the expression of ITGB4 and 
ITGA6 integrin genes, at least at the mRNA level. It has previously been shown that 
treatment of K562 cells results in stimulation of promoters such as TCRβ, MCSF and 
GM-CSF, which possess RUNX1 binding motifs (Zhang et al. 2004). While RUNX1 
mRNA levels did not increase in response to PMA treatment, it has been reported that 
treatment with PMA results in increased transcriptional activity of the RUNX1 
transcription factor in K562 cells due to phosphorylation, hence leading to increased 
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expression of RUNX1 target genes (Zhang et al. 2004). Therefore, the increase in ITGB4 
and ITGA6 expression observed in K562 cells treated with PMA in this study could be 
due at least in part to increased transcriptional activity of RUNX1.  
 
Although the ITGB5 gene was identified in the microarray studies (Ichikawa et al. 2006, 
Michaud et al. 2008, Wotton et al. 2008) to be a potential RUNX1 target gene, RUNX1 
effects on the ITGB5 promoter were not statistically significant due to variability between 
the assays. Furthermore, in contrast to the other integrins, RUNX1-ETO was found to 
increase ITGB5 promoter activity. These data reflect the microarray studies where 
regulation of ITGB5 by RUNX1 appears to be context dependent. Further investigation 
of ITGB5 may therefore be useful in deciphering some of the less typical and context 
dependent functions of RUNX1 as a transcriptional regulator. 
 
In conclusion, data presented here suggest that RUNX1 regulates the integrin genes 
ITGB4 and ITGA6, and thus expression of these genes may be altered in leukaemic cells 
with disrupted RUNX1. A question that remains is how RUNX1 regulates these genes 
and how this regulation is disrupted in leukaemia. 
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Figure 3.14 – Expression of ITGB4 in leukaemic and healthy individuals. Expression 
levels of ITGB4 mRNA in primary leukaemic cells derived from individuals with 
leukaemia positive for the inv(16) or t(8;21) chromosomal rearrangements, based on 
published microarray data analysis (Valk et al. 2004) and extracted from the Leukemia 
Gene Atlas database (http://www.leukemia-gene-atlas.org/LGAtlas/).  
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Chapter 4 
 
Regulation of ITGB4 and ITGA6 by RUNX1 in 
Myeloid Cells 
 
 
4.1 Introduction 
 
4.1.1 Complexity of RUNX1 Regulation of Gene Expression 
The RUNX1 transcription factor controls expression of its target genes through a variety 
of different mechanisms. The structure of RUNX1 allows the transcription factor to exert 
either a positive or negative influence on the transcription of its target genes due to the 
presence of both transcriptional activation and inhibition domains at its C-terminus (Blyth 
et al. 2005). Furthermore, RUNX1 regulation of gene expression, as with many 
transcription factors, is complicated by the fact that it acts in complexes with other 
transcription factors to regulate its target genes (Giese et al. 1995, Gu et al. 2000, Huang 
et al. 2009, Mao et al. 1999, Zhang et al. 1996), its ability to direct epigenetic 
modification (Kitabayashi et al. 1998, Lutterbach et al. 2000, Oakford et al. 2010, Reed-
Inderbitzin et al. 2006) and its ability to regulate genes through both promoters as well as 
distal regulatory regions such as enhancers (Bowers et al. 2010, Hernandez-Munain and 
Krangel 1994, Hernández-Munain and Krangel 2002, Meyers et al. 1993, Takahashi et 
al. 1995, Zhang et al. 1994). 
 
Early studies described RUNX1 as a transcriptional activator, which bound to the 
consensus sequence TGT/cGGT in the promoters of its target genes (Meyers et al. 1993, 
Takahashi et al. 1995). The presence of a TGT/cGGT consensus site in regulatory regions 
was therefore used to identify potential target genes (Meyers et al. 1993, Takahashi et al. 
1995, Zhang et al. 1994). However, subsequent research has demonstrated that RUNX1 
is a relatively weak activator alone and therefore commonly regulates gene expression in 
a complex with other transcription factors. 
 
Interaction of RUNX1 with other transcription factors was first reported in a study 
investigating regulation of the T-cell receptor β gene enhancer (Wotton et al. 1994).  Both 
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RUNX1 and the ETS-1 transcription factor were found to bind to the enhancer, and ETS-
1 and RUNX1 binding sites were identified directly adjacent to each other within the 
enhancer region (Wotton et al. 1994). ETS-1 and RUNX1 were found to cooperatively 
bind to the enhancer to form a high-affinity DNA-binding complex, but only when both 
binding sites were present (Wotton et al. 1994). In further studies, RUNX1 was also 
shown to cooperate with C/EBPα to synergistically activate the M-CSF receptor promoter 
(Zhang et al. 1996). RUNX1 physically interacted with C/EBPα in in vitro assays and 
simultaneous binding of the transcription factors to the DNA resulted in activation of the 
M-CSF receptor promoter by more than 60-fold (Zhang et al. 1996). This activation was 
dependent on the presence of both RUNX1 and C/EBP binding sites (Zhang et al. 1996). 
As well as ETS-1 and C/EBPα, RUNX1 can physically interact with other transcription 
factors important for haematopoiesis, such as GATA1 and FLI1, to activate gene 
promoters (Elagib et al. 2003, Huang et al. 2009, Waltzer et al. 2003).  
 
In addition to influencing the transcriptional activity of its target genes, RUNX1 can 
affect the epigenetic status of genes by interacting with epigenetic modifiers, as reviewed 
recently (Brettingham-Moore et al. 2015). To activate gene expression, RUNX1 has been 
shown to interact with the histone acetyltransferases p300 and CBP (Kitabayashi et al. 
1998). A study has shown that RUNX1 is required for the hyperacetylation of the GM-
CSF promoter via the interaction with CBP (Oakford et al. 2010). Furthermore, RUNX1 
can repress gene expression by interacting with HDACs, mSin3a and the histone 
methyltransferase SUV39H1 (Dannenberg et al. 2005, Durst and Hiebert 2004, 
Lutterbach et al. 1999, Reed-Inderbitzin et al. 2006) and a study has shown RUNX1 to 
repress and silence the CD4 gene by interacting with HDACs and SUV39H1 (Reed-
Inderbitzin et al. 2006). 
 
While much of the early work investigating RUNX1 function focussed on regulation of 
gene expression by promoter bound RUNX1, more recent genome-wide analysis has 
shown that RUNX1 binds more frequently to intragenic/intergenic regions compared to 
promoter regions (Beck et al. 2013, Wilson et al. 2010). These distal regulatory regions, 
such as enhancers, are often located several hundred kilobases either upstream or 
downstream of a gene promoter (Maston et al. 2006). For example, RUNX1 can regulate 
the GM-CSF gene through an upstream enhancer located 3 kb from the transcription start 
site (Bowers et al. 2010). In addition, RUNX1 is important for the assembly and function 
of the TCRδ enhancer, enabling c-Myb enhancer binding and activation of the gene 
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promoter (Hernández-Munain and Krangel 2002), and RUNX1 has been shown to 
function synergistically with c-Myb to activate the myeloperoxidase gene enhancer 
(Britos-Bray and Friedman 1997). Enhancers can function by interacting with the 
promoters of genes through DNA looping, which is often facilitated by transcription 
factor interactions and allows the enhancer and promoter to come into close proximity in 
the cell (Maston et al. 2006). RUNX1 has been shown to regulate the CD34 gene in this 
manner, through an enhancer located 18.8-19.6 kb downstream of the transcription start 
site (Levantini et al. 2011). The downstream enhancer region was found to physically 
interact with the CD34 promoter. Targeted mutagenesis of RUNX binding motifs within 
the enhancer led to disruption of this interaction and decreased CD34 expression in 
haematopoietic stem cells, suggesting that RUNX1 is required for these promoter-
enhancer interactions (Levantini et al. 2011). 
 
4.1.2 RUNX1 Regulation of ITGB4 and ITGA6 Integrin Genes 
Regulation of gene expression is therefore complex with RUNX1 acting at multiple levels 
to regulate gene activity. Evidence presented in Chapter 3 indicate that RUNX1 can bind 
to and regulate the ITGB4 and ITGA6 promoters, and therefore, the second aim of this 
study was to characterise the mechanisms through which RUNX1 regulates these genes.  
 
 
4.2 Results 
 
4.2.1 RUNX1 Regulation of the ITGA6 Promoter 
4.2.1.1 Characterisation of the RUNX1 Responsive Region in the ITGA6 Promoter 
Reporter assays described in Chapter 3 indicate that RUNX1 activates the ITGA6 
promoter in myeloid cells, as demonstrated by increased reporter activity when RUNX1 
was overexpressed (Figure 3.12). Bioinformatic analysis also identified a number of 
potential RUNX1 binding motifs within the -675 bp to +242 bp region analysed in 
reporter assays (Table 3.1). To determine the region of the ITGA6 promoter through 
which RUNX1 is acting, a deletion construct (Del-1) was created to delete 6 of 9 putative 
RUNX1 binding motifs within the RUNX1 responsive region (Figure 4.1A). Of these 6 
motifs, one is a 100% match to the RUNX1 consensus sequence (TGTGGT). The deletion 
construct included the region -140 bp to +242 bp relative to the transcription start site and 
removed this consensus motif at -237 to -232 bp (Figure 4.1A).  
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K562 cells were transfected with either the original ITGA6 promoter construct or the 
deletion construct along with the RUNX1 expression plasmid. Cells were harvested 24 
hours after transfection and luciferase activity was measured. To determine the effect of 
RUNX1 on the ITGA6 promoter constructs, the fold change in promoter activity in 
transfected cells following RUNX1 overexpression was compared to cells transfected 
with the promoter construct alone. Overexpression of RUNX1 in K562 cells resulted in 
an increase in reporter activity of the ITGA6 promoter construct (Figure 4.1B). Deletion 
of the region from -675 bp to -140 bp significantly reduced RUNX1 activation of the 
promoter (Figure 4.1B; p<0.001). While RUNX1 responsiveness was not completely 
removed, these results suggest that a RUNX1 responsive region of the ITGA6 promoter 
is located -675 bp to -141 bp upstream of the transcription start site. 
 
4.2.1.2 Effect of Mutation of the Consensus RUNX1 Binding Motif in the ITGA6 
Promoter 
To determine if RUNX1 was acting through the single consensus motif within the region 
-675 bp to -141 bp upstream of the transcription start site, it was mutated in the full length 
reporter construct creating an EcoRV recognition sequence (TGTGGT to GATATC) at -
237 bp to -232 bp, following the protocol described in Chapter 2, Section 2.2. To confirm 
the EcoRV recognition sequence was created, the plasmid DNA was digested with HindIII 
and EcoRV restriction enzymes, with the expected size fragments of 6504 bp and 476 bp 
produced (Figure 4.2A). The plasmid DNA was also sequenced to confirm mutation of 
the consensus RUNX1 binding motif (Figure 4.2B). 
 
K562 cells were then transfected with the wild type ITGA6, deletion and mutant reporter 
constructs (Figure 4.3A), along with the RUNX1 expression plasmid. Cells were 
harvested after 24 hours and luciferase activity was measured. Fold change in activity of 
each promoter construct with RUNX1 overexpressed was analysed. As described 
previously, RUNX1 activated the full-length reporter construct, but only had a minimal 
effect on the deletion construct (Figure 4.3B; Del-1). Mutation of the consensus RUNX1 
binding motif resulted in a significant decrease in RUNX1 activation of the promoter, to 
a similar level observed with the deletion construct (Figure 4.3B; p<0.01). These data 
therefore suggest that RUNX1 activates the ITGA6 promoter through a classical RUNX1 
binding motif located -237 bp to -232 bp upstream of the transcription start site. 
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Figure 4.1 – Identification of a RUNX1 responsive region located -141 bp to -675 bp 
upstream of the transcription start site of ITGA6. A) Schematic representation of 
ITGA6 promoter regions analysed in reporter assays. ITGA6 promoter regions were 
cloned into the pXPG plasmid containing a luciferase gene. Scale indicates base pairs 
relative to the transcription start site (indicated by arrow). White boxes represent putative 
RUNX1 binding motifs and the blue box represents a motif with 100% match to the 
RUNX1 consensus sequence. B) K562 cells were transfected with the promoter reporter 
constructs either with or without the RUNX1 expression plasmid. Protein was isolated 
from transfected cells after 24 hours and analysed in a luciferase reporter assay. Fold 
change in activity of ITGA6 and Del-1 constructs following RUNX1 overexpression in 
K562 cells is shown. Values are expressed as mean ±SEM (n=3). Statistical significance 
was determined using Student’s t Test, ***p<0.001.  
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Figure 4.2 – Mutation of the consensus RUNX1 binding motif in the ITGA6 
promoter. A) The RUNX1 consensus motif was mutated in the ITGA6 promoter creating 
an EcoRV recognition site, as described in Chapter 2, Section 2.2. The mutant promoter 
region was ligated into the pXPG plasmid and recombinant plasmids were transformed 
into E.coli cells. Single bacterial colonies were screened for the mutant promoter region 
by digestion with HindIII and EcoRV enzymes. Digested plasmid DNA was subjected to 
gel electrophoresis using a 1% agarose gel. Pink arrow shows the plasmid which is 
digested by EcoRV, suggesting incorporation of the mutant sequence. Lane 1: Lambda 
molecular weight marker; Lane 2-7: plasmid DNA from single bacterial colonies; Lane 
8: 100 bp molecular weight marker. B) Screen shot of promoter regions, viewed in 
Sequencher 4.10.1. Red boxes show the normal and mutated RUNX1 consensus binding 
motif in ITGA6 and mutant promoter regions, respectively.  
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Figure 4.3 – RUNX1 regulates the ITGA6 promoter through a consensus RUNX1 
binding motif. A) Schematic representation of ITGA6 promoter regions analysed in 
reporter assays. ITGA6 promoter regions were cloned into the pXPG plasmid containing 
a luciferase gene. Scale indicates base pairs relative to the transcription start site 
(indicated by arrow). White boxes represent putative RUNX1 binding motifs and the blue 
box represents a motif with 100% match to the RUNX1 consensus sequence. B) K562 
cells were transfected with promoter reporter constructs either with or without the 
RUNX1 expression plasmid. Protein was isolated from transfected cells after 24 hours 
and analysed in a luciferase reporter assay. Fold change in activity of ITGA6, Del-1 and 
Mutant constructs following RUNX1 overexpression in K562 cells is shown. Values are 
expressed as mean ±SEM (n=3). Statistical significance was determined using one-way 
ANOVA, Newman Keuls Multiple Comparison Test, ***p<0.001, **p<0.01, not 
significant (ns) p>0.05. 
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4.2.1.3 RUNX1 Binds to the Endogenous ITGA6 Promoter 
Reporter assays indicate that RUNX1 can activate the ITGA6 promoter in myeloid cells, 
therefore binding of RUNX1 to the endogenous ITGA6 promoter was analysed using 
ChIP assays. RUNX1 binding to the ITGA6 promoter was analysed in KG-1a and 
Kasumi-1 cell lines. RUNX1 binding was not examined in K562 cells based on the less 
reliable data generated in genome-wide analysis in these cells, as described in Chapter 3, 
which may be a result of lower RUNX1 levels in these cells. KG-1a and Kasumi-1 cells 
were fixed with formaldehyde and DNA was sheared using sonication. DNA 
immunoprecipitated with a RUNX1 antibody was analysed by qPCR with primers that 
amplify a region adjacent to the RUNX1 consensus motif in the ITGA6 promoter. As a 
control for RUNX1 binding, the promoter of the Rhodopsin gene, which is only normally 
expressed in G-protein-coupled photoreceptors in the eye (Palczewski et al. 2000) and 
therefore expected to be silenced in haematopoietic cells, and additionally does not 
contain any RUNX consensus motifs, was also analysed for RUNX1 enrichment. In both 
KG-1a and Kasumi-1 cells, there was increased RUNX1 occupancy at the ITGA6 
promoter compared to the Rhodopsin promoter (Figure 4.4). While enrichment at the 
ITGA6 promoter was statistically significant in KG-1a cells, statistical testing was not 
possible in Kasumi-1 cells as there was no PCR amplification of the Rhodopsin promoter 
in the RUNX1 ChIP in these cells. 
 
Together, these data suggest that RUNX1 binds to and activates the ITGA6 promoter 
through a RUNX1 consensus motif. 
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Figure 4.4 – RUNX1 binds the ITGA6 promoter in KG-1a and Kasumi-1 cells. A-B) 
ChIP assays were performed with an antibody against RUNX1 in A) KG-1a and B) 
Kasumi-1 cells. Immunoprecipitated DNA was analysed by qPCR with primers that 
amplify a region within the ITGA6 and Rhodopsin promoters. The data are shown as the 
ratio of immunoprecipitated DNA to total input DNA. Values are expressed as mean 
±SEM (n=3-6). Statistical significance was determined using Student’s t Test, 
***p<0.001. 
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4.2.2 RUNX1 Regulation of the ITGB4 Promoter 
4.2.2.1 Characterisation of the RUNX1 Responsive Region in the ITGB4 Promoter 
Reporter assays described in Chapter 3 indicate that RUNX1 activates the ITGB4 
promoter in myeloid cells, as demonstrated by increased reporter activity when RUNX1 
was overexpressed (Figure 3.12). To determine the region of the ITGB4 promoter through 
which RUNX1 is acting, deletion constructs were created to delete putative RUNX1 
binding motifs in this region as described in Chapter 3 (Figure 4.5A). Four deletion 
constructs were initially created to analyse regions -758 bp to +144 bp (Del-1), -295 bp 
to +144 bp (Del-2), -57 bp to +144 bp (Del-3) and -57 bp to +13 bp (Del-4) of the ITGB4 
5’UTR (Figure 4.5A). K562 cells were transfected with either the original ITGB4 
promoter construct or the deletion constructs (Del-1 to -4) along with the RUNX1 
expression plasmid. Cells were harvested 24 hours after transfection and luciferase 
activity was measured. Fold change in activity of each promoter construct following 
RUNX1 overexpression was determined. To elucidate the effect of deletions to different 
regions of the ITGB4 promoter, all fold changes for the deletion constructs were 
determined relative to the fold change of the original ITGB4 promoter construct, which 
was set to 1 (Figure 4.5B). Deletion of the region from -1199 bp to -295 bp of the ITGB4 
gene had no significant effect on RUNX1 activation of the ITGB4 promoter, as RUNX1 
activated the Del-1 and Del-2 reporter constructs similarly to the original (-1199 bp to 
+144 bp) ITGB4 reporter construct (Figure 4.5B). However, further deletion of the 
promoter from -295 bp to -58 bp, to generate a -57 bp to +144 bp construct (Del-3), 
resulted in a significant decrease in RUNX1 activation of the ITGB4 promoter (Figure 
4.5B; p<0.01). Further deletion to generate a minimal -57 bp to +13 bp promoter construct 
(Del-4), resulted in a further decrease in RUNX1 activation, although this was not 
statistically different to Del-3 (Figure 4.5B; p>0.05).  
 
These data suggest that the region from -295 bp to -58 bp upstream of the transcription 
start site contains a RUNX1 responsive region. The further decrease in reporter activity 
observed when removing the region from +13 bp to +144 bp is likely due to an effect on 
general transcription machinery assembly. To confirm these data, the -295 bp to -58 bp 
region was deleted from the larger Del-1 (-758 bp to +144 bp) construct (Figure 4.5A). 
Specific deletion of this region (Del-5) resulted in a decrease in RUNX1 activation of the 
ITGB4 promoter to a level similar to that seen when the entire region from -758 bp to -
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58 bp was deleted (Figure 4.5C), confirming that this region is required for activation of 
the ITGB4 promoter by RUNX1.  
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Figure 4.5 – Identification of a RUNX1 responsive region within the ITGB4 
promoter located -295 to -58 bp upstream of the transcription start site. A) Schematic 
representation of ITGB4 promoter regions analysed in reporter assays. ITGB4 promoter 
regions were cloned into the pXPG plasmid containing a luciferase gene for reporter 
assays. Scale indicates base pairs relative to the transcription start site (indicated by 
arrow). White boxes represent putative RUNX1 binding motifs (with a further 4 within 
the -700 to -1200 region of ITGB4 not depicted), although none are 100% matches to the 
consensus sequence. B-C) K562 cells were transfected with promoter reporter constructs 
either with or without the RUNX1 expression plasmid. Protein was isolated from 
transfected cells after 24 hours and analysed in a luciferase reporter assay. Relative fold 
change in activity of constructs following RUNX1 overexpression in K562 cells is shown. 
Values are expressed as mean ±SEM (n=3). Statistical significance was determined using 
one-way ANOVA, Newman Keuls Multiple Comparison Test, ***p<0.001, **p<0.01, 
not significant (ns) p>0.05. 
-500 -400 -300 -200 +100 +200 -700 -1200 -100 
Del-1 
Del-2 
Del-3 
ITGB4 
-600 
ITGB4 
Del-4 
Del-5 
4 RUNX1 Motifs 
Del-1 Del-3 Del-5
0.0
0.2
0.4
0.6
0.8
1.0
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 U
n
it
s
(F
o
ld
 C
h
a
n
g
e
)
 109 
 
4.2.2.2 Mutation of a Potential RUNX1 Binding Motif in the ITGB4 Promoter 
Within the RUNX1 responsive region identified in the ITGB4 promoter, located -295 bp 
to -58 bp upstream of the transcription start site (Section 4.2.2.1), there are two putative 
RUNX1 binding motifs, GGTGGC at -196 bp to -201 bp and GCCGCA at -135 bp to -
140 bp. Therefore, to determine which of these motifs may be required for RUNX1 
activation of the promoter, another deletion construct (Del-6) was created to delete only 
one of the putative RUNX1 binding sites (Figure 4.6A). Deletion from -295 bp to -176 
bp of the transcription start site and thus removing the motif at -196 bp to -201 bp 
unexpectedly resulted in a significant increase in RUNX1 activation of the promoter 
(Figure 4.6B, p<0.01). These results therefore suggest that this site is not responsible for 
RUNX1 activation of the promoter and that this activity is located within -58 bp to -175 
bp of the ITGB4 gene. 
 
A single putative RUNX1 binding motif at -135 bp to -140 bp is present in the region 
from -58 bp to -175 bp shown to be responsive to RUNX1. Therefore, to determine if 
RUNX1 is acting through this putative RUNX1 binding motif (GCCGCA), the motif was 
mutated within the reporter construct containing the region -295 bp to +144 bp (Del-2), 
creating a BglII recognition sequence (GCCCGA to AGATCT), following the protocol 
described in Chapter 2, Section 2.2. To confirm the BglII recognition sequence was 
created, the plasmid DNA was digested with BglII restriction enzyme, with the expected 
sized fragments of 6343 bp and 174 bp produced (Figure 4.7A). The plasmid DNA was 
also sequenced to confirm mutation of the potential RUNX1 binding motif (Figure 4.7B) 
 
K562 cells were transfected with Del-2 (-295 bp to +144 bp), Del-3 (-57 bp to +144 bp) 
and Mutant constructs (Figure 4.6A) along with the RUNX1 expression plasmid. Cells 
were harvested after 24 hours and luciferase activity was measured. Fold change in 
activity of each promoter construct with RUNX1 overexpressed was analysed. As 
described previously, RUNX1 activated the Del-2 construct, but only had a minimal 
effect on the Del-3 construct (Figure 4.6C). Mutation of the RUNX1 binding motif had 
no effect on RUNX1 activation of the promoter, therefore suggesting that RUNX1 does 
not activate the ITGB4 promoter specifically through this sequence (Figure 4.8C).  
 
Put together, these data demonstrate that while the region upstream of the ITGB4 
transcription start site contains a number of potential RUNX1 binding motifs, none of 
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these contributes to RUNX1 activation of the promoter in reporter assays. However, a 
RUNX1 responsive region is located at -58 bp to -175 bp, suggesting that RUNX1 is 
recruited to this region through an alternate mechanism. 
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Figure 4.6 – RUNX1 does not activate the ITGB4 promoter through a RUNX1 
binding motif. A) Schematic representation of ITGB4 promoter regions analysed in 
reporter assays. ITGB4 promoter regions were cloned into the pXPG plasmid containing 
a luciferase gene for reporter assays. Scale indicates base pairs relative to the transcription 
start site (indicated by arrow). White boxes represent putative RUNX1 binding motifs 
(with a further 4 within the -700 to -1200 region of ITGB4 not depicted), although none 
are 100% matches to the consensus sequence. B-C) K562 cells were transfected with 
promoter reporter constructs either with or without the RUNX1 expression plasmid. 
Protein was isolated from transfected cells after 24 hours and analysed in a luciferase 
reporter assay. Relative fold change in activity of constructs following RUNX1 
overexpression in K562 cells is shown. Values are expressed as mean ±SEM (n=6). 
Statistical significance was determined using one-way ANOVA, Newman Keuls Multiple 
Comparison Test, **p<0.01, *p<0.05. 
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Figure 4.7 – Mutation of a potential RUNX1 binding motif in the ITGB4 promoter. 
A) A RUNX1 binding motif was mutated in the ITGB4 promoter creating a BglII 
recognition site, as described in Chapter 2, Section 2.2. The mutant promoter region was 
ligated into the pXPG plasmid and recombinant plasmids were transformed into E.coli 
cells. Single bacterial colonies were screened for the mutant promoter region by digestion 
with BglII enzyme. Digested plasmid DNA was subjected to gel electrophoresis using a 
1% agarose gel. Pink arrow shows the plasmid which is digested by BglII, suggesting 
incorporation of the mutant sequence. Lane 1: Lambda molecular weight marker; Lane 
2-7: plasmid DNA from single bacterial colonies; Lane 8: 100 bp molecular weight 
marker. B) Screen shot of promoter regions, viewed in Sequencher 4.10.1. Red boxes 
show the normal and mutated RUNX1 binding motif in ITGB4 and mutant promoter 
regions, respectively. 
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4.2.2.3 RUNX1 Binds to the Endogenous ITGB4 Promoter 
Reporter assays indicate that RUNX1 can activate the ITGB4 promoter in myeloid cells. 
Therefore, binding of RUNX1 to the endogenous ITGB4 promoter was analysed using 
ChIP assays. RUNX1 binding to the ITGB4 promoter was analysed in KG-1a and 
Kasumi-1 cell lines. As described previously, KG-1a and Kasumi-1 cells were fixed with 
formaldehyde and DNA was sheared using sonication. DNA immunoprecipitated with a 
RUNX1 antibody was analysed by qPCR with primers that amplify a region adjacent to 
the RUNX1 responsive region in the ITGB4 promoter. Again, as a control for RUNX1 
binding, the promoter of the Rhodopsin gene was also analysed for RUNX1 enrichment. 
In both KG-1a and Kasumi-1 cells, there was increased RUNX1 occupancy at the ITGB4 
promoter compared to the Rhodopsin promoter (Figure 4.8) 
 
Together, these data suggest that RUNX1 binds to and activates the ITGB4 promoter, 
however, unlike ITGA6, RUNX1 does not bind to a consensus site within the promoter 
and therefore recruitment of RUNX1 to the promoter must occur through an alternate 
mechanism. 
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Figure 4.8 – RUNX1 binds the ITGB4 promoter in KG-1a and Kasumi-1 cells. A-B) 
ChIP assays were performed with an antibody against RUNX1 in A) KG-1a and B) 
Kasumi-1 cells. Immunoprecipitated DNA was analysed by qPCR with primers that 
amplify a region within the ITGB4 and Rhodopsin promoters. The data are shown as the 
ratio of immunoprecipitated DNA to total input DNA. Values are expressed as mean 
±SEM (n=3-6). Statistical significance was determined using Student’s t Test, ns p>0.05. 
In B), binding was not detected at the Rhodopsin region. 
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4.2.3 Regulation of ITGB4 by Distal Regions 
4.2.3.1 Identification of an ITGB4 Enhancer 
Regulation of the ITGB4 gene is altered in cells in which RUNX1 is disrupted (Ichikawa 
et al. 2006, Valk et al. 2004) and RUNX1 binds to the promoter in myeloid cells. 
However, the failure to find a RUNX1 binding motif through which it functions at the 
ITGB4 promoter suggests that its regulation of ITGB4 is complex. Higher order 
chromatin structures and complex interactions, which are not assessed in reporter assays, 
may therefore also contribute to RUNX1 regulation of the promoter. Hence, to determine 
if the ITGB4 promoter interacts with other regions of the genome, Chromatin Interaction 
Analysis with Paired-End Tag Sequencing (ChIA-PET) data (Fullwood et al. 2009) from 
the ENCODE project (ENCODE 2012) was interrogated. The specific data set analysed 
was produced in K562 cells and identifies DNA loops between regions of the genome 
that coincide with RNA polymerase II binding (GSM970213).  
 
Analysis of the ChIA-PET data revealed three interactions involving the ITGB4 
promoter; a shorter range interaction with a region located -1,805 bp to -3,459 bp 
upstream of the transcription start site; a longer range interaction with a region located 
+8491 bp to +10,343 bp downstream; and another longer range interaction with a region 
located -12,053 bp to -14,003 bp upstream (Figure 4.9). While these interactions are 
relatively weak (the strength indicated by grey scale), this may reflect the low levels of 
ITGB4 expression in K562 cells (Figure 3.6A). To determine whether any of the regions 
interacting with the ITGB4 promoter represent putative enhancer elements, the histone 
modification data from the ENCODE project (ENCODE 2012) was analysed for 
H3K4me1 and H3K27ac histone modifications representative of enhancer regions 
(Heintzman et al. 2009, Rada-Iglesias et al. 2011). Only one of these regions, located -
12,053 bp to -14,003 bp upstream of the ITGB4 transcription start site, situated towards 
the end of a SAP30BP gene, displayed chromatin features suggestive of an enhancer 
element. Both H3K4me1 and H3K27ac peaks were present, as well as a DNase 
hypersensitive site (Figure 4.9). Additionally, the H3K4me3 mark which is characteristic 
of promoters (Heintzman et al. 2007) was absent from this region, therefore suggesting 
that the region is not a gene promoter.  
 
In contrast, similar analysis of the ITGA6 promoter failed to identify a putative enhancer 
element. While two short-range, localised interactions; one located +3,330 bp to +7270 
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downstream and another located -3240 bp to -4764 bp upstream of the ITGA6 
transcription start site were detected (Figure 4.10), unlike ITGB4, neither of these regions 
displayed chromatin features suggestive of enhancer regions, with no enrichment for 
H3K27ac and H3K4me1, and no DNase hypersensitivity detected (Figure 4.10). 
 
To determine if RUNX1 may bind to the potential enhancer region for the ITGB4 
promoter, located -12,053 bp to -14,003 bp upstream of ITGB4, ChIP-seq data as 
described in Chapter 3 were interrogated for RUNX1 binding at this region (Beck et al. 
2013, Martens et al. 2012, Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 
2011, Trombly et al. 2015). RUNX1 was found to bind to the potential ITGB4 enhancer 
region in CD34+ and Kasumi-1 cells (Figure 4.11). Together, these data suggest that 
RUNX1 can be recruited to this upstream region, which interacts with the ITGB4 
promoter and is associated with chromatin features consistent with an enhancer element. 
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Figure 4.9 – Identification of a potential enhancer region upstream of the ITGB4 
promoter. A screen shot of ChIA-PET data, histone modification ChIP-seq data and 
DNase hypersensitive site (DHS) data from the ENCODE project (ENCODE 2012) 
visualised in the UCSC Genome Browser (Kent et al. 2002) is shown. ChIA-PET data 
were analysed for regions of the genome which interact with the ITGB4 promoter. The 
ITGB4 promoter is shown by the pink arrow. Three regions of DNA found to interact 
with the ITGB4 promoter through RNA polymerase II in K562 cells were identified. The 
DNA loops of the three interacting regions of DNA are shown in the black boxes. Grey-
scale of DNA loops indicates the strength of the interaction (darker shade is a stronger 
interaction whereas lighter shade is a weaker interaction). Histone modification ChIP-seq 
data were analysed for histone marks characteristic of enhancer and promoter regions 
(characteristic peaks are shown by black arrows). DNase hypersensitive site data were 
also analysed and hypersensitive sites are shown by the black arrow. ITGB4 and 
SAP30BP genes are represented at the top of the figure with exons shown as bars. The 
major transcript of ITGB4 is in black, while the major transcript of SAP30BP is in dark 
blue. 
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Figure 4.10 – Analysis of DNA loops involving the ITGA6 promoter. A screen shot 
of ChIA-PET data, histone modification ChIP-seq data and DNase hypersensitive site 
(DHS) data from the ENCODE project (ENCODE 2012) visualised in the UCSC Genome 
Browser (Kent et al. 2002) is shown. ChIA-PET data were analysed for regions of the 
genome which interact with the ITGA6 promoter. The ITGA6 promoter is shown by the 
pink arrow. Two regions of DNA found to interact with the ITGA6 promoter through 
RNA polymerase II in K562 cells were identified. The DNA loops of the two interacting 
regions of DNA are shown in the black boxes. Grey-scale of DNA loops indicates the 
strength of the interaction (darker shade is a stronger interaction whereas lighter shade is 
a weaker interaction). Histone modification ChIP-seq data were analysed for histone 
marks characteristic of enhancer and promoter regions. DNase hypersensitive site data 
were also analysed for accessible DNA. The ITGA6 gene is represented at the top of the 
figure with exons shown as bars. The major transcript is highlighted in dark blue. 
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Figure 4.11 – RUNX1 binding at the potential ITGB4 enhancer in ChIP-seq studies. 
A screen shot of ChIA-PET data from the ENCODE project (ENCODE 2012) and data 
from ChIP-seq studies (Beck et al. 2013, Martens et al. 2012, Pencovich et al. 2011, 
Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et al. 2015) visualised in UCSC 
Genome Browser (Kent et al. 2002) is shown. The DNA loop involving the potential 
ITGB4 enhancer region and ITGB4 promoter is outlined in a black box. The left grey 
rectangle represents the potential enhancer region and the right grey rectangle represents 
the ITGB4 promoter region. RUNX1 (R) and RUNX1-ETO (RE) ChIP-seq studies are 
shown for different cell types. Peaks and lines represent RUNX1/RUNX1-ETO binding. 
ITGB4 and SAP30BP genes are represented at the top of the figure with exons shown as 
bars. The major transcript of ITGB4 is in black, while the major transcript of SAP30BP is 
in dark blue. 
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4.2.3.2 Characterisation of RUNX1 Effects on a Potential ITGB4 Enhancer 
In combination, the ChIA-PET, histone modification ChIP-seq and DHS data when 
mapped to the human genome suggest the presence of an enhancer, although at the 5’ end 
of the ~2 kb region identified as interacting with the ITGB4 promoter by ChIA-PET 
(Figure 4.12). Further, this 5’ region also displays RUNX1 binding in CD34+ and 
Kasumi-1 cells (Beck et al. 2013, Ptasinska et al. 2014) (Figure 4.12). However, on 
further analysis of the potential enhancer sequence using the MatInspector tool in the 
Genomatix bioinformatics suite (http://www.genomatix.de/), a consensus RUNX1 
binding motif (TGTGGT) was identified, but towards the 3’ end of the region (Figure 
4.12). To localise RUNX1 binding to the putative enhancer, the 5’ and 3’ ends of the 
interacting region were analysed for RUNX1 binding in ChIP assays and for RUNX1 
activity in reporter assays. 
 
RUNX1 binding to the 5’ and 3’ ends of the potential ITGB4 enhancer region was 
analysed in KG-1a cells. As described previously, KG-1a cells were fixed with 
formaldehyde and DNA was sheared using sonication. DNA immunoprecipitated with a 
RUNX1 antibody was analysed by qPCR with primers, which amplify the 5’ and 3’ 
regions of the potential enhancer (Figure 4.13A). Again, as a control for RUNX1 binding, 
the promoter of the Rhodopsin gene was also analysed for RUNX1 enrichment. In KG-
1a cells, there was increased enrichment of RUNX1 at the ITGB4 promoter as observed 
previously, and RUNX1 was also enriched at the 5’ end of the potential enhancer (Distal-
1), compared to the Rhodopsin promoter (Figure 4.13B). This is consistent with the 
available ChIP-seq data (Beck et al. 2013, Ptasinska et al. 2014) (Figure 4.11). 
Interestingly, there was no RUNX1 occupancy detected at the 3’ end of the potential 
enhancer (Distal-2) containing the consensus RUNX1 binding motif (Figure 4.13B).  
 
Since RUNX1 was shown to bind to the Distal-1 region, RUNX1 binding at this region 
was also analysed in Kasumi-1 cells. In contrast to KG-1a cells, no RUNX1 binding was 
detected at the Distal-1 region in Kasumi-1 cells, while RUNX1 was significantly 
enriched at the ITGB4 promoter as expected (Figure 4.13C). Together, these data suggest 
that RUNX1 may bind to the Distal-1 region in a cell-type specific manner. The data also 
suggest that although the Distal-2 region contains a consensus RUNX1 binding motif, the 
site is not functional, at least in the cell types examined here. 
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Figure 4.12 – Potential ITGB4 enhancer region mapped to the human genome. 
Schematic representation of potential regulatory regions of the ITGB4 gene. The DNA 
loop identified in ChIA-PET data from the ENCODE project (ENCODE 2012) involving 
the potential ITGB4 enhancer region and ITGB4 promoter is shown. A DNase 
hypersensitive site (DHS) (ENCODE 2012), histone marks H3K4me1 and H3K27ac 
(ENCODE 2012), and RUNX1 binding in CD34+ (Beck et al. 2013) and Kasumi-1 cells 
(Ptasinska et al. 2014) were detected at the 5’ end of the potential enhancer region. A 
consensus RUNX1 binding motif was detected at the 3’ end of the potential enhancer 
region. Scale indicates bases pairs relative to the transcription start site (indicated by 
arrow). 
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Figure 4.13 – RUNX1 binding at the potential ITGB4 enhancer region. A) Primers 
were designed for ChIP assay to amplify the region -13,957 bp to -14,020 bp (Distal-1) 
and the region -12,246 bp to -12,354 bp (Distal-2) of the ITGB4 gene in qPCR, with the 
amplicons shown as black rectangles. Scale indicates base pairs relative to the 
transcription start site (indicated as arrow). The consensus RUNX1 binding motif and the 
region where RUNX1 was detected in CD34+ and Kasumi-1 cells (Beck et al. 2013, 
Ptasinska et al. 2014) are shown. B-C) ChIP assays were performed with an antibody 
against RUNX1 in A) KG-1a and B) Kasumi-1 cells. Immunoprecipitated DNA was 
analysed by qPCR using primers described in (A) and in Section 4.2.2.3. The data are 
shown as the ratio of immunoprecipitated DNA to total input DNA. Values are expressed 
as mean ±SEM (n=6 for KG1a and n=3 for Kasumi-1). Statistical significance was 
determined using Students’ t Test with no significant difference (p>0.05) detected for 
data in B). In C), binding was not detected at Distal-1 or Rhodopsin regions. 
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To determine if the upstream regions can function as enhancers, the regions were cloned 
together with the ITGB4 promoter and analysed using reporter assays. The 5’ end of the 
potential enhancer, which included -13,845 bp to -14,156 bp (Distal-1), and the 3’ end of 
the potential enhancer, which included -12,077 bp and -12,408 bp (Distal-2), were cloned 
into the ITGB4 Del-6 construct. The Distal-1 and Distal-2 regions were cloned directly 
adjacent to the 5’ end of the ITGB4 promoter region (-175 bp to +144 bp) in the Del-6 
construct to determine if either region had enhancer potential in combination with the 
ITGB4 promoter (Figure 4.14A). The Del-6 and Distal-Del-6 constructs were transfected 
into K562 cells and luciferase activity was measured after 24 hours. Interestingly, the 
Distal-1-Del-6 construct had a significantly higher level of reporter activity compared to 
the Del-6 construct (Figure 4.14B; p<0.05), while the Distal-2-Del-6 construct displayed 
no change in reporter activity compared to the Del-6 construct (Figure 4.14B). 
 
To determine if the Distal-1 region is responsive to RUNX1, K562 cells were transfected 
with the Del-6 and Distal-1-Del-6 constructs along with the RUNX1 expression plasmid. 
Cells were harvested after 24 hours and luciferase activity was measured. Fold change in 
each construct with RUNX1 overexpressed was analysed. While both reporters were 
activated by RUNX1, unexpectedly, addition of the distal region did not increase RUNX1 
responsiveness compared to the Del-6 region alone (Figure 4.14C). 
 
Taken together, these data suggest that the Distal-1 region can function as an enhancer 
for the ITGB4 promoter and is enriched for RUNX1 in myeloid cells; however, it does 
not provide increased activity in response to RUNX1 compared to the promoter alone at 
least in reporter assays. 
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Figure 4.14 – Effects of potential enhancer region on ITGB4 promoter activity. A) 
Schematic representation of ITGB4 promoter region and distal regions used in reporter 
assays. Del-6, Distal-1-Del-6 and Distal-2-Del-6 regions were cloned into the pXPG 
plasmid containing a luciferase gene. Scale indicates base pairs relative to the 
transcription start site (indicated by arrow). White boxes represent putative RUNX1 
binding motifs and the blue box represents a motif with 100% match to the RUNX1 
consensus sequence. B) Basal level of activity of Del-6, Distal-1-Del-6 and Distal-2-Del-
6 constructs following transfection into K562 cells. Protein was isolated from transfected 
cells after 24 hours and analysed in a luciferase reporter assay. Values are expressed as 
±SEM (n=3). Statistical significance was determined using one-way ANOVA, Newman 
Keuls Multiple Comparison Test, *p<0.05. C) K562 cells were transfected with Del-6 
and Distal-1-Del-6 constructs either with or without the RUNX1 expression plasmid. 
Protein was isolated from transfected cells after 24 hours and analysed in a luciferase 
reporter assay. Fold change in activity of Del-6 and Distal-Del-6 constructs with RUNX1 
overexpressed in K562 cells is shown. Values are expressed as mean ±SEM (n=3). 
Statistical significance was determined using Students’ t Test, ns p>0.05. 
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4.3 Discussion 
 
RUNX1 is commonly described as a sequence-specific DNA binding protein which binds 
to the consensus motif TGT/cGGT through its DNA binding Runt homology domain 
(Meyers et al. 1993). However, it is clear now that RUNX1 can regulate its target genes 
through a variety of mechanisms due to its ability to act in complexes with other 
transcription factors, its ability to direct epigenetic modification and higher order 
chromatin structures, and its ability to regulate genes through both promoters as well as 
distal regulatory regions such as enhancers (Bowers et al. 2010, Elagib et al. 2003, Huang 
et al. 2009, Kitabayashi et al. 1998, Levantini et al. 2011, Reed-Inderbitzin et al. 2006, 
Waltzer et al. 2003, Wotton et al. 1994, Zhang et al. 1996). Data presented here suggest 
that RUNX1 regulates the ITGA6 and ITGB4 integrin genes via two distinct mechanisms. 
 
In the present study, RUNX1 was shown to regulate the ITGA6 promoter via the classical 
mechanism, which is commonly described in the literature. Like most described examples 
of promoters regulated by RUNX1 (Meyers et al. 1993, Takahashi et al. 1995, Zhang et 
al. 1994), the ITGA6 promoter possesses a consensus RUNX1 binding motif (TGTGGT) 
and RUNX1 activation of the promoter was dependent on the presence of this consensus 
motif. Mutation to the site resulted in a significant decrease in the ability of RUNX1 to 
activate the promoter. RUNX1 was also shown to bind to the endogenous ITGA6 
promoter in both KG-1a and Kasumi-1 cells, therefore suggesting that RUNX1 regulates 
this gene in myeloid cells.  
 
In contrast, data presented here suggest that RUNX1 regulates the ITGB4 gene by an 
alternate mechanism. While RUNX1 was shown to activate the ITGB4 promoter in 
reporter assays and bind to the endogenous promoter in KG-1a and Kasumi-1 cells, the 
promoter did not possess a consensus RUNX1 binding motif within the RUNX1 
responsive region located -175 bp to -58 bp upstream of the transcription start site. 
However, a variant RUNX1 binding motif, which has been identified in a previous study 
to bind Runx1 (Tanaka et al. 2012), is present within the RUNX1 responsive region, but 
mutation to this site resulted in no significant decrease in RUNX1 activation of the 
promoter. The data therefore suggest that RUNX1 regulation of ITGB4 is more complex 
than that of ITGA6, and does not involve direct binding to a RUNX1 consensus motif.  
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RUNX1 is a relatively weak transcription factor on its own and therefore is often involved 
in multi-protein complexes assembled between promoters and distal regions to regulate 
its target genes (Giese et al. 1995, Gu et al. 2000, Huang et al. 2009, Mao et al. 1999, 
Zhang et al. 1996). In recent genome-wide studies RUNX1 has been found to frequently 
co-occupy regions of the genome with other transcription factors such as SCL, LYL1, 
LMO2, ERG, FLI1, GATA1 and GATA2, which are also important for haematopoiesis 
(Beck et al. 2013, Tijssen et al. 2011, Wilson et al. 2010). Interestingly, the majority of 
these regions possess GATA sites (targeted by GATA1 and GATA2) and ETS sites 
(targeted by ERG and FLI1), while 76% of regions contain E-box sites (targeted by SCL, 
LYL1 and LMO2) and only 39% contain RUNX consensus motifs (Wilson et al. 2010). 
The lack of RUNX consensus motifs despite RUNX1 occupancy of the DNA suggests 
that RUNX1 may be recruited indirectly to many regions of DNA in which these other 
transcription regulators are present, and synergistically regulate target genes in a large 
multi-transcription factor complex. 
 
Additionally, RUNX1 is often involved in higher order chromatin structures and can 
regulate its target genes by binding to both promoter and distal regulatory regions 
(Levantini et al. 2011). RUNX1 has been shown to be important to facilitate the 
interaction between a downstream enhancer and the promoter of the CD34 gene in 
haematopoietic cells (Levantini et al. 2011). RUNX1 was found to bind to a consensus 
RUNX1 binding motif present in the enhancer and mutation to this site led to disruption 
of the promoter-enhancer interaction and decreased CD34 expression (Levantini et al. 
2011). While RUNX1 binds directly to many enhancer regions through its Runt domain, 
its subsequent interaction with promoter regions may therefore be through alternative 
interactions, which do not rely on known RUNX1 motifs. 
 
Since the ITGB4 promoter does not possess any consensus RUNX1 binding motifs and 
RUNX1 activity on the promoter is not dependent on the presence of any other variant 
RUNX1 binding motifs, these data suggest that RUNX1 is recruited to the promoter 
indirectly. To determine if RUNX1 may be recruited to the promoter by other 
haematopoietic transcription factors such as SCL, LYL1, LMO2, ERG, FLI1, GATA1 
and GATA2, the promoter was examined for binding motifs of these transcription factors. 
Interestingly, a site that is recognised by a LMO2 complex, containing SCL, E2A and 
GATA1 proteins, is present in the RUNX1 responsive region of the ITGB4 promoter, 
located at -74 bp to -79 bp upstream of the transcription start site (Figure 4.15A). The site 
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identified, CAGGTG, is an E-box motif (CANNTG), which is targeted by SCL, E2A, 
SCL-E2A heterodimers, LYL1 and LYL1-E2A heterodimers (Ellenberger et al. 1994, 
Miyamoto et al. 1996, Sanda et al. 2012) and the specific sequence present in the ITGB4 
promoter has been shown to bind LMO2 complexes containing SCL, E2A and GATA1 
proteins (Wadman et al. 1997). In addition, an ETS binding motif (GGAA/T), which is 
targeted by ERG and FLI1 transcription factors (Sementchenko and Watson 2000), is also 
present in the RUNX1 responsive region of the ITGB4 promoter, located at -57 bp to -61 
bp upstream of the transcription start site (Figure 4.15A). The site identified, AGGAA, 
has been shown to bind ERG and FLI1 transcription factors in a previous ChIP-seq study 
(Wilson et al. 2010). Taken together,  this analysis suggest RUNX1 may be recruited to 
the ITGB4 promoter to form a transcription factor complex with SCL, E2A, GATA1, 
LYL1, ERG and FLI1 which bind to an E-box site and ETS motif to regulate ITGB4 
expression. 
 
While RUNX1 may be recruited to the ITGB4 promoter indirectly by interacting with 
other transcription factors present at the promoter, data presented here suggest that 
RUNX1 may also regulate the ITGB4 promoter through an enhancer located -12,053 bp 
to -14,003 bp upstream of the transcription start site. The enhancer region was identified 
to interact with the ITGB4 promoter through ChIA-PET data (ENCODE 2012), which 
showed a DNA loop between the ITGB4 promoter and enhancer regions coinciding with 
RNA PolII binding in K562 cells. Additionally, RUNX1 was shown to bind to the 5’ end 
of this region in KG-1a cells in ChIP analysis and this was supported by the ChIP-seq 
study by Beck et al. (2013), which showed RUNX1 binding at this region in CD34+ cells. 
Additionally, in contrast to this study, RUNX1 was detected at this region in Kasumi-1 
cells in the ChIP-seq study by Ptasinska et al. (2014). Furthermore, reporter assays 
demonstrated that the 5’ end of the interacting region has enhancer potential due to 
increased ITGB4 promoter activity in K562 cells. However, unexpectedly, when RUNX1 
was overexpressed in the cells, activity of the promoter was not increased. There could 
be a number of reasons for this, including the failure of the reporter construct, in which 
the enhancer and promoter are adjacent, to form the type of loop detected in the 
endogenous cells. Alternatively, RUNX1 may only bind one of the regions endogenously. 
For example, since the promoter and enhancer regions interact, RUNX1 detected at the 
enhancer in ChIP analysis, may be due to binding of RUNX1 at the promoter, and vice 
versa.  
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Similar to the ITGB4 promoter, while RUNX1 was shown to bind to the ITGB4 enhancer 
in ChIP analysis, this region does not possess any consensus RUNX1 binding motifs, 
suggesting that RUNX1 may also be recruited to the enhancer indirectly. To determine if 
RUNX1 may be recruited to the enhancer by other haematopoietic transcription factors 
such as SCL, LYL1, LMO2, ERG, FLI1, GATA1 and GATA2, the enhancer was 
examined for binding motifs of these transcription factors also. Interestingly, an E-box 
motif (CACCTG), located at -13,842 bp to -13,847 upstream of the transcription start site 
(Figure 4.15B), which is a binding motif for an E2A protein (E47) (Ellenberger et al. 
1994), was identified. Furthermore, it has been shown that the E47 protein, in association 
with the SCL protein, binds to E-box motifs found in eukaryotic enhancer regions (Hsu 
et al. 1991). Also present in the ITGB4 enhancer region is a GATA site, located -14,077 
bp to -14,080 bp upstream of the transcription start site (Figure 4.15B), which is a binding 
motif for GATA1 and GATA2 proteins, and two ETS motifs (AGGAA), located -13,810 
bp to -13,814 bp and -13,917 bp to -13,921 bp upstream of the transcription start site 
(Figure 4.15B), which are binding motifs for ERG and FLI1 proteins (Sementchenko and 
Watson 2000, Wilson et al. 2010). Taken together, this analysis suggest that RUNX1 may 
also be recruited to the ITGB4 enhancer to form a transcription factor complex with SCL, 
E2A, GATA1, LYL1, ERG and FLI1 which bind to E-box, ETS and GATA motifs 
present in the enhancer region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 129 
 
 
 
 
 
 
ITGB4 Promoter 
 
    -175 CTAGCCGATCGGGGCGCTGGGCGGGCGCCGCGGGAGCCGCAGCCCTTTCCGGGGGGCGGA 
    -105 CCCGGCTCCGGCGGCGGCACCCAGCTCCTGCCCCGACAGGTGCGCGCCGCGCGAAGGAA  
 
 
 
ITGB4 Enhancer 
 
 -14,156 GAGGCGGCAGCTCATTGTTTACAGGCAAGCCCTGCTCCTGGGAGGGCTCCTGCCACCCCA 
         CCCTTCCTCTGTGTGTTATCTCTGCCCCACAGCAGCCCCTGGGCAGCACCAGTGGCCACT 
         GGGCTCCCCCCGGGTTGAAACGGGTTTCCCAGACCAGGGGTTCAGAGGAGACTATTTACC 
         CTTCATGATCTTTGGCGATTCTCCACTGGAGCGGAAGGGCTGTGTGTCAAAAGAAGGAAG 
         CCAGGCTGTGAAGGGCCGTGTTGCTTTCAGTGGGTGGGCAGAGGTTTAGAAAGGTGGTTC 
 -13,855 TGAAATGGCACCTGGTACTCTTGTGGGACCTGGGGAATATAAGGAA 
 
 
 
 
 
Figure 4.15 – E-box, ETS and GATA binding motifs present in the ITGB4 promoter 
and enhancer regions. DNA sequences containing the ITGB4 promoter and enhancer 
regions, as well as the base pair number are shown. E-box (pink), ETS (blue) and GATA 
(green) motifs are highlighted in the sequences. 
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Interestingly, previous studies have shown the multi-transcription factor complex 
involving RUNX1, FLI1, GATA2, SCL, LYL1, LMO2, ERG, or a subset of these 
transcription factors, to be enriched at known HSC enhancers (Beck et al. 2013, Tijssen 
et al. 2011). This complex has been identified at the HHEX+1 haematopoietic 
stem/progenitor cell enhancer and ERG +85 enhancer in human haematopoietic stem 
cells, and enrichment of this transcription factor complex has been associated with active 
histone marks of enhancer regions (Beck et al. 2013). Additionally, GATA2, RUNX1, 
FLI1 and SCL have been shown to bind the RUNX1 +23 enhancer in primary human 
megakaryocytes (Tijssen et al. 2011). Furthermore, it has recently been demonstrated that 
SCL, GATA1, LMO2 and Ldb1 are required for long-range interaction between the β-
globin locus control region and active globin genes, and the SCL protein is required for 
the formation of the chromatin loop between the β-globin locus control region and globin 
genes (Yun et al. 2014). The SCL protein may therefore be essential for the long-range 
interaction between the ITGB4 promoter and enhancer regions. 
 
To provide some evidence that RUNX1 is recruited to the ITGB4 promoter and enhancer 
regions by other haematopoietic transcription factors, ChIP-seq data (Beck et al. 2013, 
Martens et al. 2012, Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 2011, 
Trombly et al. 2015) described in Chapter 3 were interrogated for binding of these 
transcription factors at these regions. Interestingly, ERG was detected at the ITGB4 
promoter in K562 cells (Figure 4.16), CD34+ cells, AML mononuclear cells from an 
individual with t(8;21)-positive AML and in APL blasts from an individual with newly 
diagnosed t(15;17)-positive AML (Martens et al. 2012), and the FLI1 transcription factor 
was detected at the ITGB4 promoter in the leukaemia cell line U937 (Martens et al. 2012). 
Additionally, ERG was detected at the ITGB4 enhancer in MCF7 cells with RUNX1-
ETO and ERG overexpressed (Martens et al. 2012), thus suggesting that ERG has the 
capacity to bind to the enhancer in haematopoietic cells. While ERG and FLI1 were 
detected at ITGB4 enhancer and/or promoter regions, other haematopoietic transcription 
factors were not detected at these regions in the ChIP-seq data (Beck et al. 2013, Martens 
et al. 2012, Pencovich et al. 2011, Ptasinska et al. 2014, Tijssen et al. 2011, Trombly et 
al. 2015), however a previous study has suggested that similar to individual transcription 
factors, multifactor combinatorial binding is cell-type specific (Tijssen et al. 2011). 
Therefore, a complex containing FLI1, GATA2, SCL, LYL1, LMO2, ERG, E2A and 
RUNX1 may be cell-type specific, which could be why binding of many of these 
transcription factors were not detected in the cell types analysed in the ChIP-seq studies. 
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Alternatively, the exact make up of such a complex may differ between cell types. 
However, this data does support the hypothesis that ERG and FLI1 may be involved in 
the regulation of ITGB4 and may also be involved in the recruitment of RUNX1 to the 
promoter and enhancer. 
 
In conclusion, RUNX1 was found to regulate the ITGA6 and ITGB4 genes by different 
mechanisms. Data presented here suggests that RUNX1 regulates the ITGA6 promoter 
through a consensus RUNX1 binding motif and RUNX1 activation of the promoter is 
dependent on the presence of this site (Figure 4.17A). In contrast, RUNX1 regulates the 
ITGB4 promoter indirectly and this may be through the interaction with other 
haematopoietic transcription factors such as FLI1, GATA1/GATA2, SCL, LYL1, LMO2, 
ERG and E2A and may also require an upstream enhancer region (Figure 4.17B). While 
previous studies have demonstrated binding of some of these transcription factors to the 
ITGB4 promoter and enhancer regions, further studies are required to test this model. 
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Figure 4.16 – ERG binding at ITGB4 promoter in K562 cells. Data from Martens et 
al. (2012) study was downloaded and visualised using the UCSC Genome Browser (Kent 
et al. 2002). Screen shot was taken from the UCSC browser and show ERG binding across 
the ITGB4 gene in K562 cells. Peaks represent ERG binding and the black right-angled 
arrow represents the transcription start site. The ITGB4 gene is represented at the bottom 
of the figure with exons shown as bars. 
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Figure 4.17 – A model for RUNX1 regulation of ITGA6 and ITGB4. A) RUNX1 
targets and regulates the ITGA6 promoter through a consensus RUNX1 binding motif. 
B) RUNX1 regulates the ITGB4 promoter indirectly via the interaction with other 
transcription factors, which bind to E-box motifs (CAGGTG and CACCTG), ETS motifs 
(AGGAA) and a GATA motif in promoter and/or enhancer regions. The SCL 
transcription factor is important for the formation of chromatin looping required for the 
interaction between ITGB4 promoter and enhancer regions (depicted by dotted arrows). 
DNA is shown as aqua lines wrapped around nucleosomes (blue balls) and CpG sites are 
shown as small circles either methylated (black) or unmethylated (white). Transcription 
start sites are shown as black right-angled arrows. 
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Chapter 5 
 
Epigenetic Regulation of ITGB4 and ITGA6 
 
 
5.1 Introduction 
 
5.1.1 Regulation of ITGB4 and ITGA6 by Epigenetic Mechanisms 
While RUNX1 was found to regulate the ITGB4 and ITGA6 integrin genes, this does not 
fully explain their differential expression patterns in the leukaemic cell lines K562, KG-
1a and Kasumi-1 (Table 5.1) and therefore additional factors must contribute to the 
differential patterns of expression. This might include other transcription factors that are 
involved in their expression, as well as epigenetic factors, and there is some evidence that 
integrin genes, including the ITGB4 and ITGA6 genes, are regulated by epigenetic 
mechanisms. 
 
Several studies have provided evidence suggesting that ITGB4 is regulated by DNA 
methylation. A study by Loss et al. (2010) aimed to identify epigenetically regulated 
genes by comparing gene expression and CpG methylation profiles in 45 breast cancer 
cell lines. Through this analysis the ITGB4 gene was predicted to be regulated by DNA 
methylation due to clustering of gene expression and DNA methylation data sets (Loss et 
al. 2010). In support of this, another study found that the DNA methylation status of the 
Itgb4 promoter was inversely correlated with expression and spatial localisation of β4 
protein in the mouse mammary gland (Yang et al. 2009). In addition, the ITGB4 gene has 
been found to be differentially methylated in individuals with diabetes with end stage 
renal disease compared to individuals with diabetes without neuropathy (Sapienza et al. 
2011) and in pancreatic islets of individuals with type 2 diabetes compared to non-diabetic 
controls (Dayeh et al. 2014). 
 
In addition to DNA methylation, histone modification has also been shown to influence 
ITGB4 expression, as well as the expression of ITGA6. Treatment of PC-3 prostate cancer 
cells with a HDAC inhibitor resulted in decreased expression of both ITGB4 and ITGA6 
(Hudak et al. 2012, Wedel et al. 2011) and treatment of a hepatocellular carcinoma cell 
line with a HDAC inhibitor also decreased ITGA6 expression (Lin et al. 2005).  
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While there is evidence that DNA methylation and/or histone acetylation has an effect on 
ITGB4 and ITGA6 expression, this has not been fully characterised in myeloid cells. 
Therefore, another aim of this study was to investigate regulation of ITGB4 and ITGA6 
by epigenetic mechanisms in myeloid cells. 
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Integrin Cell Line 
Relative 
Expression 
ITGB4 
K562 2.2 x 10-4 
KG-1a 0 
Kasumi-1 5.2 x 10-3 
ITGA6 
K562 9.7 x 10-5 
KG-1a 3.7 x 10-3 
Kasumi-1 1.7 x 10-3 
 
 
 
 
Table 5.1 – Relative expression of ITGB4 and ITGA6 in leukaemic cell lines. Mean 
values of expression of ITGB4 and ITGA6 genes in K562, KG-1a and Kasumi-1 cells 
from RT-qPCR data as depicted in Figure 3.6A (Chapter 3). Number of copies of 
ITGB4/ITGA6 mRNA relative to GAPDH are shown (n=3). 
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5.2 Results 
 
5.2.1 Identification of a CpG Island at the ITGB4 and ITGA6 Promoters 
Approximately 60% of human gene promoters are encompassed by CpG islands and are 
therefore subject to DNA methylation. To determine if ITGB4 and ITGA6 may be 
regulated by DNA methylation, genome-wide CpG island data from the ENCODE project 
(ENCODE 2012) were interrogated for the presence of a CpG island at the promoters of 
the ITGB4 and ITGA6 genes.  
 
Both ITGB4 and ITGA6 genes were found to possess large CpG islands of 824 bp and 
1084 bp, respectively, which encompass the transcription start site of the genes (Figure 
5.1). The CpG island at the ITGB4 promoter is located -642 bp to +482 bp relative to the 
transcription start site with a CpG content of 22.1%, and the CpG island at the ITGA6 
gene is located -364 bp to +1020 bp relative to the transcription start site with a CpG 
content of 21.2%. The ITGB4 gene also has three other smaller CpG islands located along 
the gene body, as shown in Figure 5.1A.  
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Figure 5.1 – CpG islands along ITGB4 and ITGA6. A screen shot of genome-wide CpG 
island data (ENCODE 2012) visualised in the UCSC Genome Browser (Kent et al. 2002) 
is shown. CpG islands along A) ITGB4 and B) ITGA6 genes are shown as green boxes. 
The numbers adjacent to the boxes represent the CpG count for the particular island. Dark 
green boxes are regions greater than 300 bp while light green boxes are regions less than 
300 bp. All transcript variants for each integrin gene are shown; the major transcript for 
each gene is shown by a black arrow.  
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5.2.2 Effect of DNA Methylation and Histone Acetylation on ITGB4 and ITGA6 
Expression 
To determine if expression of the ITGB4 or ITGA6 genes is influenced by the DNA 
methylation or histone acetylation status of the gene, their expression was examined in 
myeloid cells following treatment with epigenetic inhibitors. K562, KG-1a and Kasumi-
1 cells were treated with either 500 ng/mL of DAC for 72 hours, 200 ng/mL of TSA for 
6 hours or a combined treatment of DAC and TSA. Changes in ITGB4 and ITGA6 
expression were analysed using RT-qPCR. DAC treatment increased expression of 
ITGB4 in all cell lines examined (Figure 5.2A-C), with the fold change in ITGB4 
expression higher in K562 and KG-1a cells (Figure 5.2D). TSA also increased ITGB4 
expression in all cell lines and ITGB4 expression was increased further when TSA was 
used in combination with DAC in KG-1a cells (Figure 5.2A-C). In contrast, ITGA6 
expression only increased following DAC treatment in K562 cells (Figure 5.3A), with a 
5-fold change in gene expression compared to the untreated cells (Figure 5.3D, p<0.05). 
TSA treatment had no effect on ITGA6 expression in any of the leukaemic cell lines, 
either alone or in combination with DAC (Figure 5.3A-C). 
 
Taken together, these data suggest that both ITGB4 and ITGA6 integrin gene expression 
can be enhanced by treatment with a DNA methylation inhibitor, although this was only 
apparent for ITGA6 in K562 cells. However, only ITGB4 gene expression was responsive 
to a histone deacetylase inhibitor. 
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Figure 5.2 – Effects of DAC and TSA treatment on ITGB4 expression in leukaemic 
cell lines. Total mRNA was isolated from untreated and treated A) K562, B) KG-1a and 
C) Kasumi-1 cell lines, reversed transcribed and ITGB4 mRNA levels were analysed 
using RT-qPCR. Copy number was normalised to β2-Microglobulin and values are 
expressed as mean ±SEM (n=3). Statistical significance of treated versus untreated cells 
was determined using Student’s t Test, ***p<0.001, *p<0.05. D) Data in (A-C) 
represented as fold change in ITGB4 mRNA levels relative to untreated cells. 
 
 
 
 
 
 141 
 
 
 
A    B    C 
 
D 
 
       
 
 
 
Figure 5.3 – Effects of DAC and TSA treatment on ITGA6 expression in leukaemic 
cell lines. Total mRNA was isolated from untreated and treated A) K562, B) KG-1a and 
C) Kasumi-1 cell lines, reversed transcribed and ITGA6 mRNA levels were analysed 
using RT-qPCR. Copy number was normalised to β2-Microglobulin and values are 
expressed as mean ±SEM (n=3). Statistical significance for treated versus untreated cells 
was determined using Student’s t Test, *p<0.05. D) Data in (A-C) represented as fold 
change in ITGA6 mRNA levels relative to untreated cells are shown. 
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5.2.3 DNA Methylation of ITGB4 and ITGA6 Promoters in Myeloid Cells 
Since both ITGB4 and ITGA6 responded to DAC treatment, at least in some cell lines, 
their expression may therefore be regulated by promoter methylation. To determine if the 
CpG islands located at the ITGB4 and ITGA6 promoters are differentially methylated in 
the leukaemic cell lines, which express these genes at different levels (Table 5.1), DNA 
methylation was analysed in K562, KG-1a and Kasumi-1 cells using bisulphite 
sequencing. 
 
Genomic DNA was isolated from K562, KG-1a and Kasumi-1 cells and was subjected to 
bisulphite conversion, as described in Chapter 2, Section 2.6. PCR primers were designed 
to amplify the region -516 bp to +276 bp of ITGB4, encompassing 85 CpG sites. PCR 
products were cloned into the pGEM-T Easy vector and single clones were selected for 
sequencing. Interestingly, the ITGB4 promoter was found to be differentially methylated 
in the cell lines examined. The promoter was highly methylated in KG-1a cells, but was 
relatively unmethylated in K562 and Kasumi-1 cells (Figure 5.4). The DNA methylation 
pattern in KG-1a cells was striking, while there was some methylation upstream of the 
transcription start site (including through the RUNX1 responsive region), the region 
downstream of the transcription start site was completely methylated (Figure 5.4).  
 
Taken together, these data suggest that in both K562 and Kasumi-1 cells the ITGB4 
promoter is likely to be relatively accessible, whereas the ITGB4 promoter in KG-1a cells 
is likely to be less accessible due to higher levels of DNA methylation. DNA methylation 
is generally associated with gene silencing, and therefore the methylation patterns 
observed at the promoter in KG-1a and Kasumi-1 cells reflects the expression of ITGB4 
in these cells (ie. expression in Kasumi-1 but not KG-1a), whereas in K562 cells the 
ITGB4 promoter is largely unmethylated which does not explain the low expression of 
ITGB4 in these cells (Table 5.1). 
 
To determine how the methylation pattern of the ITGB4 promoter in leukaemic cell lines 
compares to human samples, DNA methylation of the ITGB4 promoter was analysed in 
whole blood samples from individuals with (LK7770) and without leukaemia (LK004 
and LK124). Interestingly, the ITGB4 promoter was relatively unmethylated in all 
samples (Figure 5.5) and most similar to the pattern seen in Kasumi-1 cells. While the 
leukaemic sample, which is positive for the t(8;21) chromosomal translocation, showed 
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a similar methylation pattern to the t(8;21)-positive Kasumi-1 cell lines, with most 
methylation located at the 3’ end (Figure 5.5), this pattern was also seen in the non-
leukaemic cells. These data therefore suggest that the ITGB4 promoter is normally 
unmethylated in human blood cells, and the presence of the RUNX1-ETO fusion protein 
does not appear to have an effect on the DNA methylation pattern at the ITGB4 promoter.   
 
DNA methylation of the ITGB4 promoter was also analysed in treated and untreated cell 
lines to determine if DAC caused demethylation at this region. K562, KG-1a and Kasumi-
1 cells were treated with DAC for 72 hours. Genomic DNA was isolated and subjected to 
bisulphite conversion, as described in Chapter 2, Section 2.6. Due to difficulty in 
amplifying the region -516 bp to +276 bp from DAC treated cells, a different set of PCR 
primers were used to amplify a smaller region of the ITGB4 CpG island, located -390 bp 
to +276 bp of ITGB4, encompassing 72 CpG sites. The PCR products were cloned into 
the pGEM-T Easy vector and single clones were sequenced. Treatment of cells with DAC 
had no effect in K562 cells, which is unsurprising because the ITGB4 CpG island is 
unmethylated in these cells (Figure 5.6). Kasumi-1 cells displayed demethylation at the 
3’ end, where most of the methylation is observed (Figure 5.6). Surprisingly, DAC 
treatment had no effect on DNA methylation of the ITGB4 promoter in KG-1a cells, 
although this region is heavily methylated in these cells (Figure 5.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 144 
 
 
 
 
 
 
Figure 5.4 – DNA methylation patterns at the ITGB4 CpG island in leukaemic cell 
lines. CpG sites located in a region of -516 bp to +276 bp of ITGB4 within the ITGB4 
promoter CpG island were analysed for methylation in K562, KG-1a and Kasumi-1 cell 
lines using bisulphite sequencing. Sequencing was analysed using BiQ Analyzer software 
and bubble maps were generated using CpG Bubble Chart Generator, Version 20061209 
(created by Mark A. Miranda). Each line represents a single clone and circles represent 
CpG sites. White circles represent unmethylated CpG sites whereas black circles 
represent methylated sites and crosses are CpG sites with a mutation. Schematic 
representation of the ITGB4 promoter is shown above and the scale represents base pairs 
relative to the transcription start site (indicated by arrow). 
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Figure 5.5 – DNA methylation patterns at the ITGB4 CpG island in t(8;21)-positive 
leukaemia and non-leukaemia samples. CpG sites located in a region of -516 bp to 
+276 bp of ITGB4 within the ITGB4 promoter CpG island were analysed for methylation 
in non-leukaemia (LK004 and LK124) and t(8;21)-positive leukaemia individual samples 
(LK7770) using bisulphite sequencing. Sequencing was analysed using BiQ Analyzer 
software and bubble maps were generated using CpG Bubble Chart Generator, Version 
20061209 (created by Mark A. Miranda). Each line represents a single clone and circles 
represent CpG sites. White circles represent unmethylated CpG sites whereas black 
circles represent methylated sites and crosses are CpG sites with a mutation. Schematic 
representation of the ITGB4 promoter is shown above and the scale represents base pairs 
relative to the transcription start site (indicated by arrow). 
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Figure 5.6 - DNA methylation patterns at the ITGB4 CpG island in untreated and 
DAC treated leukaemic cell lines. CpG sites located in a region of -390 bp to +276 bp 
of ITGB4 within the ITGB4 promoter CpG island were analysed for methylation in 
untreated and DAC treated K562, KG-1a and Kasumi-1 cell lines using bisulphite 
sequencing. Sequencing was analysed using BiQ Analyzer software and bubble maps 
were generated using CpG Bubble Chart Generator, Version 20061209 (created by Mark 
A. Miranda). Each line represents a single clone and circles represent CpG sites. White 
circles represent unmethylated CpG sites whereas black circles represent methylated sites 
and crosses are CpG sites with a mutation. Schematic representation of the ITGB4 
promoter is shown above and the scale represents base pairs relative to the transcription 
start site (indicated by arrow). 
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To determine if the ITGA6 promoter CpG island, similar to the ITGB4 promoter CpG 
island, is differentially methylated in the leukaemic cell lines and if DAC treatment causes 
demethylation of the CpG island, bisulphite sequencing was similarly used to analyse 
CpG methylation at the promoter. K562, KG-1a and Kasumi-1 cells were treated with 
DAC for 72 hours. Genomic DNA was isolated from treated and untreated cells, and 
subjected to bisulphite conversion, as described in Chapter 2, Section 2.6. PCR primers 
were designed to amplify the region surrounding the ITGA6 transcription start site in two 
sections located -329 bp to +240 bp (Fragment A) and +216 bp to +821 bp (Fragment B). 
PCR products were cloned in the pGEM-T easy vector and single clones were selected 
for sequencing. 
 
Fragment A, which incorporates the transcription start site of ITGA6, was largely 
unmethylated in all leukaemic cell lines analysed (Figure 5.7). Not surprisingly then, 
DAC treatment did not result in any significant decrease in methylation at this region 
(Figure 5.7). Similarly, Fragment B, which incorporates the gene body adjacent to the 
transcription start site, including the translation start site, was largely unmethylated, 
although there was some methylation towards the 3’ end of the region in K562 cells 
(Figure 5.8). Similar to Fragment A, treatment with DAC had little effect on methylation 
of Fragment B due to the existing low levels of methylation (Figure 5.8). 
 
Taken together, these data suggest that the ITGA6 promoter is likely to be relatively 
accessible in K562, KG-1a and Kasumi-1 cell lines due to low levels of DNA 
methylation. Unmethylated promoters are typically associated with actively transcribed 
genes, and therefore the methylation patterns observed at the ITGA6 promoter in KG-1a 
and Kasumi-1 cells reflects expression of ITGA6 in these cells (ie. expressed in both cell 
lines), whereas in K562 cells, the ITGA6 promoter is largely unmethylated which does 
not explain the low expression of ITGA6 in these cells (Table 5.1). 
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Figure 5.7 – DNA methylation patterns of Fragment A at the ITGA6 CpG island in 
untreated and DAC treated leukaemic cell lines. CpG sites located in a region of -329 
bp to +240 bp of ITGA6 within the ITGA6 promoter CpG island were analysed for 
methylation in untreated and DAC treated K562, KG-1a and Kasumi-1 cell lines using 
bisulphite sequencing. Sequencing was analysed using BiQ Analyzer software and bubble 
maps were generated using CpG Bubble Chart Generator, Version 20061209 (created by 
Mark A. Miranda). Each line represents a single clone and circles represent CpG sites. 
White circles represent unmethylated CpG sites whereas black circles represent 
methylated sites and crosses are CpG sites with a mutation. Schematic representation of 
the ITGA6 promoter is shown above and the scale represents base pairs relative to the 
transcription start site (indicated by arrow). 
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Figure 5.8 – DNA methylation patterns of Fragment B at the ITGA6 CpG island in 
untreated and DAC treated leukaemic cell lines. CpG sites located in a region of +216 
bp to +821 bp of ITGA6 within the ITGA6 promoter CpG island were analysed for 
methylation in untreated and DAC treated K562, KG-1a and Kasumi-1 cell lines using 
bisulphite sequencing. Sequencing was analysed using BiQ Analyzer software and bubble 
maps were generated using CpG Bubble Chart Generator, Version 20061209 (created by 
Mark A. Miranda). Each line represents a single clone and circles represent CpG sites. 
White circles represent unmethylated CpG sites whereas black circles represent 
methylated sites and crosses are CpG sites with a mutation. Schematic representation of 
the ITGA6 promoter is shown above and the scale represents base pairs relative to the 
transcription start site (indicated by black arrow). Translation start site is indicated by the 
green arrow. 
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5.2.4 Histone Occupancy at the ITGB4 and ITGA6 Promoters in KG-1a and 
Kasumi-1 Cells 
The positioning of nucleosomes throughout the genome plays a key role in the regulation 
of gene expression. For most genes there is a well-positioned nucleosome located 
upstream of the transcription start site, covering a region -300 bp to -150 bp of the 
transcription start site, which regulates the accessibility of the promoter to regulatory 
proteins (Jiang and Pugh 2009). When transcription occurs, this nucleosome often 
undergoes changes which can include histone replacement, histone acetylation and 
methylation, repositioning of the histone and removal of the histone from the DNA (Jiang 
and Pugh 2009). Promoters of active genes are often more accessible to regulatory 
proteins due to decreased histone occupancy. 
 
Since ITGB4 and ITGA6 promoter DNA methylation reflected expression of these genes 
in KG-1a and Kasumi-1 cells, these promoters may also be affected by other epigenetic 
mechanisms in these cells. To determine if histone occupancy reflects ITGB4 and ITGA6 
expression in KG-1a and Kasumi-1 cells, ChIP assays were used to analyse histone H3 
occupancy at the integrin promoters. KG-1a and Kasumi-1 cells were fixed with 
formaldehyde and DNA was sheared using sonication. DNA immunoprecipitated with a 
histone H3 antibody was analysed by qPCR with primers designed to amplify promoter 
regions of ITGB4 and ITGA6. As a control, histone H3 occupancy was also measured at 
the inactive Rhodopsin promoter. 
 
Histone H3 occupancy at the ITGA6 promoter was similar between the two cell lines and 
was lower than the histone H3 occupancy measured at the silenced Rhodopsin gene, 
therefore reflecting ITGA6 expression in these cells (Figure 5.9). In contrast, histone H3 
occupancy at the ITGB4 promoter in KG-1a cells was similar to levels seen at the 
Rhodopsin promoter, which may reflect low levels of ITGB4 expression in these cells. In 
contrast, lower histone H3 occupancy was detected at the ITGB4 promoter in Kasumi-1 
cells, which was similar to levels observed for the ITGA6 promoter and reflects higher 
ITGB4 expression detected in these cells (Figure 5.9). 
 
Taken together, these data show differences in histone H3 occupancy at the integrin gene 
promoters, which is inversely correlated with expression of these genes in the leukaemic 
cell lines KG-1a, and Kasumi-1.  
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Figure 5.9 – Histone H3 occupancy of ITGB4 and ITGA6 promoters in KG-1a and 
Kasumi-1 cells. ChIP assays were performed in KG-1a and Kasumi-1 cells with an 
antibody against histone H3. Immunoprecipitated DNA was analysed by qPCR with 
primers, which amplify a region of ITGB4, ITGA6 and Rhodopsin promoters. The data 
are shown as the ratio of immunoprecipitated DNA to total input DNA. Values are 
expressed as mean ±SEM (n=3-6). Statistical significance was determined using 
Students’ t Test, comparing occupancy at integrin promoter regions to the Rhodopsin 
promoter, ***p<0.001, *p<0.05, ns p>0.05. No significant difference in histone 
occupancy was detected between cell lines at any region tested. 
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5.2.5 Histone Acetylation of the ITGB4 and ITGA6 Promoters in KG-1a Cells 
Histone acetylation is strongly associated with transcriptional activation of genes (Virani 
et al. 2012). It is thought to enhance transcription through disrupting the interaction 
between the negatively charged DNA and the positively charge histones by neutralising 
the charge on the histone proteins (Virani et al. 2012). In KG-1a cells, ITGB4 and ITGA6 
have different DNA methylation patterns and histone H3 occupancy that reflects their 
different expression levels in these cells. Therefore, to determine if different levels of 
histone acetylation also reflect expression of these genes in KG-1a cells, ChIP assays 
were used to determined histone acetylation at the integrin promoters. KG-1a cells were 
fixed with formaldehyde and DNA was sheared using sonication. DNA 
immunoprecipitated with an acetyl-H3 antibody was analysed by qPCR with primers 
designed to amplify promoter regions of ITGB4 and ITGA6. Again, as a control, histone 
acetylation was also measured at the inactive Rhodopsin promoter. As expected, there 
was enrichment of acetylation of histone H3 at the promoter of ITGA6, compared to the 
ITGB4 promoter, which was at a similar level to the silenced Rhodopsin promoter (Figure 
5.10).  
 
Taken together, these data suggest that expression of ITGA6 in KG-1a cells is facilitated 
by low levels of DNA methylation and histone H3 occupancy, and higher levels of histone 
acetylation at the promoter; whereas low expression of ITGB4 in KG-1a cells is in part 
due to higher levels of DNA methylation and histone H3 occupancy, and lower levels of 
histone acetylation at the promoter. 
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Figure 5.10 – Histone H3 acetylation of ITGB4 and ITGA6 promoters in KG-1a 
cells. ChIP assays were performed in KG-1a cells with an antibody against acetyl-H3. 
Immunoprecipitated DNA was analysed by qPCR with primers that amplify a region of 
ITGB4, ITGA6 and Rhodopsin promoters. The data are shown as the ratio of 
immunoprecipitated DNA to total input DNA. Values are expressed as mean ±SEM 
(n=3). Statistical significance was determined using Students’ t Test, with no significant 
difference detected (p>0.05). 
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5.2.6 Effect of DAC on Histone Occupancy, Histone Acetylation and RUNX1 
Binding at the ITGB4 and ITGA6 Promoters in KG-1a Cells 
Cells treated with DAC undergo genome-wide changes which causes global 
demethylation and activation of many genes, including tumour suppressor genes 
(Momparler et al. 2014). While DAC treatment had no effect on DNA methylation at the 
ITGB4 promoter in KG-1a cells, it increased expression of ITGB4 in these cells (Figure 
5.2). Therefore, to investigate how DAC is influencing expression, effects on histone H3 
occupancy, histone acetylation and/or RUNX1 binding at the ITGB4 promoter in KG-1a 
cells were examined. Additionally, the ITGA6 promoter was examined to determine the 
effects of DAC on a gene that is normally expressed in the cells. KG-1a cells were treated 
with DAC for 72 hours. Untreated and treated cells were fixed with formaldehyde and 
DNA was sheared using sonication. DNA immunoprecipitated with histone H3, acetyl-
H3 and RUNX1 antibodies was analysed by qPCR with primers designed to amplify 
promoter regions of ITGB4 and ITGA6. Again, as a control, occupancy of histone H3, 
acetyl-H3 and RUNX1 was also analysed at the inactive Rhodopsin promoter. 
 
Treatment of KG-1a cells with DAC resulted in increased histone acetylation at both the 
ITGB4 and ITGA6 promoters, reaching statistical significance for ITGA6 (Figure 5.11A; 
p<0.05). As seen before, histone H3 levels were higher at the ITGB4 promoter compared 
to the ITGA6 promoter, but DAC treatment had no effect on histone H3 occupancy at 
either ITGB4 or ITGA6 promoter regions (Figure 5.11B). Interestingly, DAC treatment 
caused a trend in increased RUNX1 binding at the ITGB4 promoter, while RUNX1 
binding decreased at the ITGA6 promoter in DAC treated KG-1a cells (Figure 5.12). 
 
Taken together, these data suggest that while DAC treatment does not directly affect DNA 
methylation at the ITGB4 and ITGA6 promoters, it leads to increased histone acetylation 
at ITGB4 and ITGA6 promoters in KG-1a cells. The increase in ITGB4 expression 
observed in DAC treated KG-1a cells may therefore be due to increased histone 
acetylation at the promoter.  
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Figure 5.11 – Effect of DAC treatment on histone H3 and histone H3 acetylation 
ITGB4 and ITGA6 promoters in KG-1a cells. ChIP assays were performed in untreated 
and DAC treated KG-1a cells with an antibody against A) acetyl-H3 and B) histone H3. 
Immunoprecipitated DNA was analysed by qPCR with primers that amplify a region of 
ITGB4, ITGA6 and Rhodopsin promoters. The data are shown as the ratio of 
immunoprecipitated DNA to total input DNA. Values are expressed as mean ±SEM 
(n=3). Statistical significance was determined using Students’ t Test, *p<0.05, ns p>0.05. 
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Figure 5.12 – RUNX1 binding at ITGB4 and ITGA6 promoters in untreated and 
DAC treated KG-1a cells. ChIP assays were performed in untreated and DAC treated 
KG-1a cells with an antibody against RUNX1. Immunoprecipitated DNA was analysed 
by qPCR with primers that amplify a region of ITGB4, ITGA6 and Rhodopsin promoters. 
The data are shown as the ratio of immunoprecipitated DNA to total input DNA. Values 
are expressed as mean ±SEM (n=3). Statistical significance was determined using 
Students’ t Test, ns p>0.05. 
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5.3 Discussion 
 
It is evident now that epigenetic mechanisms play a key role in the regulation of genes 
and are commonly disrupted in cancer. Data presented here suggest that integrin genes 
ITGB4 and ITGA6 are regulated by DNA methylation, histone acetylation and histone 
occupancy, and changes to these epigenetic components contributes to the differential 
expression observed in the leukaemic cell lines (as summarised in Table 5.2). 
 
DNA methylation is a well characterised epigenetic modification and at the promoter of 
genes is commonly associated with gene repression or gene silencing (Sharma et al. 
2010). Evidence presented here suggests that the ITGB4 gene is regulated by DNA 
methylation. Expression of ITGB4 in KG-1a and Kasumi-1 cells was inversely correlated 
with methylation of the large CpG island present at the promoter. The low expression of 
ITGB4 in KG-1a cells was associated with a higher level of methylation at the promoter, 
while higher expression of ITGB4 in Kasumi-1 cells was associated with an unmethylated 
promoter and methylated gene body. These data are consistent with a previous study 
which found that DNA methylation of the Itgb4 promoter in mouse mammary gland cells 
is inversely correlated with expression of Itgb4 in these cells (Yang et al. 2009). In 
contrast, ITGB4 expression in K562 cells was not correlated with DNA methylation of 
the ITGB4 promoter, as the promoter was unmethylated in these cells. These data 
therefore suggest that K562 cells may be missing a factor that is required for the 
expression of the endogenous ITGB4 gene. 
 
While ITGA6 is expressed at higher levels in both KG-1a and Kasumi-1 cells, and lower 
levels in K562 cells, the ITGA6 promoter was found to be unmethylated in all cell lines 
examined in this study. Therefore, from this data it is not clear whether ITGA6 is 
regulated by DNA methylation. However, the ITGA6 gene possesses some gene body 
DNA methylation in K562 cells. Recent studies have indicated that intragenic CpG 
methylation regulates the use of alternative promoters in gene bodies, therefore leading 
to the expression of variant transcripts (Bert et al. 2013, Maunakea et al. 2010). The 
production of variant transcripts provides another mechanism of gene regulation in a cell, 
and commonly arise from alternative splicing of pre-mRNA and/or through the use of 
alternative promoters (Black 2003). Variant transcripts can give rise to protein isomers 
which differ in chemical and biological activity (Black 2003). To determine if ITGA6 has 
an alternative promoter, FANTOM5 data, which has information on the location and 
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usage of transcription start sites along the genome in human cells and mouse primary 
cells, cell lines and tissues, and is available from the FANTOM5 project (Lizio et al. 
2015), was interrogated. These data showed that ITGA6 has many alternative 
transcription start sites, however, interestingly, there is a region located approximately 
+7.1 kb downstream of ITGA6, which possesses alternative transcription start sites 
(Figure 5.13). Furthermore, interrogation of ChIP-seq data from studies described in 
Chapter 3 (Beck et al. 2013, Martens et al. 2012, Pencovich et al. 2011, Ptasinska et al. 
2014, Tijssen et al. 2011, Trombly et al. 2015) showed RUNX1 binding at this region in 
CD34+ cells, SKNO-1 cells and Kasumi-1 cells, and RUNX1-ETO binding in Kasumi-1 
cells (Figure 5.13). Interestingly, within this region there is also a consensus RUNX1 
binding motif located +7,391 to +7396 bp downstream of ITGA6. Taken together, the 
ITGA6 gene body methylation observed in K562 cells may span to a region 
approximately +7.1 kb downstream of ITGA6 and block transcription factors from 
binding to an alternative promoter located within this region, therefore, inhibiting the 
expression of a variant transcript. Since the primers used for RT-qPCR analysis in this 
study were designed in the last exon of the full-length ITGA6 mRNA and can detect 
transcript variants 1, 2 and 3 (Accession number: NM001079818, NM00210 and 
NM001316306, respectively), the primers may also be able to detect the variant transcript 
produced from the use of the alternative promoter and therefore expression of this variant 
transcript cannot be distinguished from the other transcripts detected in this analysis. 
Further studies are therefore required to determine if the leukaemic cell lines produce a 
different ITGA6 transcript and whether expression of this transcript is inhibited in K562 
cells. 
 
While DNA methylation plays a critical role in regulating gene expression, modification 
to the histone proteins associated with the DNA is also an important epigenetic regulatory 
mechanism. The accessibility of a gene to its regulators in the nucleus is important for 
optimal expression within a cell. Nucleosomes, which are comprised of histone proteins, 
are not only important for packaging of DNA within a cell, but also play a key role in 
regulating the accessibility of genes. Additionally, acetylation of these histone proteins at 
the promoters of genes is strongly associated with transcriptional activation (Virani et al. 
2012). In the present study, both ITGB4 and ITGA6 integrin gene expression was 
influenced by both histone occupancy and histone acetylation at their promoters in KG-
1a and/or Kasumi-1 cells, with higher gene expression associated with decreased histone 
occupancy and increased histone acetylation. Not surprisingly, these data suggest that for 
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optimal expression of these genes, the promoters must be accessible to regulatory 
proteins. 
 
Epigenetic inhibitors, such as the demethylating agent DAC, are a useful tool to study the 
regulation of genes by epigenetic modifications. In this study, treatment of myeloid cell 
lines K562, KG-1a and Kasumi-1 with DAC increased ITGB4 expression, while ITGA6 
expression only increased in the K562 cells. However, the increase of ITGB4 and ITGA6 
expression in these cell lines, particularly K562 and KG-1a, was not due to demethylation 
of their promoter, suggesting that DAC had an indirect effect on these genes. This may 
have been due to the activation of genes encoding other transcription factors required for 
the expression of ITGB4 and ITGA6, or alternatively, data presented here suggest that 
DAC can affect other epigenetic modifications. DAC was shown to increase histone 
acetylation at the promoters of ITGB4 and ITGA6, which may have contributed to 
increased expression of these genes. This is supported by a previous study which found 
that the demethylating agent 5-azacytidine can alter genomic histone modification 
patterns (Komashko and Farnham 2010). Certain genes were shown to switch repressive 
histone marks from histone H3K27me3 to histone H3 lysine 6 trimethylation (H3K9me3) 
and interestingly, most genes which displayed altered expression did not possess DNA 
methylation at their promoters prior to treatment (Komashko and Farnham 2010). Taken 
together, these data suggest that DAC may have increased ITGB4 and ITGA6 expression 
in myeloid cells indirectly by altering histone acetylation as well as other histone 
modifications at the promoters of these genes. 
 
Interestingly, while DAC did not cause demethylation of ITGB4 and ITGA6 promoters 
in most of the cell lines examined in this study, unexpectedly, DNA methylation increased 
in many of the clones analysed using bisulphite sequencing. The increase in DNA 
methylation after treatment with DAC has also been observed in a previous study 
(Chowdhury et al. 2015). It was found that while DAC causes decreased levels of 
methylated cytosines (5mC), it increases 5-hydroxymethylcytosine (5hmC) (Chowdhury 
et al. 2015). 5hmC is an intermediate of the demethylation process via the oxidation of 
5mC by the ten-eleven-translocation (TET) DNA dioxygenases (Tahiliani et al. 2009). 
TET DNA dioxygenases play an important role in gene regulation for early embryonic 
development (Ficz et al. 2011), as well as differentiation of haematopoietic cells by 
priming genes for expression which regulate myeloid and lymphoid lineage commitment 
(Caron et al. 2015, Madzo et al. 2014, Tekpli et al. 2016, Tsagaratou et al. 2014). The 
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increase in 5hmC with DAC treatment is thought to result from TET enzymes targeting 
hemi-methylated DNA (Chowdhury et al. 2015). Furthermore, although 5hmC reacts 
with bisulphite and is converted to 5-methylenesulphonate while 5mC is resistant to 
bisulphite conversion, 5hmC cannot be distinguished from 5mC using bisulphite 
sequencing as they are both recognised as cytosines after treatment (Huang et al. 2010). 
Interestingly, DNA which possess a large fraction of 5-methylenesulphonate after 
bisulphite treatment is less efficiently amplified in PCR, as 5-methylenesulphonate sites 
are able to stall the Taq polymerase (Huang et al. 2010). Taken together, with the 
observation that ITGB4 and ITGA6 promoter regions were difficult to amplify by PCR 
and that there was also an increase in methylation at those regions in K562 and KG-1a 
cells, it might suggest that DAC treatment may have increased 5hmC during the de-
methylation process. Further studies using different sequencing approaches such as 
pyrosequencing and high-throughput sequencing, which can distinguish 5hmC from 5mC 
(de la Rica et al. 2016), are therefore required to determine if 5hmC levels increase at 
ITGB4 and ITGA6 promoters in DAC treated leukaemic cell lines. 
 
In addition to the DNA methylation inhibitor DAC, leukaemic cell lines were also treated 
with the histone acetyltransferase inhibitor TSA. While data presented here suggest that 
histone acetylation at the promoter is important for both ITGB4 and ITGA6 expression, 
only a combined treatment of DAC and TSA showed a significant increase in ITGB4 
expression, while TSA had no effect on ITGA6 expression. This is in contrast to previous 
studies which have shown a decrease in both ITGB4 and ITGA6 expression upon 
treatment with the HDAC inhibitor valproic acid in PC-3 cells (Hudak et al. 2012, Wedel 
et al. 2011) and a decrease in ITGA6 expression upon treatment of a hepatocellular 
carcinoma cell line with TSA (Lin et al. 2005). While it is expected that treatment of cells 
with HDAC inhibitors should increase the expression of genes regulated by histone 
acetylation, the decrease in ITGB4 and ITGA6 expression observed in these studies may 
be due to an indirect effect via the activation of repressors, which regulate ITGB4 and 
ITGA6. Additionally, in these previous studies (Hudak et al. 2012, Lin et al. 2005, Wedel 
et al. 2011) cells were treated for much longer periods from 1-5 days, whereas in the 
present study cells were only treated for 6 hours. Longer treatment times may therefore 
result in indirect effects on expression of the integrin genes. Additionally, a previous 
study has observed that TSA treatment does not always result in increased histone 
acetylation at gene promoters and also does not always inhibit histone deacetylation 
(Mulholland et al. 2003). 
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In conclusion, data presented here provides evidence that both ITGB4 and ITGA6 are 
regulated by epigenetic mechanisms in myeloid cells. ITGB4 is regulated by DNA 
methylation of a large CpG island located at its promoter, and both ITGB4 and ITGA6 
expression is dependent on having an accessible promoter, due to decreased histone H3 
and increased histone acetylation. In addition, the present study has further elucidated the 
effects of the de-methylating agent DAC, which is currently being used as a treatment for 
leukaemia (Blum et al. 2010, Cashen et al. 2010, Issa et al. 2004). DAC is thought to 
demethylate the whole genome, however evidence from previous studies and the current 
study suggest that its effects on the genome are more complex than previously thought 
and can lead to changes in other epigenetic modifications, including histone acetylation 
and methylation, and DNA hydroxymethylation (Chowdhury et al. 2015, Hagemann et 
al. 2011, Komashko and Farnham 2010). 
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ITGB4 ITGA6 
KG-1a Kasumi-1 K562 KG-1a Kasumi-1 K562 
Normal 
expression 
Low Medium Low High Medium Low 
Response to 
DAC ↑ ↑ ↑ 
No 
Change 
No 
Change ↑ 
Response to 
TSA ↑ ↑ ↑ 
No 
Change 
No 
Change 
No 
Change 
DNA 
methylation 
at the 
promoter  
High Low Low Low Low Low 
Histone 
occupancy 
at the 
promoter 
High Low - Low Low - 
Histone 
acetylation 
at the 
promoter 
Low - - High - - 
 
 
Table 5.2 – Epigenetic modifications to ITGB4 and ITGA6 in myeloid cell lines. This 
table summarises the expression of ITGB4 and ITGA6, as well as the DNA methylation, 
histone occupancy and histone acetylation status at the promoters of ITGB4 and ITGA6 
in KG-1a, Kasumi-1 and/or K562 cells. The change in gene expression is also shown in 
response to treatment with DAC or TSA (arrow indicates an increase in gene expression). 
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Figure 5.13 – Alternative transcription start sites for ITGA6. Screen shot of 
FANTOM5 data from the FANTOM5 project (Lizio et al. 2015) and data from ChIP-seq 
studies (Beck et al. 2013, Martens et al. 2012, Pencovich et al. 2011, Ptasinska et al. 
2014, Tijssen et al. 2011, Trombly et al. 2015) visualised in UCSC Genome Browser 
(Kent et al. 2002). Peaks in the FANTOM5 data represent transcription start sites used in 
human cells and mouse primary cells, cell lines and tissues, and the arrow indicates the 
region that possesses alternative transcription start sites located approximately +7.1 kb 
downstream of ITGA6. Peaks and lines in the ChIP-seq data represent RUNX1 (R) and 
RUNX1-ETO (RE) binding in the different cell types. The ITGA6 gene is represented at 
the top of the figure, with exons shown as bars. The major transcript is highlighted in 
blue. 
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Chapter 6 
 
Final Conclusions and Future Directions 
 
 
Disruption to regulatory mechanisms controlling gene expression is a hallmark of 
leukaemia, with disruption to transcription factors being one of the most prevalent 
(Brettingham-Moore et al. 2015, Döhner and Döhner 2008). By identifying the gene 
expression profile under the control of these transcription factors, and understanding how 
the target genes are regulated, critical insight can be gained into the role of these 
transcription factors in haematopoiesis, as well as their role in leukaemia development. 
Additionally, this may identify potential biomarkers or therapeutics targets for the 
disease. In this study, the integrin genes ITGA6 and ITGB4 were identified as novel target 
genes of RUNX1. 
 
RUNX1 is commonly described as a sequence-specific DNA binding transcription factor 
which binds to the promoters of its target genes and regulates their transcriptional activity 
(Meyers et al. 1993, Takahashi et al. 1995). However, it is evident now that RUNX1 
regulation of gene expression is more complex than this, encompassing multiple 
regulatory layers involving interaction with other co-factors or transcription factors, distal 
regulatory elements and epigenetic factors (Bowers et al. 2010, Elagib et al. 2003, Huang 
et al. 2009, Kitabayashi et al. 1998, Levantini et al. 2011, Reed-Inderbitzin et al. 2006, 
Waltzer et al. 2003, Wotton et al. 1994, Zhang et al. 1996). Data presented in this thesis 
identified two distinct mechanisms by which RUNX1 regulates its target genes, as 
demonstrated by the ITGA6 and ITGB4 integrin genes. In addition, epigenetic 
modifications also play an important role in regulating their expression. 
 
RUNX1 was demonstrated to regulate the ITGA6 promoter via the well described 
traditional model of RUNX1 function. RUNX1 was found to bind to a RUNX1 consensus 
motif within the ITGA6 promoter, as mutation to this site resulted in a significant 
reduction in RUNX1 activation of the promoter in reporter assays. In contrast, RUNX1 
regulation of the ITGB4 promoter was found to be more complex. The data presented 
here suggest that RUNX1 may regulate the ITGB4 promoter indirectly through 
interactions with other haematopoietic transcription factors which may potentially bind 
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to the promoter. Additionally, RUNX1 may require an upstream enhancer to regulate the 
ITGB4 promoter, and may also interact with this region indirectly by binding to other 
haematopoietic transcription factors. 
 
A further regulatory layer in ITGA6 and ITGB4 gene expression was epigenetic 
modifications. Data presented in this thesis suggest that promoter accessibility is 
important for the expression of ITGA6 and ITGB4, as expression of these genes was 
higher in leukaemic cells with lower occupancy of histone H3 and higher levels of histone 
acetylation at the promoter regions. The data also suggest that the expression of ITGB4 is 
influenced by DNA methylation of a CpG island present at the promoter. In two of the 
three myeloid cells analysed in this study, DNA methylation levels at the ITGB4 promoter 
was inversely correlated with expression of this gene. 
 
While it is clear that the regulation of ITGA6 and ITGB4 is multi-layered, including 
transcriptional and epigenetic factors, there is interplay between these different layers. 
There is evidence in the literature that RUNX1 can also influence gene transcription 
through interaction with epigenetic modifiers that drive epigenetic changes at target 
genes. The outcome of gene activity is therefore dependent on the balance of activating 
and repressive factors associated with RUNX1, as reviewed in (Brettingham-Moore et al. 
2015). For example, to repress gene expression RUNX1 can interact with the repressive 
factors mSin3A, SUV39H1 and HDACs to create condensed chromatin via histone 
deacetylation and DNA demethylation (Lutterbach et al. 2000, Reed-Inderbitzin et al. 
2006). However, RUNX1 can also activate gene expression by interacting with histone 
acetyltransferases p300 and CBP (Kitabayashi et al. 1998, Oakford et al. 2010). 
Furthermore, a recent study has demonstrated RUNX1 binding to be associated with 
increased histone acetylation in haematopoietic development (Lichtinger et al. 2012). The 
presence of histone acetylation at the ITGA6 and ITGB4 promoters in leukaemic cell 
lines in this study may therefore be facilitated by RUNX1 and/or other transcription 
factors complexing with RUNX1. 
 
Additionally, the RUNX1 protein itself can be modified by epigenetic factors which can 
alter its activity on its target genes. Acetylation of RUNX1 by p300 can increase its DNA 
binding and transcriptional activity (Oakford et al. 2010, Yamaguchi et al. 2004). 
Furthermore, methylation of RUNX1 by the histone methyltransferase PRMT1 results in 
increased RUNX1 transcriptional activity due to the disruption to the interaction of 
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RUNX1 and the co-repressor complex involving mSin3A (Zhao et al. 2008). In contrast, 
interaction of RUNX1 with the histone methyltransferase SUV39H1 results in inhibition 
of RUNX1 activation of target genes due to decreased binding of RUNX1 at gene 
promoters (Chakraborty et al. 2003). Additionally, methylation by the histone 
methyltransferase PRMT4 also leads to gene repression due to the formation of a methyl-
RUNX1-dependent co-repressor complex (Vu et al. 2013). Further studies are therefore 
required to determine if there is interplay between RUNX1 and epigenetic factors at the 
ITGA6 and ITGB4 promoters. 
 
In the present study, leukaemic cell lines K562, KG-1a and Kasumi-1 cells were used as 
a model system to elucidate the transcriptional and epigenetic regulation of integrin genes 
ITGA6 and ITGB4. These cell lines have been useful in dissecting the mechanisms of 
regulation of ITGA6 and ITGB4 as they display differential expression of these genes. 
While it is clear that epigenetic mechanisms have an effect on ITGA6 and ITGB4 
expression in the leukaemic cell lines KG-1a and Kasumi-1, low expression of ITGA6 
and ITGB4 was not correlated with DNA methylation in K562 cells. It was hypothesised 
that the low expression of ITGA6 and ITGB4 in K562 cells may be due to low levels of 
RUNX1 present in these cells, however, overexpression of RUNX1 in K562 cells only 
resulted in an increase in ITGA6 expression (data not shown). These data therefore 
suggest that the K562 cells may not express a co-factor or transcription factor which is 
required for the expression of ITGB4. 
 
Data presented here suggest that RUNX1 may regulate the ITGB4 promoter in a large 
transcription factor complex with other haematopoietic transcription factors such as E2A, 
SCL, FLI1, ERG, GATA1/GATA2, LYL1 and LMO2. RUNX1 regulation of ITGB4 may 
therefore be dependent on the presence of these transcription factors. To determine if one 
of these haematopoietic transcription factors may be missing in K562 cells, expression 
data from published microarray studies were interrogated (de Jonge et al. 2011, Johnson 
et al. 2010, Ptasinska et al. 2012, Shia et al. 2012). Interestingly, the FLI1 transcription 
factor is expressed at very low levels in K562 cells (Figure 6.1), while other transcription 
factors such as E2A, SCL, ERG, GATA1 and LMO2 are present (GATA2 and LYL1 
expression was not analysed in this data). In support of these findings, other studies have 
also detected either no or very low levels of FLI1 in K562 cells (Athanasiou et al. 1996, 
Watson et al. 1992). Interestingly, FLI1 plays an important role in haematopoietic cell 
differentiation through both positive and negative regulation, and has been shown to act 
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synergistically with GATA1 to regulate megakaryocyte-specific genes (Athanasiou et al. 
2000, Eisbacher et al. 2003). Furthermore, treatment of K562 cells with PMA results in 
increased expression of FLI1 and overexpression of FLI1 in K562 cells causes changes 
similar to what is observed with PMA treatment, such as altered cell morphology and 
increased adherence (Athanasiou et al. 1996). Therefore, increased expression of ITGB4 
in PMA treated K562 cells, described in Chapter 3, may not only be due to activation of 
RUNX1 via phosphorylation as hypothesised, but may also be due to increased 
expression of FLI1. Interestingly, FLI1 has been shown to bind to the ITGB4 promoter 
in the leukaemic cell line U937, suggesting that it has the potential to bind to ITGB4 in 
other cell types and further supporting its involvement in regulating ITGB4 expression 
(Martens et al. 2012). While RUNX1 was shown to activate the ITGB4 promoter in 
reporter assays in K562 cells in the absence of FLI1, this overexpression of RUNX1 to 
abnormal levels may artificially force DNA-protein interactions, allowing RUNX1 to 
activate the promoter without FLI1. Alternatively, FLI1 may be important for the 
promoter-enhancer interaction highlighted in this study which may be required for 
RUNX1 regulation of the endogenous ITGB4 gene. If this were the case the absence of 
FLI1 in reporter assays would not have an effect on RUNX1 activation of the promoter 
alone. 
 
Taking the results presented here, a model for the regulation of ITGB4 in different cell 
lines has been proposed (Figure 6.2). This model proposes that ITGB4 is expressed in 
Kasumi-1 cells due to the presence of all transcription factors required for the 
transcription of the gene and an unmethylated promoter. In KG-1a cells, although the 
transcription factors required for expression may be present, ITGB4 is expressed at low 
levels, and this may due to high levels of DNA methylation and reduced accessibility at 
the promoter, which is preventing transcription factors from binding. In K562 cells, 
ITGB4 is expressed at low levels although the promoter is unmethylated, this model 
proposes that this is because these cells are missing the FLI1 transcription factor. These 
findings suggest that for efficient expression of ITGB4, the promoter must be 
unmethylated and at least RUNX1 and FLI1 must be expressed. Additionally, although 
Kasumi-1 cells possess the RUNX1-ETO fusion protein, ITGB4 is expressed at higher 
levels in these cells. However, as discussed in Section 3.3 (Chapter 3), the variant 
transcript RUNX1-ETO9a, which is expressed in Kasumi-1 cells, can act as a strong 
activator due to the absence of the C-terminal inhibitory domains (Yan et al. 2004, Yan 
et al. 2006). In this model, RUNX1-ETO9a may also interact with these haematopoietic 
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transcription factors in Kasumi-1 cells, causing increased expression of ITGB4 in these 
cells. Further studies would therefore be required to determine if FLI1 is a critical factor 
in the regulation of ITGB4 and to determine if RUNX1-ETO9a regulates ITGB4 similarly 
to RUNX1. 
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Figure 6.1 – FLI-1 expression in haematopoietic cells. Screen shot of FLI1 expression 
in CD34+ cells (GSE30029), megakaryocytes (E-TABM-633), SKNO-1 cells 
(GSE34594) and K562 cells (GSE28135) from genome-wide microarray expression data 
(de Jonge et al. 2011, Johnson et al. 2010, Ptasinska et al. 2012, Shia et al. 2012) viewed 
in the BloodChIP database (Chacon et al. 2014). Non-normalised expression data from 
illumina expression arrays were log2 transformed and quantile normalised. Range of FLI1 
expression for 3-31 replicates is shown, as well as the mean expression (horizontal line) 
and standard deviation (whiskers). 
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A 
 
B 
C 
 
 
Figure 6.2 – A model for the regulation of ITGB4 in different leukaemic cell lines. 
Depiction of ITGB4 regulation in A) Kasumi-1, B) KG-1a and C) K562 cells. DNA is 
shown as aqua lines wrapped around nucleosomes (blue balls) and CpG sites are shown 
as small circles either methylated (black) or unmethylated (white). Transcription start 
sites are shown as black right-angled arrows. The ITGB4 promoter is unmethylated in 
Kasumi-1 cells, therefore allowing the binding of the transcription factor complex and 
interaction with the upstream enhancer, resulting in the expression of ITGB4. The ITGB4 
promoter is methylated in KG-1a cells which causes tight packing of DNA, therefore 
necessary transcription factors are unable to easily bind to the ITGB4 promoter and results 
in little/no expression. The ITGB4 promoter is unmethylated in K562 cells, therefore 
allowing transcription factors to bind, however, FLI1 is not expressed in these cells, 
which may lead to a less efficient assembly of the transcription factor complex at the 
ITGB4 promoter. Therefore, the absence of FLI1 may be the cause of low expression of 
ITGB4 in K562 cells. 
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Although the traditional model of RUNX1 regulation of genes via a RUNX1 consensus 
motif is well described in the literature and was identified in this study to be the 
mechanism by which RUNX1 regulates ITGA6, recent evidence suggests that this 
mechanism only represents a small proportion of RUNX1 target genes. Analysis 
conducted by our research group using ChIP-seq data from the study by Trombly et al. 
(2015) determined the proportion of RUNX1 binding in either promoter or 
intragenic/intergenic regions across the genome and which occurred in the presence of a 
RUNX consensus binding motif (Woodworth and Holloway, unpublished). Interestingly, 
only 21% of RUNX1 binding was located in promoter regions of genes while the other 
79% was located in intragenic or intergenic regions. These findings are supported by other 
ChIP-seq studies which have also observed a higher percentage of RUNX1 binding in 
intragenic/intergenic regions compared to promoter regions (Beck et al. 2013, Wilson et 
al. 2010). Unexpectedly, of the sites found to be bound by RUNX1 in promoter regions, 
only 57% contained a RUNX motif. Together, these data suggest that the mechanism by 
which RUNX1 regulates ITGB4 may occur more frequently than the traditionally 
described mechanism in which RUNX1 regulates expression via a binding motif in a 
promoter, as found here for ITGA6. It also suggests that the way in which RUNX1 is 
disrupted in leukaemia may therefore affect its target genes differently. For example, if 
there is a mutation which disrupts the DNA binding domain of RUNX1, this may affect 
the expression of genes that are regulated by RUNX1 through its binding to RUNX 
consensus sequences, such as ITGA6, differently to genes such as ITGB4, where RUNX1 
is recruited independently of a canonical sequence motif. This therefore warrants further 
investigation. 
 
The different mechanisms by which RUNX1 can regulate genes identified in this study, 
advances our knowledge of transcriptional regulation. While these mechanisms are true 
for RUNX1, they may also be relevant for other transcription factors. Interestingly, recent 
studies of other transcription factors such as Myc and NF-κB, have similarly found a 
significant proportion of binding occurs independently of DNA binding motifs (Guo et 
al. 2014, Kolovos et al. 2016). In addition, these findings may have implications for other 
types of cancer. The mechanisms described here for RUNX1 may also apply to the RUNX 
family members, RUNX2 and RUNX3, which are often disrupted in prostate, breast, 
gastric and brain cancer. 
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